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Abstract 
Myeloperoxidase (MPO) forms the reactive oxidants hypochlorous acid (HOCl) and 
hypothiocyanous acid (HOSCN) in inflammatory environments in vivo. HOCl is highly reactive, 
causing extensive damage to biomolecules and has been implicated in the progression of 
numerous inflammatory conditions. In contrast, HOSCN reacts preferentially with protein 
thiols, and can form a number of reversibly oxidised products. The targeting of thiols can 
lead to protein inactivation and inhibition, which has led to HOSCN being implicated in the 
alteration of cellular redox signaling pathways. Gaining an understanding of the reactivity of 
HOSCN in vivo has been limited by the lack of a specific biomarker for this oxidant. Indirect 
evidence supports a role of HOSCN in promoting inflammation and disease. However, the 
role of HOSCN in biological systems is currently debated, with evidence also for a protective 
role of this oxidant, preventing cellular damage from MPO by removal of the more damaging 
HOCl. 
The studies in Chapter 3 compare the ability of both HOCl and HOSCN to form reversibly 
oxidsed cysteine products in J774A.1 macrophages after treatment. In these studies, the 
ability of these oxidants to reduce the intracellular thiol pool was examined using the 
fluorescent thiol probe, ThioGlo-1, where it was shown that HOSCN depleted cellular thiols 
to a greater extent than HOCl under comparable conditions. Evidence for reversible protein 
thiol modification in macrophages exposed to HOSCN but not HOCl, was obtained using the 
thiol alkylating agent 5-iodoacetamidofluorescein (IAF), which was supported by studies with 
sulfenic acid probes and antibodies recognizing glutathionylated proteins. In contrast, HOCl 
is believed to form irreversible cysteine oxidation products. Subcellular fractionation studies 
revealed that HOSCN targeted thiol-containing proteins in both the cytosol and mitochondria 
on exposure to macrophages. 
HOSCN is a bacteriostatic agent, inhibiting bacterial cell growth and proliferation, and its 
ability to inhibit these bacterial processes is attributed to its action on the glycolytic 
pathways. Studies on isolated proteins and in vitro have linked HOSCN with the inactivation 
of proteins such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and creatine kinase 
(CK), which are involved in metabolism of glucose in mammalian cells. Chapter 4 explored 
the functional effects of HOSCN-induced oxidation of J774A.1 macrophages on the glycolytic 
pathway. Exposure of cells to HOSCN resulted in the inhibition of glycolysis as determined by 
a functional glycolysis assay using the Seahorse XF bioanalyser and by assaying the glycolytic 
end-product, lactate. The results of this Chapter also showed that the inhibition of glycolysis 
xiii 
 
was not due to an inhibitory effect on the glucose uptake proteins, or because of a reduction 
in cell viability, but was consistent with HOSCN-induced targeting and oxidation of proteins 
involved in glycolysis, including GAPDH, aldolase and triosephosphate isomerase. 
The experiments performed in Chapter 5 studied the effects of mitochondrial thiol oxidation 
and the reduced substrate formation from glycolysis on mitochondrial respiration. Exposure 
of macrophages to HOSCN resulted in a significant loss in mitochondrial respiration, and 
changes consistent with damage to the electron transport chain. Moreover, HOSCN induced 
a loss in mitochondrial membrane permeability and reduction in intracellular ATP 
concentration, which could be mitigated to some extent by pre-treatment with the 
mitochondrial permeability transition inhibitor cyclosporin A. 
In Chapters 6 and 7, Fourier transform infra-red spectroscopy (FTIR) and Raman spectroscopy 
were employed as a novel and alternate method to quantify and visualise the oxidative 
damage caused by HOSCN and HOCl in J774A.1 cells. The results of these studies determined 
that HOSCN and HOCl, collectively, were able to interact with a multitude of biomolecules 
including proteins, lipids and nucleic acids. These studies also corroborated data from the 
previous Chapters, by showing that HOSCN influenced the intracellular concentrations and 
locations of carbohydrates, glucose, lactate and NADH, a by-product of glycolysis.  
In summary, the studies of this Thesis provide valuable information relating to the action and 
functional effect of HOSCN on the targeting and oxidation products formed on cellular 
proteins in macrophages, particularly mitochondrial proteins and proteins involved in the 
metabolism of glucose and production of ATP. The observation that HOSCN has a significant 
role in the inhibition of key cellular bioenergetic processes provides new insight into the 
potential role of HOSCN in the induction of macrophage dysfunction, which may contribute 
to the progression of lesion development and instability in the inflammatory disease 
atherosclerosis. This may be particularly significant for smokers, who have elevated plasma 
thiocyanate, the precursor to HOSCN and are at greater risk of developing atherosclerosis 
and complications from this disease.  
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1 Introduction 
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1.1 Oxidative stress 
Oxidative stress can be defined as the imbalance between the creation of reactive oxygen 
species (ROS) in biological systems and the inability of the system to detoxify/remove these 
reactive intermediates or repair the damage caused by ROS [1]. ROS refer to radical and non-
radical chemical species that contain oxygen (O2) derivatives. Chemically, radicals can be 
formed by a number of routes, such as by the loss of a single electron from a non-radical, or 
on the other hand, the gain of an electron by a non-radical. Non-radical oxidants, such as 
hydrogen peroxide (H2O2) and peroxynitrite, can be formed via many processes, particularly 
in vivo by the action of peroxidases [2]. 
Inflammation is a major initiator of ROS formation, inflammatory stimuli recruit leukocytes 
to the site of injury, where they are activated and release enzymes from intracellular 
granules, resulting in the generation of superoxide (O2•-) and H2O2, which is driven by 
membrane NADPH complexes [3, 4]. Another source of ROS is from the leakage of electrons 
from the electron transport chain (ETC), which reduce O2, forming O2•- [5]. O2•- is a weak 
base, that does not appear to react readily with biomolecules, but its role seems to be 
involved in the formation of more potent oxidising agents [6]. The formation of O2•- can lead 
to the formation of numerous ROS, such as H2O2 which is formed via the addition of an 
electron, either enzymatically (by superoxide dismutase) or spontaneously [7, 8]. H2O2 is a 
non-radical oxidant that plays a role in various cell signalling pathways, and is involved in the 
oxidation of halide and (pseudo)halide ions [9-11]. The donation of another electron to H2O2 
via Fenton chemistry with Fe2+, results in the formation of the hydroxyl radical (HO•), an 
extremely reactive and short-lived species that can react with nearly all types of biological 
molecules, including lipids, nucleic acids, proteins and carbohydrates at diffusion-controlled 
rates [12]. An important of ROS in biological systems are the hypohalous acids (HOX) 
(hypochlorous; HOCl, hypobromous; HOBr, and hypothiocyanous; HOSCN), formed by 
lactoperoxidase (LPO), eosinophil peroxidase (EPO) and myeloperoxidase (MPO), enzymes 
that catalyse the reaction between H2O2 and halide anions (Cl-, Br- and SCN-) [11]. The 
properties of these oxidants differ, which influences their roles in a biological setting and 
determines their role in the formation of further oxidants. 
Thus, in the past few decades, excessive ROS production has been associated with 
detrimental biological effects in terms of playing a role in cellular dysfunction and disease. 
However, ROS are also formed via a myriad of normal physiological and cellular processes, 
such as by the ETC [13]. These processes create ROS as intermediates or by-products of 
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reactions in healthy cells, where they can play an important role in redox cell signalling in 
response to external stimuli such as infection [14]. Given the increasing importance of 
oxidative stress in the propagation of disease, significant research has been dedicated to 
understanding the cellular pathways modulated by ROS to be able to reverse the production 
and/or the damage caused by oxidants, particularly in the context of inflammatory disorders 
[15]. 
 
1.2 Inflammation 
Inflammation is a complex process, which is defined as the biological response of body 
tissues to damaging stimuli, such as irritants and invading pathogens [16]. A hallmark of 
inflammation is the infiltration and subsequent extravasation of leukocytes [17]. Neutrophils 
are a key inflammatory leukocyte, which once at the site of inflammation will release MPO 
from azurophilic granules into their phagosomal compartment or extracellularly [18]. MPO 
catalyses the formation of hypohalous acids, which are potent antimicrobial agents, by 
utilising H2O2 [19]. However, excessive production of these oxidants, or the production of 
them at inappropriate times or locations, can lead to tissue damage [20]. Because of this 
reason, hypohalous acids, especially HOCl have been implicated in chronic inflammatory 
diseases [21, 22]. It has been hypothesised that the cellular damage during chronic 
inflammation is associated with the reaction of HOCl, HOBr and HOSCN with a multitude of 
biological molecules, particularly targeting a number of protein residues, which causes a 
change in the tertiary structure of proteins, thereby influencing their activity [23].  
It has also been postulated that inflammation is associated with a change in the proper 
function of cellular energy producing pathways within the cytosol and the mitochondria [24-
26]. In the cytosol, it has been shown that hypoxia (deficiency in O2 in the cellular 
environment) enhances the glycolytic flux of macrophages together with an increase in pro-
inflammatory activity [26] and glucose transporter 1 (GLUT1) mediated increases in glycolysis 
also drive inflammatory phenotypes in macrophages [27]. In the mitochondria, it is proposed 
that electron leak via the ETC, leads to the incidental liberation of ROS and subsequent 
increase in cellular concentrations of ROS [28]. It has been postulated that this release of 
ROS induces damage to major constituents of the mitochondria, which include the thousands 
of copies of mitochondrial DNA within each cell [29]. This link between an increase in cellular 
ROS, a decrease in mitochondrial function and a reduced ability to remove ROS has therefore 
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been hypothesised as a cause of inflammatory disorders and diseases [30-32] including, but 
not limited to, cancer, rheumatoid arthritis and cardiovascular disease [33, 34].  
 
1.2.1 Immune Response 
Leukocytes are the cells involved in the immune response and are largely responsible for 
protecting the body from harmful infections and foreign invaders. MPO is particularly useful 
in bacterial cell killing, while EPO (localised within granules of eosinophils) is largely used in 
defense against parasitic infection and LPO (secreted from salivary and mucosal glands) is an 
antibacterial agent in saliva, milk and tears [11, 35, 36]. Studies have shown that MPO, H2O2 
and halide ions are able to effectively kill bacteria in vitro [37]  and to serve as potent innate 
immune cells neutrophils are packed with these cytotoxic granules. Peroxidase positive 
granules (positive MPO content) [38] that are activated via increases in intracellular Ca2+ 
levels or various inflammatory stimuli release vesicles that express vesicle-associated 
membrane protein 2 (VAMP-2) into the extracellular environment [39, 40].  
1.3 Haem Peroxidases 
Peroxidases are a family of enzymes that catalyse the general reaction (Reaction 1.1): 
ROOR’ + 2e- + 2H+  ROH + R’OH    Reaction 1.1 
The optimal substrate for these enzymes is H2O2 and haem peroxidases contain haem 
cofactors at their active sites [11]. The role of many human peroxidases, including MPO, LPO 
and EPO is the utilization of H2O2 to form further oxidising chemical species such as HOSCN, 
HOBr and the well-documented HOCl [41-43]. 
These particular peroxidases have genes that originate from chromosome 17 with similar 
exon and intron patterns [44], with each playing an important role in the innate arm of the 
human immune system, by synthesising powerful antimicrobial oxidants. The haem 
contained within the active site of MPO can react with H2O2, the original Fe3+ form of the 
haem becomes Fe5+, also referred to as Compound I. Compound I is now able to undergo a 
two-electron reduction reaction known as the “halogenation cycle”, returning back to its 
native Fe3+ state. This allows for the oxidation of halides and thiocyanate into their respective 
hypohalous acids [45]. Compound I is also able to undergo two sequential one-electron 
reactions, known as the “peroxidase cycle” to regenerate its native Fe3+ state, through the 
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creation of an intermediate known as “Compound II”, which forms oxidising radical species 
in the process. Finally, Compound II can react with H2O2 to bring about an inactive form of 
MPO, Compound III. Native MPO can also react with O2•− to form Ferrous MPO, which 
subsequently reacts with molecular O2 to form Compound III (Figure 1.1).  
 
 
Figure 1.1: Catalytic cycle of peroxidases including MPO, EPO and LPO. 
 Using MPO as an example, oxidation of MPO by H2O2 forms Compound I, which can undergo 
a two-electron reduction with halide or pseudohalide ions to form the pseudo and hypohalous 
acids (halogenation cycle). Compound I can also undergo two successive one-electron 
reductions (peroxidation cycle), forming radicals via Compound II and returning to the native 
state. Compound III can be formed via a reaction of native MPO with O2•− via Ferrous MPO.  
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With MPO, during the peroxidase cycle, organic substrates can be converted to radicals via 
a one-electron oxidation by Compound I to Compound II, or by Compound II to native MPO 
(Figure 1.1). MPO has a ride range of substrates for peroxidation including tyrosine, 
ascorbate, steroidal hormones, as well as various xenobiotics and drugs, including 
paracetamol [46, 47]. 
When considering the peroxidases, their substrates and their possible physiological roles, 
many conditions and variables must be identified. At physiological pH and halide 
concentrations, MPO preferentially generates both HOCl and HOSCN, despite the large 
difference in plasma concentrations of the parent halides (and pseudohalides). Plasma 
concentrations of Cl- are ca. 100 - 150 mM and SCN- is typically 50 – 100 μM [48]. However, 
SCN- has a higher specificity for MPO than Cl- (rate constants, k of 9.6 × 106 M–1 s–1 for SCN–, 
cf. 2.5 × 104 M–1 s–1 for Cl– and 1.1 × 106 M–1 s–1 for Br– and specificity constants 730:1:60, 
respectively) due in part to the lower standard reduction potential for the 2e- HOSCN/SCN- 
redox couple [48, 49]. Thus, at physiological pH and concentrations of the parent anions in 
plasma, it is estimated that 50 % of the H2O2 utilised by MPO is used to create HOSCN [48]. 
EPO preferentially generates HOBr (plasma Br-, 100 μM) and LPO preferentially generates 
HOSCN [11]. 
 
1.4 Hypohalous acids 
The hypohalous acids have been studied extensively due to their role in the innate arm of 
the human immune response [50-52], and are much more reactive and bactericidal than 
H2O2 [42, 53-56]. The most studied of these oxidants is HOCl, a powerful oxidant created by 
MPO that exists with hypochlorite (OCl-, its conjugate base) in equilibrium at physiological 
pH (pKa, 7.59) [57]. At physiologically relevant temperature and pH, HOBr is prevalent when 
compared to its conjugate base hypobromite (pKa, 8.7) [58], while on the other hand 
hypothiocyanite (OSCN-) rather than HOSCN is the predominate species under physiological 
conditions (pKa, 5.3) [57, 59]. From here on, the terms HOCl, HOBr and HOSCN, will be used 
to represent physiological mixtures of acids and their conjugate bases. 
 
7 
 
1.4.1 Hypochlorous and hypobromous acids 
HOCl and HOBr are both strong oxidants that are also capable of performing halogenation 
reactions in vivo [11]. At acidic pH and with excess amounts of Cl- and Br- ions, HOCl and 
HOBr exist in equilibrium with molecular chlorine (Cl2) and bromine (Br2) [60]. It has been 
suggested that these species exist within the phagosomes and that they contribute to 
peroxidase–mediated damage [60, 61]. 
HOCl and HOBr can avidly react with biomolecules that contain amines, organic compounds 
or functional groups that contain nitrogen with lone pairs, and amides to create N-
chlorinated or N-brominated species [62, 63]. The species derived from amines are known 
as “halamines” (chloramines, RR’NCl and bromamines, RR’NBr). Primary halamines can react 
further with either HOCl or HOBr to create dihalamines (RNX2, X = Cl, Br) [64]. Reaction of 
these oxidants with amides forms “halamides” (chloramides, RC(O)N(R’)Cl and bromamides, 
RC(O)N(R’)Br) [62-67]. These halamines and halamides can be generated on a variety of 
biological molecules such as the α-amino groups of proteins and certain residues that contain 
nucleophilic nitrogens such as, arginine (Arg), lysine (Lys) and histidine (His) and DNA bases 
[41, 65, 68].  
 
1.4.1.1 Halamines 
Halamines and halamides are major products of the reaction between HOCl/HOBr and 
biological molecules, which can preserve the oxidising capacity of the parent oxidant [69]. In 
some cases, these reactive intermediates can induce further reactions, some of which 
restore the amine/amide, owing to a transfer of the halogen [41, 67, 70]. Halamines and 
halamides can also dissociate the nitrogen-halide (N-X) bond, producing nitrogen-centred 
radicals, which can undergo further reactions to damage biomolecules [71]. 
 
1.4.2 Hypothiocyanous acid  
HOSCN is not a hypohalous acid in the classical sense of the term, though it shares many 
common traits, and is therefore referred to as a (pseudo)hypohalous acid. It is theorised that 
SCN- is either oxidised to HOSCN directly by peroxidases (Reaction 1.2) [72-74] or that 
thiocyanogen ((SCN)2) is hydrolysed to HOSCN (Reaction 1.3) [75, 76], However, recent 
evidence suggests that thiocyanogen may not be formed at physiological pH [77]. SCN- is 
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derived from the ingestion of foods, such as cassava and cruciferous vegetables [78, 79]. SCN- 
is also derived from rhodanese, a protein that catalyses the detoxification of plasma cyanide 
(CN-) and thiosulfate [80]. Instead, a prime source of SCN- is from the detoxification of 
hydrogen cyanide via cigarette smoke inhalation [81, 82]. In non-smokers, plasma 
concentrations of SCN- are usually between 10 – 100 μM [42], but plasma SCN- levels in 
smokers have been reported to reach and exceed 300 μM [80, 82, 83].  
SCN– + H2O2  OSCN– + H2O     Reaction 1.2 
 (SCN)2 + H2O  HOSCN + H+ + SCN–    Reaction 1.3 
Debate exists about the exact nature of the oxidant formed from SCN- by peroxidases [84-
86]. Data suggest that numerous oxidising species can be formed such as CN-, cyanate (OCN-
), cyanosulfurous (HO2SCN) and/or cyanosulfuric (HO3SCN) acid on decomposition of HOSCN 
[42]. In addition, certain studies support the formation of radical species including SCN• and 
OSCN-• [86-88]. HOSCN is not only formed by peroxidases, as HOCl, HOBr or secondary 
oxidants such as chloramines may oxidise SCN- directly [89, 90]. This mechanism has been 
suggested to occur as both a protective mechanism and as a harmful factor in certain 
inflammatory situations [89, 91, 92]. 
HOSCN decomposes into numerous products at physiological pH and temperature, with 
much debate about the mechanisms involved and the intermediates formed, owing to their 
instability [93]. It has been shown that at neutral pH, the final products formed from the 
decomposition of HOSCN are anions such as SCN–, SO32–, SO42– and OCN– [77]. A number of 
reactive intermediates have been proposed, including (SCN)2 (Reaction 1.4), HO2SCN 
(Reaction 1.5), HO3SCN (Reaction 1.6), HCN (Reaction 1.7) and trithiocyanate (SCN)3– 
(Reaction  1.8) [55, 72, 73, 75, 85, 94]. However, no direct evidence exists for the formation 
of some of these species due to the lack of stability, rather, their formation is inferred from 
the ratio of the final products. 
H2O2 + 2H++ 2SCN–  2H2O + (SCN)2    Reaction 1.4 
2HOSCN  HO2SCN + H+ + SCN–    Reaction 1.5 
HOSCN + HO2SCN  HO3SCN + H+ + SCN–   Reaction 1.6 
HO3SCN + H2O  HCN + H2SO4     Reaction 1.7 
 (SCN)2 + SCN–  (SCN)3     Reaction 1.8 
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HOSCN is generally classified as a weak oxidant, while HOCl and HOBr are strong oxidants, 
but the difference in chemistry and reactivity between HOCl/HOBr and HOSCN is seen in the 
number of their targets. HOCl and HOBr will react readily with lipids, nucleic acids and 
numerous amino acids, while HOSCN will preferentially oxidise cysteine (Cys) thiols and few 
others. 
 
1.5 Hypohalous acid induced damage to cellular constituents 
Hypohalous acids, in vivo, can cause damage to biomolecules, in addition to affording 
protection against bacteria and a multitude of pathogens [11]. The susceptibility of individual 
substrates to the damaging effects of hypohalous acids are defined by: 1) the location of the 
substrate in comparison to the oxidant, 2) the concentration of the substrate, 3) the second 
order reaction rate between the substrate and the oxidant and, 4) the concentration of 
antioxidants in particular biological compartments.  
 
1.5.1 Proteins 
Proteins exist in nearly every biological compartment and are favourable targets due to their 
abundance and high reactivity with hypohalous acids [95]. Kinetically, hypohalous acids 
preferentially react with the side chains of amino acids rather than the backbone amide sites 
[49, 68, 95, 96]. For example, HOCl will react with Cys thiols to a greater extent than the 
backbone amines and will only react with glutamine (Gln) or  aspartic acid (Asp) to a limited 
extent (Met > Cys >Cystine ≈ His > Trp > Lys > Tyr ≈ Arg > backbone amines > Gln ≈ Asp) [96], 
a similar order of reactivity has been noted for HOBr (Cys > Trp ≈ Met ≈ His > Cystine > Lys ≈ 
Tyr > Arg > backbone amines > Glu) [68]. In comparison, HOSCN is extremely selective, 
reacting almost exclusively with thiol containing amino acids (Cys), and selenols (seleno-
cysteine and seleno-methionine) residues, with some evidence for the reaction of HOSCN 
with tryptophan (Trp) (Seleno-Cys > Cys > Seleno-Met > Trp) [95, 97-99]. There are a few 
factors that govern which of these α-amino side chains will make a suitable substrate, which 
include, ease of accessibility due to protein structure and the pKa of the residue, which can 
also be affected by neighbouring amino acid residues [96].  
Due to the diverse nature of proteins with almost countless combinations of amino acids, 
peptide chain length and tertiary structure, the individual sensitivity of particular proteins to 
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oxidation by hypohalous acids can be difficult to determine, even using computational 
models. Thus, the susceptibility of a specific protein to oxidation by HOCl, HOBr or HOSCN is 
best determined by quantifying the reactions between the hypohalous acid and the protein 
directly. For example, computational data predicted that at a ratio of 300:1 HOCl:LDL, 30 % 
of tryptophan (Trp) residues would be oxidised, while experimental data showing that under 
these conditions HOCl, 60 % of the Trp residues contained on LDL were oxidised [100]. 
 
1.5.1.1 Sulfur-containing amino acids (Cysteine and Methionine) 
Organosulfur compounds containing a carbon-bonded sulfhydryl group are found on the α-
amino residues Cys and methionine (Met). These groups are nucleophilic, as Cys in the 
presence of a base is readily oxidised to give the covalently-linked organic disulfide, cystine. 
Despite HOSCN having a reaction rate with thiols (k, in the range of 104 – 106 M-1 s-1 [98]) that 
is significantly less than the rate between HOCl or HOBr, and thiols (k = 3 × 107 M-1 s-1 [68, 
96]), under some conditions, HOSCN can induce more damage at susceptible sites on account 
of its reduced activity with other targets [84, 91]. 
The reaction between Cys and a hypohalous acid will yield the sulfenyl halide (RS-X, where 
X= Cl, Br, SCN) (Reaction 1.9) [101, 102]. These species can be hydrolysed to the reversible 
sulfenic acid (RS-OH) (Reaction 1.10), or to form a disulfide bridge with another Cys residue 
(RS-SR’) (Reaction 1.11) [62]. It should be noted that these species are “reversibly oxidised”, 
as they can be reduced back to the parent thiol. The formation of all these species is strongly 
dependent on the immediate environment and pKa, which can be influenced by neighbouring 
amino acids. 
RSH + HOX (X=Cl, Br, SCN)  RS-X + H2O   Reaction 1.9 
RS-X + H2O  RS-OH + H+ + X     Reaction 1.10 
RS-X + R’SH  RS-SR’ + H+ + X-     Reaction 1.11 
The species described above can be reduced by the low-molecular mass thiol-containing 
tripeptide, glutathione (GSH) [103]. This results in the formation of a mixed disulfide (GS-SR) 
between GSH and the oxidised thiol (protein S-glutathionylation) [104]; GS-SR further reacts 
with glutaredoxin, recycling these species back to their original reduced thiol configuration 
(Reaction 1.12) [105]. These species are important in biological systems, as this action 
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between the oxidised thiols and GSH allow for the utilisation of cellular redox switches and 
various regulatory pathways [106]. 
RS-OH + GSH  GS-SR + H2O     Reaction 1.12 
When thiols are exposed to strong oxidising agents, such as HOCl, they can yield higher 
oxyacids, or the “irreversibly oxidised” products such as sulfinic (RS-O2H) (Reaction 1.13) and 
sulfonic (RS-O3H) (Reaction 1.14) acids [42, 107]. The formation of these higher oxyacids can 
lead to irreversible enzyme inactivation and the possible failure of essential redox switches 
within the cell [9, 108-110]. 
RS-OH + HOX  RS-O2H + H+ + X-    Reaction 1.13 
RS-O2H + HOX  RS-O3H + H+ + X-    Reaction 1.14 
Together with Cys, Met is another sulfur-containing α-amino acid and a major target of 
oxidation by HOCl and HOBr [68, 111]. Methionine residues are quite hydrophobic, and tend 
to exist close to or within the cell’s lipid bilayer. Thus, the residues most exposed to the 
aqueous cytosol tend to be at greater risk of oxidation [112, 113]. Oxidation of Met by either 
HOCl or HOBr leads to the formation of methionine sulfoxide (Reaction 1.15), this species 
can be reduced back to the original Met by methionine sulfoxide reductases or can be further 
oxidised to methionine sulfone (Reaction 1.16) [111, 112, 114]. Currently, there is no 
evidence for the oxidation of Met by HOSCN [48, 115]. 
RSCH3 + HOCl  RS(O)CH3 + H+ + Cl-    Reaction 1.15 
RS(O)CH3 + HOCl  RS(O)OCH3 + H+ + Cl-    Reaction 1.16 
 
1.5.1.2 Tryptophan (Trp) 
Trp is an essential amino acid in humans and the precursor to many biochemical-signalling 
molecules (e.g. serotonin) [116]. It is a favoured target of hypohalous acids [97] and the 
reaction between hypohalous acids (HOCl or HOBr) and Trp is determined by the 
environment surrounding the Trp residue, accessibility, pH and pKa [117, 118]. When a 
hypohalous acid (either HOCl or HOBr) oxidises a Trp residue, two intermediate species are 
hypothesised to be formed, the 3-halo-indolenine and/or N-halo-indole [119]. These two 
species rapidly react to yield oxyindolyalanine and/or 2-hydroxytryptophan [120]. The 
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products of the reaction between HOSCN and Trp have yet to be wholly understood, though 
Hawkins et al. have provided evidence for the formation of oxindolyalanine via the formation 
of an SCN-indole intermediate and other related oxidation products [97]. Another study has 
shown that HOSCN may play an indirect role in lipid dysfunction via the oxidation of Trp 
residues within apolipoprotein A-1 (apoA-1) of high density lipoproteins (HDLs) [121]. The 
study noted that HOSCN-modified apoA-1 caused a reduced efflux of cholesterol from 
cholesterol-loaded macrophages, which is another important role in the progression of 
atherosclerosis [121].  However, more recently, the role of HOSCN in mediating Trp oxidation 
in vivo has been questioned, owing to the fact that significant Trp loss requires a low pH 
[122]. 
 
1.5.1.3 Tyrosine (Tyr) 
Tyr is commonly found to exist in high levels within proteins and plays an important part in 
cell signalling cascades and transduction events and is probably the best characterised and 
documented substrate of hypohalous acids [123, 124]. HOCl and HOBr both undergo 
addition to the aromatic ring of Tyr to form 3-chlorotyrosine (3-Cl-Tyr) and 3-bromotyrosine 
(3-Br-Tyr), respectively [125, 126]. For years now, these species have been used extensively 
as biomarkers for hypohalous acid-mediated oxidative damage in vivo, as MPO is the only 
known enzyme to produce HOCl. Therefore, 3-Cl-Tyr production and detection in vivo is 
indicative of MPO specific oxidation. Secondary halogenation reactions result in the 
formation of 3,5-dichlorotyrosine or 3,5-dibromotyrosine (Figure 1.2) [127]. A major 
difference between HOCl and HOBr is the kinetics of the reaction with aromatic rings and 
double bonds, as seen by the difference between the halogenation of Tyr, with reports that 
bromination by HOBr occurs ≈5000-fold faster than the corresponding chlorination reactions 
[95]. These rate constants have been disputed recently; with a report describing a difference 
between HOBr and HOCl of only 250 fold, these differences in reactivities are most likely due 
to the slight differences in substrate composition and the pH at which the experiments were 
conducted [128]. 
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Figure 1.2: Formation of 3-chloro/bromotyrosine and 3,5-dichloro/dibromotyrosine after 
the halogenation of tyrosine by either hypochlorous or hypobromous acid. 
 
Tyr modifications have also been noted on exposure of proteins to the LPO/H2O2/SCN– 
system, however, the reaction is hypothesised to be caused by (SCN)2 rather than HOSCN 
[107]. Another report has also noted that a lack in reactivity between HOSCN and Tyr in the 
absence of LPO [97]. 
 
1.5.1.4 Histidine (His) 
Histidine is an amino acid with an imidazole functional group, that can react with HOCl and 
HOBr to form halamines [62, 67, 129]. The reactivity of the imidazole group with hypohalous 
acids is dependent on the protein environment [96]. The imidazole-derived halamines can 
rapidly transfer the Cl- or Br- to other amines, generating stable halamines with the 
regeneration of the parent compound [41]. 
The oxidation of His has been reported with both HOSCN and the LPO/H2O2/SCN- system 
[130]. His has been reported to stabilise the oxidising amino thiocyanate (RN-SCN) product, 
lowering the concentration of HOSCN and inhibiting its decomposition. The RN-SCN product 
still maintains the oxidising potential of HOSCN, allowing for the transfer of the SCN- to thiols 
[59]. 
 
1.5.1.5 Lysine (Lys) 
As outlined in Section 1.4.1, amines such as ys are able to react with HOCl and HOBr to form 
reactive chloramines and bromamines, respectively, though bromamines are generally less 
stable than chloramines [69]. These oxidants can retain the oxidising ability of HOCl or HOBr, 
and are able to mediate secondary oxidative reactions [131]. Depending on their structure, 
chloramines can oxidise Cys and Met to form disulfides and sulfonic acids [96]. 
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Lys is not thought to be a major target of HOSCN-induced oxidation, though RN-SCN species 
can be generated on Lys residues, they tend to be unstable at physiological pH [59]. 
 
1.5.2 DNA 
Experimental evidence suggests that both HOCl and HOBr can target nucleic acids, resulting 
in modification of bases and strand cleavage [132, 133]. There is little to no evidence showing 
any reaction between HOSCN and nucleic acids. Even at concentrations exceeding 5-fold the 
concentration required to produce antibacterial effects in the human mouth, HOSCN is 
reported to pose no threat to the genetic material of host tissues [134].  
HOCl reacts with DNA, RNA, free bases and nucleosides to form base-derived chloramines 
[71]. Initially, an unstable intermediate is formed after the reaction of HOCl with the 
heterocyclic ring NH groups of each nucleoside [66, 132]. The exocyclic NH2 groups of 
guanosine, adenosine and cytidine ribonucleosides are also sensitive to HOCl-induced 
modification [135]. These products are quite unstable and once formed, undergo a 
secondary chlorination, where the chlorine is transferred to the ring carbons, to give stable 
chlorinated products. These secondary products include 8-chloro-2’(deoxy)guanosine, 5-
chloro-2’(deoxy)cytidine, 8-chloro-2’(deoxy)adenosine and 5-chloro-uracil (a mutagenic 
thymine analog) (Figure 1.3) [136-139]. The formation of these products is theorised to cause 
the dissociation of the DNA double strand through a loss in Van der Waals force [135].  
 
Figure 1.3: The stable chlorinated nucleoside products. 
The products formed after the reaction of HOCl with various nucelosides (adenosine, 
guanosine and cytidine) and the nucleotide uracil (from top left to bottom right). 
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1.5.3 Lipids 
Phospholipids, cholesterol, and free fatty acids, all of which are important in the integrity of 
cellular membranes, are susceptible to reaction with one or more of the hypohalous acids. 
Lipid oxidation can occur with both HOCl and HOBr, but evidence for reaction with HOSCN is 
limited. There are reports that the MPO/H2O2/SCN- system is able to promote the 
peroxidation of plasma lipids (e.g. 17β-estradiol) suggesting that HOSCN may be able to play 
some part in the dysfunction of lipid transport [140] affecting arterial blood flow in women 
with coronary heart disease [141]. Recent evidence has also shown that HOSCN can oxidise 
low-density lipoprotein (LDL) cholesteryl esters to form F2-isoprostanes, lipid hydroperoxides 
and 9-hydroxy-10, 12-octadecadienoic acid (9-HODE) [142]. This is postulated to contribute 
to the progression of atherosclerosis via macrophage oxidised LDL (oxLDL) accumulation and 
foam cell formation [142]. The role of HOCl is relatively more defined, HOCl can react with 
the double bond of unsaturated fatty acids to produce oxysterols, and α- and β-chlorohydrins 
[143]. A similar reaction also occurs upon the addition of HOBr to unsaturated fatty acids to 
produce bromohydrins [144] (Figure 1.4A). Chlorohydrins are also produced in the reaction 
between HOCl and the carbon-carbon double bonds of fatty acyl groups of phospholipids 
[145], and the reaction between HOCl and cholesterol has, in one report produced 
chlorohydrins and epoxides [146], with another report describing the production of epoxides 
and hydroxyl derivatives of cholesterol [147].  The resulting chlorohydrin (also known 
generally as a halohydrin) can lead to the dysfunction of the cell’s lipid bilayer, increasing the 
cell’s permeability and causing cell death [148, 149]. 
Plasmalogens are phospholipids that are augmented in numerous organ systems such as the 
nervous and especially the cardiovascular system, and have been shown to play a role in 
cellular protection against certain ROS [150-152]. Plasmalogens can be readily halogenated 
by HOCl and/or HOBr at their vinyl ether bond, where the major products are α-halo-fatty 
aldehydes, 2-chlorohexadecanals, and lysophosphatidylcholines (LPC) (Figure 1.4B). All of 
which can further react with HOCl, and possibly HOBr, to form halohydrin-LPC [153-155]. 
These products may have possible roles the progression of atherosclerotic plaques [156]. 
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Figure 1.4: Products of the reactions between hypohalous acids and lipids.  
(A) Reaction between hypohalous acids with the double bond of unsaturated fatty acids, 
producing the oxysterols, chlorohydrin or bromohydrin. (B) Reaction between hypohalous 
acids and plasmalogens, forming lysophosphatidylcholine and a α-halo-fatty aldehyde. 
 
1.5.4 Carbohydrates 
Carbohydrates have a number of roles in biology. Polysaccharides, such as starch and 
glycogen, are involved in energy storage, while the monosaccharide, ribose, is an important 
part of co-enzymes (ATP, NAD and FAD) [157].  Most importantly, monosaccharides, the 
smallest unit of carbohydrates, such as glucose, play an integral part in metabolism 
(glycolysis), where glucose is converted into pyruvate and the free energy of the reaction is 
used to create the high-energy compounds, adenosine triphosphate (ATP) and reduced 
nicotinamide adenine dinucleotide (NADH) [158, 159]. 
Compared to other biomolecules, less is known of the role of hypohalous acids in the 
oxidation of sugars, possibly due to less favourable reaction kinetics [95]. It has been 
reported that the reaction between HOCl with mannitol and ribose is quite slow [23, 135]. 
The reaction of HOCl with proteoglycans of the extracellular matrix has been shown to 
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liberate polysaccharides via the interaction of HOCl with glycosaminoglycan chains [160]. As 
HOCl has also been shown to preferentially react with the nitrogen side-chains of amines 
contained on glycosamines, these modifications to the extracellular matrix have effects on 
cell adhesion and proliferation. The oxidation of sugars of the extracellular matrix has been 
hypothesised to have an effect in disease states such as atherosclerosis, where the 
extracellular matrix is involved in lesion formation [160].  
There is currently no data reporting reactions of sugars with HOSCN, though recently, 
monosaccharides have been modified into selenium-containing species to act as scavengers 
of hypohalous acids [161]. The results indicate that these selenium-sugars are potent 
scavengers of HOCl and HOBr oxidation (ca. 1 × 108 M-1 s-1 for HOCl, ca. 1.5 × 107 M-1 s-1 for 
HOBr), only being minimally slower than the reaction of HOCl/HOBr with the most reactive 
targets, such as Met, His, Tyr, Trp and Lys. The reaction of HOSCN with these selenium-sugars 
was considerably slower though (ca. 1 × 102 M-1 s-1), but the results demonstrate that the 
modification of simple sugars, by the addition of moieties that are reactive with hypohalous 
acids are potential scavenging and antioxidant molecules [161]. 
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1.6 Hypohalous acids and the cell 
1.6.1 Hypohalous acids and cellular constituents 
The interaction between hypohalous acids and cells can lead to a change in cellular 
homeostasis, either beneficially or detrimentally. Examples for the former include changes 
in immune status involved with the targeting and destruction of invading pathogens [51, 56]. 
On the other hand, excessive formation of hypohalous acids, especially in areas of 
inflammation can lead to the damage of otherwise healthy tissues [162].  
 
1.6.2 Cell signalling 
Calcium ions (Ca2+) are important regulators in cell signalling, as Ca2+ exerts many regulatory 
effects on cytoplasmic proteins. This effect is the result of the activation of ion channels or 
due to Ca2+ as a secondary messenger [163]. Ca2+ signalling plays an important role in the 
heart during ventricular contraction, acting to maintain ventricular depolarisation and HOCl 
is able to reversibly disrupt cellular Ca2+ that is dependent on protein thiols in rabbit 
ventricular myocytes. The rise in cytosolic Ca2+ was from internal sources, which has been 
hypothesised to be a major factor contributing to the mechanical dysfunction of the 
myocardium [164, 165]. HOCl has also be shown to induce the release of Ca2+ by activating 
the sarcoplasmic reticulum Ca2+ release channel of skeletal muscles, implying a role of HOCl 
in the regulation of calcium signalling [166]. Furthermore, HOCl and HOSCN have been shown 
to increase intracellular Ca2+ concentrations, via the inhibition of sarco/endoplasmic 
reticulum Ca2+-ATPases (SERCAs), which regulate the flux of Ca2+ between the 
sarco/endoplasmic reticulum and the cytosol [167]. By regulating the flux, SERCAs can 
mediate smooth, skeletal and cardiac muscle relaxation, growth and proliferation [168, 169]. 
HOCl and HOSCN, at concentrations as low as 10 µM, increase the intracellular Ca2+ levels of 
human coronary artery endothelial cells (HCAECs) via SERCA inhibition, leading to a loss of 
Ca2+ homeostasis, causing a stress response which is postulated to ultimately lead to cell 
death via apoptosis [170]. 
Mitogen-activated protein kinases (MAPK) are serine/threonine specific protein kinases 
[171] that  are involved in the direct signalling responses of a multitude of different stimuli. 
Such stimuli include mitogens, heat shock and pro-inflammatory cytokines, and they regulate 
processes such as apoptosis, mitosis, proliferation, gene expression and differentiation [172, 
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173]. Data shows that HOSCN can influence cellular signalling in HUVECs, leading to an 
upregulation of various tissue factors and monocyte adhesion molecules which is attributed 
to the activation of the transcription factor NF-κB [174, 175]. The activation of NF-κB may be 
the result of protein tyrosine phosphatase (PTP) inactivation, resulting in the 
hyperphosphorylation of MAPK and various other signalling molecules [176]. Another group 
of signalling proteins are the extracellular signal-regulated kinases (ERK), ubiquitously 
expressed protein kinases that are involved in survival pathways, mitosis and meiosis with 
the disruption of ERK commonly noted in various cancers [177]. ERK has two major isoforms, 
p44 (ERK 1) and p42 (ERK 2) and it has been shown that HOCl can activate ERK1/2 in HUVEC 
and fibroblasts [173], which are known to play a role in cell growth and differentiation as 
well as cell survival pathways [172]. In a model of arthritis, chondrocytes were exposed to 
HOCl and increases were detected in the phosphorylation of ERK1/2, p38 (another major 
class of MAP kinases) and c-Jun N-terminal kinase (JNK), and while JNK activation remained 
at basal levels, ERK1/2 and p38 was increased after a 20 min treatment with 30 µM HOCl. 
These results indicated that HOCl treatment led to pro-survival mechanisms within the cell 
due to a loss in viability and decreases in ATP and GSH concentrations [178]. Similar results 
were also noted upon the treatment of HUVECs with HOSCN [175]. In the J774A.1 murine 
macrophage cell line, HOSCN activated ERK 2 and p38, which was attributed to a disruption 
in phosphorylation within the cell due to the inactivation of PTPs [179]; this has been 
attributed to the low pKa active site Cys in PTPs, making them excellent targets for HOSCN 
oxidation. This oxidation by HOSCN and the inhibition of PTP is again similar to the effects of 
HOCl oxidation, in that the hyperphosphorylation of p38α, ERK1/2, MKK3/6 and MAPK 
signalling are the hallmarks of a survival/stress reaction which cause apoptotic cell death 
[179]. 
 
1.6.3 Hypohalous acids and cell death 
Cell lysis has been observed upon exposure of erythrocytes, neutrophils, macrophages, 
endothelial cells and epithelial cells to HOCl [180-183]. HOCl-induced cell lysis can usually be 
attributed to the oxidation of membrane proteins, which attenuates the transport of 
molecules across the cell membrane, leading to cell swelling and lysis [184]. However, this 
seems to be cell-type specific [19], and there are multiple targets and pathways known to be 
activated by HOCl, as HOSCN induced cell lysis to a greater extent in J774A.1 macrophages 
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than HOCl or HOBr, while HOCl lysed human coronary endothelial cells to a greater extent 
than HOSCN [91, 185]. 
Apoptosis, also known as “programmed cell-death”, is a cascade of biological events that 
ultimately leads to cell death. This is in contrast to necrosis, a form of traumatic cell death 
due to an acute injury. It has been accepted that the treatment of many different cell types 
with hypohalous acids can result in apoptosis [186-188]. Apoptosis is usually described as 
having two distinct mechanisms, caspase-dependent and caspase-independent pathways 
[189]. 
HepG2 and human foetal liver cells undergo apoptosis after treatment with HOCl at low 
concentrations (60 µM) via an increase in mitochondrial membrane permeability and the 
ensuing cytochrome c release resulting in caspase activation [187]. However in 
macrophages, the concentration of HOCl required to cause mitochondrial permeability 
transition (MPT) pore opening, and cytochrome c release is much higher, which tended to 
cause necrotic cell death before apoptotic cell death [190]. The ryanodine receptor (RyR) has 
also been implicated in the process of HOCl-induced cell death, as pre-treatment of human 
monocyte-derived macrophages (HMDM) with dantrolene completely abolished HOCl-
induced damage and cell death, implicating a strong connection between protein thiols and 
their control of intracellular Ca2+ in cell death [190]. In endothelial cells, it has been reported 
that if the caspases are inhibited, HOCl is unable to elicit apoptosis [191]. 
 Lloyd et al. [91] provided a case for HOSCN-induced apoptosis. HOSCN (50 µM) was 
postulated to be pro-apoptotic, due to its selectivity in targeting important mitochondrial 
thiol-containing proteins [192]. The evidence provided has shown that HOSCN is able to 
cause apoptosis more efficiently than the corresponding hypohalous acids, despite HOCl and 
HOBr reacting indiscriminately with numerous targets, especially membrane-bound proteins 
(resulting in cell lysis).  
The role of HOBr and HOSCN in apoptosis and necrosis has also been studied. H2O2 in the 
presence of SCN– has been shown to inhibit apoptosis, while H2O2 in the presence of Br– has 
been shown to induce apoptosis in HL-60 cells, SCN– has also been shown to inhibit apoptosis 
induced by EPO in eosinophils [174, 193]. Various studies have shown that exposure of 
HCAECs to HOSCN induces both apoptosis and necrosis while the exposure of HUVECs to 
HOSCN has been shown to inhibit apoptosis via the inhibition of caspase 3 cleavage in 
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HUVECs, meaning that these cells become resistant to apoptosis, perhaps via survival 
pathways [92, 174].  
These mixed results can be explained by differences in the cells used, and their unique 
reaction to the hypohalous acid, HOSCN. Another way these results can be rationalised is by 
the intrinsic differences in these studies such as treatment times, concentrations and media 
used. As explained previously, HOSCN is able to reversibly oxidise thiols, so lower 
concentrations, longer treatment periods and the replacing of treatment media with 
oxidant-free media, would allow for the repair of any damage. 
 
1.6.4 Hypohalous acids and bioenergetics 
1.6.4.1 Glycolysis 
HOSCN has long been known to inhibit bacterial glycolysis [194, 195]. In milk and the oral 
cavity, the requirement for H2O2 in the catalysis of HOSCN in the LPO (or SPO)/SCN-/H2O2 
system is met by bacterial metabolism [196], as the addition of catalase inhibits the 
formation of HOSCN and allows for the growth of Streptococcus cremoris (strain 972) in milk 
or Lactobacillus acidophilus in saliva [196]. 
When washed, stationary phase Streptococcus mutans incubated with LPO/SCN- and glucose 
had the utilisation of glucose inhibited by up to 90 %, [197]. This LPO/SCN-/H2O2 system was 
shown to be more bactericidal than H2O2 alone [198], due to the product formed in the 
reaction, HOSCN.  The product of the lactoperoxidase-catalysed oxidation of SCN- was found 
to inhibit glycolysis in strain 972 Streptococci after a 30 min treatment at 30 C. Analysis of 
the glycolytic enzymes revealed that hexokinase, aldolase and glucose 6-phosphate 
dehydrogenase were all inhibited to some degree [199]. The removal of LPO/SCN-/H2O2 from 
Streptococci led to the restoration of these enzymes activities. Growth inhibition was 
hypothesised to occur via the incorporation of a product from the LPO/SCN-/H2O2 system 
into protein thiols, removing these proteins from the functional pool, especially proteins 
involved in cell growth, glycolysis and glucose transport [200].  
In regards to mammalian glycolytic proteins, HOCl has also been found to oxidise 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in HCAECs, HUVECs and HMDMs after 
exposure, and it has been hypothesised that thiol targeting is the cause [103, 181, 185, 191]. 
Data have shown that HOSCN inhibits mammalian GAPDH and creatine kinase (CK) upon 
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exposure to cell lysates, and intact J774A.1 murine macrophages with evidence indicating 
the formation of sulfenyl thiocyanate species on these proteins, similar reactivity is reported 
with HOSCN and GAPDH in HCAECs [185, 201]. Exposure of erythrocytes to HOSCN resulted 
in the inactivation of glutathione S-transferases, ATPases and GAPDH, finding that the thiol 
specificity of HOSCN accounted for the deactivation, which for the ATPases, occurred 10 – 
10,000 times more potently than HOCl [84].  
 
1.6.4.2 The mitochondria 
The mitochondria are organelles found within most eukaryotic cells and are commonly 
known as the “powerhouse of the cell”, as they generate the majority of the ATP, the biologic 
energy currency [202]. However, the mitochondria are involved in multiple cellular pathways 
in addition to producing energy. Including roles in cellular signalling, differentiation, growth 
and death [203]. The role of mitochondria in these crucial mechanisms has implications for 
several disease processes, such as cardiomyopathy and ageing [32]. 
Many of the functional proteins and groups of the mitochondrial membrane are sensitive to 
modification by ROS, including complexes I (NADH dehydrogenase) and V (ATP synthase) 
[204]. Increases in the generation of ROS can cause damage to and cause alterations in 
mitochondrial proteins [205, 206]. Many mitochondrially-associated proteins contain critical 
thiols, such as iron-sulfur clusters, that could be oxidised by both HOSCN and HOCl, including 
aconitase 2, complexes I, II, III and V, and voltage-dependent anion channel 1 (VDAC-1) [207-
215]. The oxidation of these proteins has multiple consequences on the cell, as published 
data has shown that HOSCN is able to induce mitochondrial dysfunction, as assessed by 
changes in mitochondrial membrane permeability, at 100 µM after 2 h in HCAECs while HOCl 
was able to induce mitochondrial dysfunction at concentrations as low as 25 µM (1 h) and 
30 µM (20 min), respectively in HCAECs and HepG2s [185, 187]. 
 
1.7 Antioxidants and inhibitors of MPO 
Molecules that inhibit or have the ability to reverse the oxidation of other molecules, 
particularly biomolecules, are called antioxidants. Antioxidant systems are a defence to 
protect organisms from the potentially deleterious effects of ROS, reactive nitrogen species 
(RNS), free radicals, hypohalous acids and various biological oxidants, all of which are normal 
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metabolic by-products. In humans, the antioxidant system can be divided up into 2 broad 
sections, enzymatic and non-enzymatic antioxidants [216, 217]. These antioxidants include, 
but are not restricted to, superoxide dismutase (SOD), catalase, glutathione (GSH), 
glutathione reductase (GR), glutaredoxin (Grx), glutathione peroxidase (GPx), thioredoxin 
(Trx), peroxiredoxin (Prx) ascorbate (vitamin C), α-tocopherol (vitamin E), β-carotene, uric 
acid and ubiquinol. Additionally, given the role of MPO-derived oxidants in disease, there is 
significant interest in the development of MPO inhibitors, to prevent hypohalous acid 
formation and hence mitigate damage. 
 
1.7.1 Enzymatic antioxidants 
1.7.1.1 Superoxide dismutase 
SOD for a long time were known only as metalloproteins with unknown functions [218]. Now, 
SOD are recognised as a group of enzymes (CuZn-SOD and MnFe-SOD and Ni-SOD) that 
catalyse the dismutation of O2•− to H2O2 and O2 [7]. The SOD-catalysed dismutation of O2•− 
may be written as (Reaction 1.17); 
 2O2•− + 2H+ + 2e–  H2O2 + O2     Reaction 1.17            
In eukaryotic cells, the most common type of SOD is the CuZn (Copper-Zinc) form of the 
enzyme, found in the cytosol of virtually all animal cells. In humans, 3 forms of the SOD 
enzyme exist, SOD1 (CuZn-SOD, dimer) is located in the cytosol, SOD2 (Mn-SOD, tetramer) 
exists in the mitochondria and SOD3 (CuZn-SOD, tetramer) is located extracellularly [7, 219, 
220]. SOD is considered the major defensive antioxidant system against the damaging effects 
of O2•−, and research has demonstrated that the cellular damage caused by O2•− can be 
exacerbated by the inactivation of SOD by HOCl and chloramines [221]. 
 
1.7.1.2 Catalase 
Catalase is found in nearly every living organism that is exposed to oxygen. It catalyses the 
decomposition of H2O2 into water and molecular oxygen (Reaction 1.18) [222]. 
2H2O2  2H2O + O2      Reaction 1.18 
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Catalase also has one of the highest kcat of all enzymes known, converting ca. 5 × 106 of 
molecules of H2O2 to O2 and H2O per second [223]. H2O2 is a normal, but sometimes harmful 
by-product of cellular metabolism. Cells use catalase to yield less reactive molecules, 
removing an integral substrate from use by MPO to create hypohalous acids. In most 
eukaryotic cells, catalase is commonly found within peroxisomes [224], an organelle 
interestingly involved in the catabolism of long chain fatty acids, polypeptides, and in the 
biosynthesis of plasmalogens [225]. 
 
1.7.1.3 Glutathione antioxidant system 
GSH, GR, Grx, GPx and NADPH make up the glutathione antioxidant system. GSH is a 
tripeptide, specifically noted due to its active Cys residue, which is important in its 
antioxidant role [226, 227]. GSH acts by reducing disulfide bonds formed between 
cytoplasmic proteins, to Cys, by acting as an electron donor. In this process, GSH is oxidised 
to glutathione disulfide (GS-SG), which can be reduced back to GSH, through the action of 
the enzyme, GR and NADPH, as an electron donor (Figure 1.5) [228].  
GSH is a major antioxidant in cells, with concentrations varying between 0.1 – 10 mM in 
different cell types and it reacts directly with HOCl, with a rate constant in excess of 107 M-1 
s-1, making it an extremely good defence against oxidative onslaught [229]. These factors 
help to explain why a loss of macrophage and endothelial cell viability is only observed after 
treatment with HOCl on depletion of GSH [181, 230]. Other studies have noted that 
depending on the cell type being studied, GSH also seems to be able to protect membrane 
thiols from oxidation by HOCl [231, 232] and that it may be the primary antioxidant in 
preventing oxidation by HOCl in human monocyte-derived macrophages [103]. Not only is 
GSH a major target for HOCl, but also for HOBr and HOSCN [181, 232] as they are also 
reported to deplete intracellular GSH levels [91]. 
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Figure 1.5: Interrelationship of various roles played by the GSH antioxidant system in 
cellular redox homeostasis. 
 
Glutathione peroxidase (GPx) utilises GSH to catalyse the reduction of H2O2 to H2O, and lipid 
hydroperoxides to their corresponding alcohols. Several isozymes exist, each varies in their 
compartmentalisation and specificity, but interestingly, several of these isozymes (GPx 1, 2, 
3 and 4) contain seleno-cysteines in their active sites [233].  Reports have given evidence for 
the inactivation of GPx by HOSCN and HOCl via the rapid oxidation of seleno-cysteine 
residues important to the function of GPx [99, 234]. Protein S-glutathionylation occurs during 
times of increased oxidative stress, this is hypothesised to be a protective mechanism of the 
cell [235]. It is believed to protect key residues from becoming oxidised, while also reserving 
the pool of GSH in the cell, through their attachment to Cys residues.  Glutaredoxin (Grx) is 
responsible for catalysing the removal of GSH groups from proteins, thus also implicating this 
enzyme in cellular redox state and signalling [106].  
 
1.7.1.4 Peroxiredoxin antioxidant system 
Peroxiredoxins (Prx) are a family of enzymes (3 classes; 2-Cys Prx, 1-Cys Prx and atypical 2-
Cys Prx) that exist in many compartments of the cell such as the cytosol, mitochondria, 
plasma membranes and the peroxisomes [236]. Prx exhibit peroxidase activity that is 
dependent on the reduction status of GSH or thioredoxin and they exist as homodimers with 
an active site Cys (the peroxidatic Cys), that is oxidised to sulfenic acid after reaction with the 
ROS substrate [237]. The sulfenic acid is an intermediate that can react with the Cys of the 
other subunit, forming a disulfide that can be reduced by thioredoxin (Trx), regenerating the 
parent enzyme (Figure 1.6) [238]. 
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Figure 1.6: The mechanism of the Peroxiredoxin (Prx) antioxidant system, using the typical 
2-Cys Prx as an example. 
 
Work carried out by Stacey et al. showed that treatment of human umbilical vein endothelial 
cells (HUVEC) and Jurkat cells with HOCl led to the reversible oxidation of the active site, 
peroxidatic Cys residue of 2-Cys Prx [239, 240]. This work suggests that even at low levels of 
exposure, HOCl can modulate the redox status of Prx, possibly contributing to endothelial 
dysfunction in inflammatory states. While the effect of HOCl on Prx has been studied, little 
is known about the role of HOSCN in Prx modulation. 
 
1.7.1.5 Thioredoxin 
Thioredoxins (Trx) are a class of redox proteins that play a role in redox signalling and act as 
antioxidants by catalysing the reduction of protein Cys by thiol-disulfide exchange [241]. It 
reduces protein disulfides by attacking one of the sulfur atoms with a thiolate (S-) within the 
Trx protein, and its action has been found to promote the differentiation of the anti-
inflammatory M2 macrophage phenotype, offering protective effects against oxidative stress 
and cardiovascular disease [242-244]. 
Thioredoxins share many functions with Grx, but a major difference between them relates 
to the method by which they are reduced. Grx are reduced by GSH, while Trx is reduced by 
a reductase, the flavoenzyme thioredoxin reductase, in a reaction that is dependent on 
NADPH activity [245]. 
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1.7.2 Non-enzymatic antioxidants 
1.7.2.1 Ascorbate 
Ascorbic acid (vitamin C), is a water-soluble antioxidant present in many tissues throughout 
the human body, and present in plasma at concentrations between 25 – 150 μM [246]. It is 
a naturally occurring compound, found in fruits including oranges (≈50 mg/100 g), with one 
of the highest known natural sources being the camu-camu fruit (2400-3000 mg/100 g) [247]. 
For almost all animals, uptake of ascorbic acid is not essential, as they are able to synthesise 
it enzymatically, using glucose as a substrate, whereas certain primates including humans, 
and other animals such as guinea pigs and bats require dietary sources of ascorbic acid [248, 
249]. This can make it difficult when trying to study the effects of vitamin C supplementation 
in human disease. In vitro, ascorbate (the biologically active and dominant form of ascorbic 
acid) can scavenge O2•−, peroxyl radicals, HOCl (k ≈ 2 x 105 M-1 s-1 [23]), and it can inhibit LDL 
oxidation (Figure 1.7) [250]. Under certain conditions, ascorbate can also behave as a “pro-
oxidant”. In vitro, it is capable of reducing transition metals, and the conversion from 
ascorbate to dehydroascorbate can generate ROS [251], though this may be limited in a 
biological system, as any transition metals would likely be chelated or bound to proteins 
[252].  
 
 
Figure 1.7: Different forms of ascorbate and their reducing ability. AscH2, Ascorbic acid; 
AscH−, Ascorbate; Asc•−, Ascorbate radical; DHA, Dehydroascorbate. 
 
1.7.2.2 Urate 
Uric acid is the final product of purine catabolism in humans, and is produced via the 
oxidation of hypoxanthine by xanthine oxidase and xanthine dehydrogenase. At 
physiological pH, the majority of uric acid exists as the urate anion.  Urate exists in the blood 
plasma at concentrations ca. 300 μM [253] but is found in much lower concentrations inside 
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cells. Like ascorbate, urate is a strong reducing agent as it is attributed to over 50% of the 
antioxidant capacity in blood plasma [254]. 
Urate can directly react with singlet oxygen (1O2), HO•, and free radicals produced from 
peroxynitrite (ONOO–) [253]. But more importantly, urate is able to bind transition metals 
[255], this ability of urate may be important in the prevention of LDL peroxidation in the 
vessel wall [256]. Once urate reacts with a 1e-oxidant, the urate radical is formed, which can 
then be reduced by ascorbate. Urate is also a substrate of MPO, it is oxidised by MPO and 
H2O2 to 5-hydroxyisourate, which decays to allantoin, a marker of oxidative stress, and has 
been implicated in the progression of inflammation and cardiovascular disease [257-259]. 
 
1.7.3 MPO inhibitors 
MPO inhibitors are compounds used in an attempt to prevent hypohalous acid production 
and hence the pro-oxidative and inflammatory action of MPO. The inhibitors fall into three 
different classes, those that promote the accumulation of Compound II, irreversible 
inhibitors and those that bind reversibly to native MPO. The first two types of inhibitors act 
as alternative substrates that shift MPO away from its normal catalytic cycle and include 
chemicals such as dapsone, nitroxides, tryptophan analogues, 4-aminobenzoic acid 
hydrazide and 2-thioxanthines [260-265]. These methods of MPO inhibition are not 
necessarily effective, and research of late has preferred the use of reversible inhibitors, such 
as hydroxamate HX1, which competes with MPO substrates by filling the MPO haem binding 
pocket, blocking the oxidative capability of the enzyme without altering it permanently. 
Though the results indicate a drawback of these hydroxamates seems that they can be 
metabolised by MPO [266]. Moreover, because MPO is a haem peroxidase, with a strong 
oxidising ability, most of the inhibitors are oxidised by it, forming reactive radicals which can 
promote other potentially damaging reactions in vivo [267]. 
There is significant interest in the development of novel MPO inhibitors, as MPO and the 
oxidants formed by it are indicated to play a role in numerous diseases and disorders. The 
development of potent MPO-inhibitors would potentially therefore be an attractive 
therapeutic approach to prevent oxidant damage by MPO in inflammatory disease states, 
such as atherosclerosis and cystic fibrosis [22, 268, 269]. 
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1.8 The beneficial role of MPO and hypohalous acids 
1.8.1 Immune role and the destruction of invading pathogens 
MPO has been studied extensively in relation to bacterial cell killing. MPO, H2O2 and halide 
ions are able to induce cell death after exposure to bacteria, though this is generally 
attributed to the formation of hypohalous acids [52, 270]. As mentioned previously, MPO is 
an important part of neutrophil-mediated defence against infectious agents, with evidence 
of MPO-deficient mice being increasingly prone to bacterial infection compared to wild-types 
[271, 272]. In addition, the use of peroxidase inhibitors affects the ability of peroxidase-
positive neutrophils to destroy invading pathogens, but had little-to-no effect on peroxidase-
negative neutrophils, indicating a major role of MPO in the process of bacterial clearing 
[270]. A major part of neutrophil-mediated cell killing is the formation of HOCl in the 
phagosome and the reaction of HOCl with bacterial proteins, causing bacterial cell death [51, 
273]. Instead of causing cell death, HOSCN is widely considered to be a bacteriostatic agent, 
with the ability to reversibly modify bacterial cell proliferation and growth by interacting with 
critical thiols [56, 274]. Evidence for the bacteriostatic role of HOSCN is highlighted by 
observations of dysregulated or dysfunctional SCN- efflux in the epithelial secretions of cystic 
fibrosis affected cells where these cells have an impaired ability to kill bacteria [275, 276]. 
The cystic fibrosis transmembrane conductance regulator (CFTR) is the mechanism by which 
SCN- is transported into the airway epithelial mucosa. SCN- is found in abundant levels within 
the mucosa, along with enzymatically active LPO, leading to favourable conditions for HOSCN 
formation [36, 277]. Despite HOSCN being formed at high concentrations within the airway 
mucosa, there is no apparent damage to the host tissue [277-279]. It has been suggested 
that SCN- plays a protective role, preventing exposure of lung cells from the damaging effects 
of HOCl or H2O2, and that SCN- can inhibit the cytotoxic effects by reacting with HOCl and 
removing it [280]. 
 In spite of this evidence, it seems that humans deficient for MPO are not plagued by bacterial 
infections, and it has been argued that HOCl and HOSCN do not confer any advantage in 
bacterial cell killing [53, 281, 282]. However, evidence has shown that the MPO/H2O2/Cl– 
system does play an integral role in the destruction of invading bacteria [283, 284], but the 
part of the system that specifically destroys invaders has yet to be fully elucidated.  
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1.8.2 Oral health 
The predominate enzymes within the oral cavity are LPO and salivary peroxidase (SPO), 
which are closely related enzymes [73]. HOSCN plays a key role in maintaining oral health, 
with the formation of HOSCN determined by the availability of H2O2 and this requirement for 
H2O2 in the LPO (or SPO)/SCN-/H2O2 system is met by bacterial metabolism [196]. Due to the 
high levels of SCN- (ca. 1 mM) in saliva, HOSCN tends to be the main oxidant formed within 
the oral cavity, also because SCN- is the preferred substrate for LPO/SPO [285]. 
The role of HOSCN in the mouth is to inhibit glucose metabolism in cariogenic bacteria, and 
by inhibiting glucose metabolism in these bacteria HOSCN reduces the formation of dental 
caries [286, 287]. HOSCN is formed in the mouth because of its apparent innocuity to the 
cells of the oral cavity. This is in contrast to the formation of other hypohalous acids within 
the oral cavity, such as HOCl formed during gingivitis, which can cause host tissue damage 
[288]. 
 
1.9 MPO, hypohalous acids and disease progression 
MPO and hypohalous acids have been implicated to have a role in a wide number of non-
infectious and inflammatory diseases. There is considerable evidence on the role of MPO and 
hypohalous acids in the progression of cystic fibrosis (CF), a chronic inflammatory disease 
characterised by fibrotic scarring, and abnormal Cl- and Na+ transport via the CFTR channel 
across airway epithelial cells [289, 290]. CF is associated with chronic inflammation and the 
formation of hypohalous acids, owing to the infiltration of macrophages into the pulmonary 
tract and the dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) 
[22, 291].  Considerable levels of enzymatically active MPO are found within the sputum of 
CF patients [292], while 3-Cl-Tyr is detected at high concentrations in the sputum and 
bronchoalveolar lavage fluid of CF patients [293]. This implicates MPO and HOCl as a 
damaging oxidant that could incite further inflammation under these conditions. 
SCN– is also transported into the bronchi by the CFTR channel [294], and it has been noted 
that SCN– is not released in cells without the CFTR channel [276], therefore it has been 
hypothesised that inflammation and damage to the pulmonary tract can be exacerbated by 
the reduction of SCN–, which is postulated to scavenge the more damaging hypohalous acids, 
HOCl and HOBr [275, 276]. 
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There is also evidence for the hypohalous acid-induced oxidation of DNA, that can cause 
mutations to various suppressor genes, which have been hypothesised as a beginning step 
in cancer progression, with various studies showing that chlorinated bases are able to be 
incorporated into genomic DNA [295-298]. An increase in the expression of MPO, along with 
the presence of the biomarkers for HOCl and HOBr induced damage (3-Cl-Tyr and 3-Br-Tyr) 
in diseased tissue, has also been linked to the progression of various neurodegenerative 
diseases such as Alzheimer’s disease and Parkinson’s disease, and atherosclerosis, consistent 
with the role of MPO in pathogenesis [165, 269, 299, 300].  
 
1.9.1 Atherosclerosis 
Evidence linking MPO with atherosclerosis is extensive. This disease is a major source of 
morbidity and mortality in the western world [301]. It is marked by the deposition of 
cholesterol and macrophages in medium and large sized arteries [302]. These depositions 
form “fatty streaks”, and can be seen in otherwise healthy people [303]. The fatty streaks 
become enlarged over many years by causing cellular proliferation and the deposition begins 
to invade the vessel lumen, obstructing blood flow, becoming an atherosclerotic 
plaque/lesion. Rupture of the lesion can occur, leading to thrombosis and jeopardising 
oxygen supply to vital organs, especially the heart and brain [304].  
There are a number of hypotheses postulated to explain the initiation and early stages of 
atherosclerosis. One being the oxidative modification hypothesis [305], that states that LDL 
is atherogenic once it has been modified or oxidised into a product that is readily internalised 
by macrophages [306]. The accumulation of this oxidised LDL (oxLDL) results in the formation 
of foam cells, a hallmark of atherosclerosis (Figure 1.8) [305, 307, 308]. MPO-derived 
oxidants are postulated to play a key role in this process, with the H2O2/MPO/Cl- system 
known to be a promoter of LDL oxidation [309, 310]. Foam cells are fat-laden macrophages 
formed when macrophages are recruited to inflammatory areas, such as a lesion of a blood 
vessel, where oxLDL is recognised by scavenger receptors such as CD36 and SRB1, and 
oxidised by hypohalous acids, in an attempt to correct the inflammatory stimuli [142, 311, 
312]. The foam cells then migrate into the subendothelial space, where they perpetuate the 
inflammatory situation [313]. 
Atherosclerotic lesions contain cells of an inflammatory nature, such as neutrophils, 
monocytes and tissue macrophages, all of which are known to release MPO upon activation 
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[314]. There is evidence that these cells release enzymatically active MPO in lesions of all 
grades in humans [269]. Lesion formation also induces the release and activation of other 
inflammatory mediators, such as, interleukin-1, tumour necrosis factor and interferon-γ 
[314, 315]. The MPO-derived oxidants are implicated in disease development owing to the 
detection of the HOCl biomarker, 3-Cl-Tyr in atherosclerotic lesions [299, 316]. Additionally, 
3-Cl-Tyr and MPO have also been found to co-localise in atherosclerotic lesions, with MPO 
acting as a predictive marker for adverse cardiac events in patients with angina, with 
evidence showing those deficient in circulating MPO having lower chances of adverse 
cardiovascular events [21, 317, 318].  
 
 
Figure 1.8: The oxidative modification hypothesis of atherosclerosis. 
LDL becomes trapped and oxidised by smooth muscle cells, endothelial cells or macrophages, 
and oxidised LDL stimulates the recruitment of monocytes. Monocytes differentiate into 
macrophages which uptake oxidised LDL, becoming foam cells. Oxidised LDL can lead to foam 
cell necrosis, which causes the release of lysosomal enzymes, and endothelial damage. Taken 
from Diaz et al. [305]. 
 
There is also evidence that shows MPO co-localising with macrophages in atherosclerotic 
plaques, implicating MPO and its products as an important factor in plaque progression 
and/or plaque formation [269, 317]. Not only does the MPO/H2O2/Cl- system and HOCl 
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promote LDL oxidation [131, 310], aggravating the problem in the vasculature, but MPO has 
also been reported to attenuate the protective effects of high density lipoproteins (HDL) via 
the modification of apoA-1 [319, 320]. The oxidation of apoA-1 directly affects HDL’s ability 
to remove cholesterol from the circulation, accelerating the formation of lipid-laden foam 
cells [320, 321]. When analysed, the HDL-derived apoA-1 is found to contain 3-Cl-Tyr in 
elevated levels when compared against healthy samples, further increasing the evidence for 
HOCl involvement in the inflammatory process of atherosclerosis. [322]. 
Notwithstanding the wealth of knowledge about the role of HOCl, less is known about the 
mechanisms controlling MPO and HOSCN in the disease process. This is possibly due to the 
lack of a biomarker of HOSCN-specific oxidation; however evidence suggests that there is 
indeed a role for HOSCN in atherosclerosis. Serum SCN- levels correlate with increased LDL 
deposition and fatty streak formation in the aorta, and levels of SCN- increase in areas with 
MPO-induced damage to lipids and LDL [87, 140]. There is also evidence of HOSCN modifying 
Cys residues contained on apoB-100, and oxidising cholesteryl esters, resulting in formation 
of lipid hydroperoxides, 9-HODE and F2-isoprostanes, resulting in macrophage lipid 
accumulation and foam cell formation [142]. 
There is further, indirect evidence that implicates HOSCN in the progression of 
atherosclerosis, such as elevated levels of homocitrulline, a carbamylated protein product of 
the reaction between OCN- and Lys residues, have been detected within diseased arteries 
and used as an independent marker to predict future adverse events [81]. As OCN- is a major 
breakdown product of HOSCN, HOSCN may be an important factor in the oxidation process, 
it has long been known that smokers are at an increased risk of developing many diseases, 
particularly atherosclerosis, coupled with evidence that smokers have high plasma SCN- (up 
to 300 μM in excessive smokers), it implicates the MPO/H2O2/SCN- system in the 
development/exacerbation of atherosclerosis [80, 82, 83]. 
 
1.9.1.1 Biomarkers for hypohalous acid detection 
The role of HOCl in disease, such as atherosclerosis, is supported by the detection of elevated 
levels of a HOCl-specific marker of oxidative damage, 3-Cl-Tyr [125, 126, 299]. Similarly, 3-
Br-Tyr has been employed as a biomarker for HOBr-induced damage [127]. However, there 
is no specific biochemical marker for HOSCN induced damage. Despite the evidence given, 
the destructive role of HOSCN in the disease process has only been evinced indirectly. 
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Homocitrulline formation has been suggested, as one of the decomposition products of 
HOSCN, OCN-, can cause protein carbamylation [81]. But a problem arises when trying to 
detect homocitrulline formation in a cardiovascular disease setting, being that OCN- is also 
elevated under uremic conditions, meaning that implicating HOSCN as responsible for tissue 
damage during cardiovascular disease is not absolute. HOSCN has been shown to oxidise Trp 
residues on proteins [97], so a biomarker based on a Trp oxidation product has been 
proposed. However, it has been noted that the HOSCN oxidation of Trp requires strongly 
acidic conditions, making it an unlikely candidate to detect HOSCN-induced oxidation in vivo 
[122]. Despite the drawbacks, the identification of a HOSCN-specific biomarker, or new 
methods to determine HOSCN-induced damage to biomolecules would allow further insights 
into the role played by HOSCN in disease. 
 
1.10 Summary 
The data compiled supports theories that explain the roles of haem peroxidases in normal 
cellular function and their roles in cellular dysfunction. The peroxidases are capable of 
oxidising halide anions (Cl–, Br– and SCN–) into their respective hypohalous (HOCl and HOBr) 
and (pseudo)hypohalous (HOSCN) acids. With SCN– being the preferred substrate for MPO, 
it is estimated that ca. 50% of the H2O2 consumed by MPO is utilised to create HOSCN. 
Considering this, less is known about the physiological role of HOSCN, other than its 
antimicrobial role in the human immune system. This warrants further investigations of 
HOSCN and its ability to cause cellular dysfunction, as published data has currently identified 
HOSCN as being as able to oxidise proteins related to glucose metabolism, but does not 
investigate the functional effect of HOSCN in regards to affecting the energy producing 
pathways such as glycolysis and oxidative phosphorylation. HOSCN is a chemical that oxidises 
thiols; therefore it has the potential to perturb the activity of several key thiol-dependent 
enzymes. Additionally, due to its reversible nature and similarity to other hypohalous acids, 
a biomarker for HOSCN-induced oxidation has not been identified. Therefore this Thesis 
explores the role of HOSCN in the induction of macrophage damage, which is relevant to the 
pathological process of atherosclerosis. It will also assess the utility of vibrational 
spectroscopy as a tool to determine the patterns of damage induced by HOSCN to cells. 
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1.11 Hypothesis 
The oxidant, HOSCN, generated by MPO from SCN- ions, targets critical thiol containing 
proteins, such as those related to glucose metabolism and mitochondrial respiration, 
modulating macrophage cell function in a detrimental manner. HOSCN attenuates the 
biologic process of energy production, more potently than HOCl via its specificity for thiol 
oxidation, which could promote the development of atherosclerosis. 
 
1.12 Aims of this Thesis 
Chapters 3 – 7 of this thesis will address the following experimental aims based on the 
projects hypothesis. 
1) To determine the mode of oxidation and assess the ability of HOSCN and HOCl to 
target intracellular thiols in macrophages. 
2) Identify, establish and understand the consequences of reversible thiol 
modifications on energy production, mitochondrial function and cellular function in 
HOSCN-oxidised macrophages. 
3) To use novel methods to detect, identify and understand the damage caused by 
HOSCN. 
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2 Materials and Methods 
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2.1 General Information 
This Chapter details the methods and materials used throughout the thesis. All 
concentrations noted are the final concentration unless stated otherwise. 
The pH of all solutions was measured using a Radiometer Analytical PHM220 pH meter with 
a pHC2401 probe (Radiometer Analytical, France) calibrated with pH 4 and 7 or pH 7 and 10 
standards. 
Centrifugation was performed on all samples using an Eppendorf Refridgerated Micro-
Centrifuge (Model 5215R, Eppendorf, Germany), unless stated otherwise. 
Nanopure water, hereinafter referred to as npH2O, was filtered through a four stage Milli-Q 
sysem (Millipore Water, Australia). 
 
2.2 Materials 
All chemicals and solutions were purchased commercially, were of the highest purity 
available and were stored and used as instructed by the manufacturer, unless stated 
otherwise. All aqueous solutions were prepared in npH2O. 
Table 2.1: Suppliers of Reagents 
Reagent Supplier 
Acetone Merck 
Aldolase antibody (IgG) Abcam 
ATPlite Luminescence ATP Detection Assay System Perkin Elmer 
Bicinchoninic Acid (BCA) Reagent Pierce 
Bio-Spin 6 Columns in Tris Buffer BioRad 
p-Biotin Cayman Chemical 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Bradford Assay Reagent BioRad 
L-Buthionine Sulfoximine Sigma-Aldrich 
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) Life Technologies  
Catalase Sigma-Aldrich 
Cell Lytic M Cell Lysis Reagent Sigma-Aldrich 
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Cell-Tak Cell and Tissue Adhesive BD Bioscience 
CHAPS Sigma-Aldrich 
COX-4 antibody (IgG) Abcam 
Complex II Enzyme Activity Microplate Assay Kit Sapphire Bioscience 
Coomassie Blue G-250 Dye Sigma-Aldrich 
DAz-2 Cayman Chemical 
DCP-Bio1 Merck Millipore 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Dulbecco’s Modified Eagles Medium (DMEM) JRH Biosciences 
ECL-Plus, Enhanced Chemiluminescence Substrate  Perkin-Elmer 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Foetal Calf Serum Invitrogen 
GAPDH antibody (IgG) Abcam 
Glucose Uptake Cell-Based Assay Kit Cayman Chemical 
Glutathione (Reduced) (GSH) Sigma-Aldrich 
Glycolysis Cell-Based Assay Kit Cayman Chemical 
GSH Antibody (IgG2a) ViroGen Corp. 
HEPES Sigma-Aldrich 
High Sensitivity Streptavidin-HRP Thermo-Fisher 
30% (v/v) Hydrogen Peroxide (H2O2) Merck Millipore 
5-Iodoacetamidofluorescein (IAF) Invitrogen 
JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’ - 
tetraethylbenzimidazolylcarbocyanine iodide) 
Life Technologies 
L-Lactate Sigma-Aldrich 
Lactoperoxidase (LPO) Calbiochem 
Lowry DC Protein Assay Reagents Biorad 
Mammalian Mitochondrial Isolation Kit Thermo Fisher Scientific 
N-ethylmalemide (NEM) Sigma-Aldrich 
Nicotinamide adenine dinucleotide (NADH), disodium salt Roche 
NuPAGE Novex 4-12% Bis-Tris Gel (1 mm, 10 well) Invitrogen 
Phenylmethylsulfonyl Fluoride (PMSF) Sigma-Aldrich 
Phosphate Buffered Saline (PBS) Amresco 
Protease Inhibitor (Complete) Roche Diagnostics 
RIPA Buffer Sigma-Aldrich 
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Ruthenium(II)tris(bathophenantrolinedisulfonate) (RuBPS) Jomar Bioscience 
Seahorse XF Base Medium In Vitro Technologies 
Seahorse XF Calibrant Solution In Vitro Technologies 
Seahorse XF Mito Stress Test Kit In Vitro Technologies 
Seahorse XF Glycolysis Stress Test Kit In Vitro Technologies 
Skim Milk Powder Bonlac Foods Ltd 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich 
10 – 15 % (v/v) Sodium Hypochlorite Sigma-Aldrich 
Sodium Diphosphate Sigma-Aldrich 
Sodium Monophosphate Sigma-Aldrich 
Sodium Pyruvate Sigma-Aldrich 
Sodium Thiocyanate Sigma-Aldrich 
ThioGlo-1 Berry & Associates Inc 
Trichloroacetic acid (TCA) Sigma-Aldrich 
Tris Sigma-Aldrich 
Trisephosphate isomerase antibody (IgG) Abcam 
Triton X-100 Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
 
 
2.3 Methods 
2.3.1 Tissue Culture 
2.3.1.1 J774A.1 Murine Macrophage Cells 
The cell experiments performed in this Thesis were carried out using J774A.1 cells, a murine 
macrophage-like cell line. J774A.1 cells were obtained from the American Type Culture 
Collection (ATCC, USA) (cat. no TIB-67). Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% v/v foetal bovine serum (FBS) and 2 mM L-
glutamine that was warmed to 37 ˚C prior to use. During passaging cells were maintained in 
a 175 cm2 flask under sterile conditions in an incubator of humidified 5% CO2 at 37 ˚C. When 
cells had reached 80 - 90% confluency, cells were washed twice with DMEM, and then 
scraped from the flask into 10 mL of fresh DMEM, with 2 mL of the cell suspension then 
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transferred into a new flask and the total volume adjusted to 25 mL with DMEM. Cells 
reached confluency 3-4 days after splitting. 
Prior to experiments (excluding experiments using the Seahorse XF24), cells were washed 
with fresh DMEM, followed by scraping from the flasks into 10 mL of DMEM and counted 
using a haemocytometer in the presence of 0.2% v/v trypan blue to exclude dead cells. Cells 
were then centrifuged in an Allegra X-15R centrifuge (Beckman Coulter) at 400 g for 5 min at 
22 ˚C to form a cell pellet. The pellet was then resuspended in DMEM to the required density 
of cells (1 × 106 cells mL-1) before being transferred to 12-well plates and incubated in a sterile 
environment, overnight at 5% CO2 and 37 ˚C. 
 
2.3.1.2 Oxidant treatment of J774A.1 cells 
For the experiments detailed in this Thesis, cells were plated at a density of 1 × 106 cells mL-
1 in DMEM into 12-well plates and allowed to adhere overnight in an incubator of humidified 
5% CO2 at 37 ˚C. The next day, cells were washed twice with HBSS prior to incubation with 
oxidant (at 22 ˚C). Following oxidant treatment, the oxidant was removed and the cells were 
again washed with HBSS to prevent confounding reactions resulting from residual oxidant or 
media components. 
 
2.3.1.3 Mitochondrial isolation of J774A.1 cells 
The mitochondrial isolation was performed using a mammalian mitochondrial isolation kit 
(Thermo Fisher Scientific). Before the isolation of J774A.1 mitochondria, protease inhibitors 
(1x) were added to the volumes of Reagent A and C to be used in the experiment. After the 
cells had been treated with oxidant (Section 2.3.1.2), 3 wells (1 × 106 cells/well) of cells were 
combined and then the consolidated cell suspension (3 × 106 cells) was pelleted by 
centrifugation at 900 g for 2 min at 4 ˚C. The supernatant was carefully removed and 
discarded before 800 µL of Reagent A was added and the mixture was vortexed at medium 
speed for 5 sec and incubated on ice for exactly 2 min. After the incubation, 10 µL of Reagent 
B was added, and the mixture was vortexed at high speed for 5 sec. The tube was then 
incubated on ice for 5 min, with vortexing at maximum speed for 5 sec every minute. After 
the final vortexing, 800 µL of Reagent C was added to the tube and it was inverted several 
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times to mix (being careful not to use the vortex again). The tube was then centrifuged at 
700 g for 10 min at 4 ˚C. After centrifugation, the supernatant was removed, being careful 
not to disturb the pellet. The supernatant was transferred to a new tube and the pellet was 
discarded. The supernatant was then centrifuged at 3000 g for 15 min at 4 ˚C. After the 
centrifugation, the supernatant was a purified fraction of the cytosol, while the pellet 
contained the mitochondria. The supernatant was removed carefully and placed into new 
tubes to be stored on ice. The pellet was then washed with 1 mL of Reagent C and centrifuged 
at 12,000 g for 5 min at 4 ˚C. After centrifugation, the supernatant was removed and 
discarded, then the pellet was lysed in 75 µL mitochondrial lysis buffer (0.5% Triton X-100; 
30 mM Tris, pH 7.4; 200 mM KCl; 5 mM Ethylenediaminetetraacetic acid [EDTA]; 0.5 mM 
phenylmethylsulfonyl fluoride [PMSF]; 1x protease inhibitors) with vigorous vortexing for 1 
min, after which the samples were stored on ice. To determine the protein concentration of 
both the cytosolic and mitochondrial fractions, a DC Lowry protein assay was performed and 
concentration was determined against a BSA standard curve (Section 2.3.12.3). 
 
2.3.2 Preparation and Quantification of Oxidants 
2.3.2.1 Generation of HOSCN and decomposed HOSCN 
HOSCN was produced enzymatically from the reaction of H2O2 with SCN- in the presence of 
LPO [91]. 2 µM LPO was incubated with 7.5 mM NaSCN in 10 mM pH 6.6 potassium 
phosphate buffer. The solution was then left on ice and aliquots of H2O2 (3.75 mM) were 
added every minute for 5 min. The suspension was then left to incubate on ice for 10 min, 
prior to the addition of 200 IU of catalase for 5 min. The solution was then filtered through a 
10 kDa molecular mass cut-off filter (Pall Corporation) by centrifugation 12,000 g for 5 min 
at 4 ˚C to remove the LPO and catalase from the solution. The concentration of HOSCN 
generated was quantified immediately by the TNB assay (Section 2.3.2.3) using the molar 
absorption coefficient (ε)  ε412 = 14150 M-1 cm-1 [323]. 
Decomposed HOSCN (dHOSCN) was generated by producing HOSCN and leaving it in the dark 
for at least 24 h at 22 ˚C. This control is limited by the variability of HOSCN’s breakdown 
products, and the individual chemicals and their concentrations can differ between samples, 
and the products added to the cell may vary slightly. 
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2.3.2.2 Preparation of HOCl 
HOCl was prepared by diluting a concentrated stock solution of 1 M NaOCl into npH2O to a 
final concentration of 1 mM. This solution was then diluted further into HBSS immediately 
prior to addition to the cells. The concentration of –OCl in the stock solution was determined 
at pH 11 after the dilution into 0.1 M NaOH and measured using the optical absorbance at 
292 nm, where ε292 = 350 M-1cm-1 [57]. 
 
2.3.2.3 TNB assay 
The yellow coloured 5-thio-2-nitrobenzoic acid (TNB) reacts with hypohalous acids (HOX) and 
N-chloramines to produce a colourless dimer 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB). The 
concentration of HOX can be determined by monitoring the consumption of TNB, noting the 
1:2 stoichiometry as shown in Reaction 2.1 using the ε412= 14150 M-1cm-1 [41]. 
HOX + 2 RSH  RSSR + H2O + H+ + X-    Reaction 2.1 
The TNB reagent is prepared before each experiment by alkaline hydrolysis of DTNB. DTNB 
(0.4 mg mL-1) was prepared in 50 mM NaOH and incubated in the dark for 10 min to produce 
a dark yellow stock TNB solution. The TNB was diluted 1:50 into 100 mM sodium phosphate 
buffer (pH 7.4) to attain a working solution with an optical absorbance of 0.4 – 0.5 at 412 
nm. The oxidant (5 µL) was then added to the diluted TNB reagent (1 mL final volume), and 
incubated in the dark for 10 min. The absorbance was measured at 412 nm and the 
consumption of TNB was determined by comparison to a blank solution containing TNB and 
an identical volume of buffer [115]. 
The samples were pipetted into plastic cuvettes (1 cm path length) and the absorbance was 
measured on a UV-Vis spectrophotometer (Shimadzu). 
 
2.3.3 Intracellular thiol quantification 
2.3.3.1 ThioGlo-1 assay 
Methyl-maleimidobenzochromenecarboxylate (ThioGlo-1) (Berry & Associates Inc) was used 
for the determination of the concentration of free thiols and reduced protein thiols in cell 
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lysate preparations via a fluorometric method [324]. ThioGlo-1 is a maleimide-based 
fluorescent dye that binds to thiols within a sample, resulting in an increase in fluorescence. 
A stock solution of ThioGlo-1 (2.4 mM) was prepared in acetonitrile and stored at 4 ˚C in the 
dark. Prior to addition to the sample cells were treated with oxidant (Section 2.3.1.2) and 
then lysed in npH2O (1 mL). An equal volume (50 µL) of sample was added to a solution of 
ThioGlo-1, diluted 1:100 in PBS (pH 7.4). The resulting solutions were incubated in the dark 
for 5 min at 22 ˚C in a 96-well plate. Thiol concentrations were determined by fluorescence 
spectroscopy at λex = 360 nm and λem = 530 nm using a SpectraMax M2e plate reader. The 
concentration of thiols in each sample was determined by constructing a GSH (0 – 10 µM) 
standard curve [324] and an N-Ethylmaleimide (NEM) (1 mM; 15 min) control to block 
available thiols in the sample and probe for any sample auto-fluorescence or non-thiol 
interactions that would cause fluorescence.  
 
2.3.3.2 5-Iodoacetamidofluorescein (IAF) labelling 
The thiol-reactive fluorescent probe, 5-iodoacetamidofluorescein (IAF) was used in 
conjunction with N-ethylmaleimide (NEM), a thiol reactive alkene, to probe oxidant treated 
samples for reversible protein thiol oxidation (Figure 2.1). 
 
 
Figure 2.1: Using IAF to probe for reversible oxidation products. 
The outline of the IAF labelling procedure used to probe J774A.1 proteins for reversible thiol 
oxidation. Beginning with reduced thiols (1) certain thiols are oxidised by treatment of 
J774A.1 cells with hypohalous acids. (2) After oxidation, residual reduced thiols were 
alkylated with NEM to block them from taking part in further reactions. (3) Oxidised thiols 
were then reduced using DTT and (4) alkylated with the fluorescent probe, IAF. 
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 Cells were plated at a density of 1 × 106 cells mL-1 and exposed to oxidant (Figure 2.1, Step 
1). After oxidant treatment, cells were lysed in 225 µL of labelling buffer (35 mM HEPES, 0.1% 
Triton X, 100 mM NEM and 1 × Roche complete protease inhibitor), scraped with a syringe 
plunger and left to incubate on an orbital shaker for 30 min at 22 ˚C. NEM was present in the 
lysis buffer to alkylate any protein thiols that were in a reduced state (Figure 2.1, Step 2). 
After incubation, the lysate was centrifuged at 8000 g for 5 min at 4 ˚C. The supernatant was 
then passed through a Bio-Spin 6 spin column (BioRad) to remove excess NEM, according to 
the manufacturer’s instructions. The solution that passed through the spin columns was then 
removed and transferred into new 1.5 mL tubes. Dithiothreitol (DTT) was then added to a 
final concentration of 1 mM and the samples were incubated for 10 min at 22 ˚C to reduce 
any thiols that had been reversibly oxidised (Figure 2.1, Step 3). Solutions were passed 
through Bio-Spin 6 spin columns to remove residual DTT, and  IAF (80 mM in DMSO) was 
added to the sample solution (to a final concentration of 100 µM) and left to react with 
reduced thiols for 10 min at 22 ˚C in the dark (Figure 2.1, Step 4) [325]. The protein 
concentration was determined at this time using the Bradford protein assay (Section 
2.3.12.1). Protein precipitation was performed via the addition of TCA (10% w/v) to the 
sample, followed by incubation for 20 min at -20 ˚C. Protein was pelleted by centrifugation 
at 8000 g for 15 min at 4 ˚C. The supernatant was then removed and the protein pellet was 
washed with ice-cold acetone (80% v/v) and stored either overnight or for 2 h at -20 ˚C. 
Following the incubation, samples were centrifuged at 10000 g for 15 min at 4 ˚C and the 
acetone was removed. The protein pellet was then dissolved in lithium dodecyl sulfate (LDS) 
sample buffer (Invitrogen, CA) for gel loading. The pellets were dissolved in various volumes 
of PBS to ensure equal protein loading onto the gel (800 µg mL-1) [185, 326]. 
 
2.3.3.3 DAz-2 derivatisation 
 DAz-2 is a cell permeable probe used to detect protein sulfenic acid formation [327, 328]. 
Modification of protein cysteines and sulfenic acid formation can result in the modification 
of protein function, with these species reported to act as molecular switches, responsible for 
activating or deactivating enzyme activity [109, 329]. Cells (1 × 106 cells mL-1 in a 12-well 
tissue culture plate) were loaded with DAz-2 in DMSO (to a final concentration of 500 µM) 
or a vehicle control (DMSO – 1% v/v) in DMEM (1 mL) for 1 h at 37 ˚C and 5% CO2. After 
incubation with DAz-2, the cells were washed three times with HBSS and treated with HOSCN 
or HOCl for 1 h at 22 ˚C (Section 2.3.1.2). Following treatment, the cells were washed three 
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times with HBSS and then lysed with 100 µL cold lysis buffer (50 mM Tris pH 8.0, 150 mM 
NaCl, 1% NP-40, 2 × Roche complete protease inhibitor), scraped with a syringe plunger and 
incubated on an orbital shaker for 20 min at 4 ˚C. Lysates were centrifuged 10000 g for 20 
min at 4 ˚C to remove insoluble cell debris and the supernatant was collected. Protein 
concentration was determined at this time using the BCA protein assay (Section 2.3.12.2). 
Following the incorporation of DAz-2 into the cellular proteins, the DAz-2 azide-tagged 
proteins were ligated to p-Biotin via the click reaction [330]. The lysate was incubated with 
p-Biotin (200 µM) and DTT (5 mM) for 2 h at 37 ˚C while being shaken. The reaction was then 
quenched by protein precipitation with ice-cold acetone (1 mL) and the samples were 
incubated for 2 h at -20 ˚C or overnight at -80 ˚C. Following incubation, the samples were 
collected and centrifuged at 10000 g for 20 min at 4 ˚C to pellet the proteins. The pellets 
were washed once again and centrifuged before being dissolved in LDS sample buffer 
(Invitrogen) (assuming complete recovery after acetone-precipitation). The protein pellets 
were dissolved in various volumes to ensure equal protein loading onto the gel 
(800 µg mL-1). 
2.3.3.4 DCP-Bio1 derivitisation 
DCP-Bio1 is a cell permeable probe, similar to DAz-2, in that it displays specificity for sulfenic 
acid formation. However, the DCP-Bio1 is already conjugated to biotin, which removes the 
need to perform a click reaction. Cells (1 × 106 cells mL-1 in a 12-well tissue culture plate) 
were loaded with DCP-Bio1 in DMSO (to a final concentration of 500 µM) or a vehicle control 
(DMSO) in DMEM (1 mL) for 1 h at 37 ˚C and 5% CO2. After incubation with DCP-Bio1, the 
cells were washed three times with HBSS and treated with HOSCN (0, 50, 100 or 200 µM) for 
1 h at 22 ˚C (Section 2.3.1.2). After oxidant treatment, the cells were washed three times in 
HBSS and then mitochondrial isolation was performed (Section 2.3.1.3). After mitochondrial 
isolation and protein concentration determination, the samples were prepared in LDS 
sample buffer (Invitrogen) and reducing buffer (Invitrogen) to a volume of 40 µL and a 
protein concentration of 800 µg mL-1 before being loaded onto the gel. 
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2.3.4 SDS-PAGE 
2.3.4.1 Gel electrophoresis 
SDS-PAGE was used to separate proteins and was carried out using either 10- or 12-well pre-
cast mini-format 4-12% acrylamide Bis-Tris gels (Life Technologies). Samples were loaded 
into wells and separated at 80 V until the dye front reached the gel interface (typically 15 
min); samples were then run at 120 V for 1 h or until the dye front reached the bottom of 
the gel. Gels which were used to separate samples labelled with IAF were run in the dark. 
The running buffer contained 50 mM Tris, 0.38 M glycine and 0.1% (w/v) SDS, pH 7.4. 
 
2.3.4.2 IAF visualisation 
Following electrophoresis, gels were transferred to npH2O and then scanned for IAF 
fluorescence at λex = 488 nm and λem = 530 nm on the PharosFX system (BioRad, USA). The 
gels were then fixed in 200 mL of 30% (v/v) methanol and 10% (v/v) acetic acid for 4 h  
at 22 ˚C. 
2.3.4.3 Protein staining 
The protein loading was assessed after fixing the gels in gel-fixing solution (30% (v/v) 
methanol and 10% (v/v) acetic acid in npH2O) overnight at 4 ˚C in the dark. Gels were stained 
in a solution of 200 nM ruthenium (II) tris (bathophenantroline disulfonate) (RuBPS), 30 % 
(v/v) methanol and 10 % (v/v) acetic acid, overnight at 22 ˚C in the dark. Gels were then 
washed in npH2O for 10 min in the dark, prior to measuring RuBPS fluorescence at  λex = 532 
nm and λem = 605 nm, by scanning the gel on the PharosFX system (BioRad, USA).  
 
2.3.5 Western blotting 
Following electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF) 
membranes (iBlot transfer stacks, Life Technologies) using an iBlot 2 transfer device 
(Invitrogen). The transfer occurred for 7 min (program 0), prior to blocking of the membrane 
as described below. 
 47 
 
2.3.5.1 DAz-2, DCP-Bio1 derivatisation and biotinylated proteins 
The membrane was blocked in 3 % (w/v) BSA in PBS containing Tween 20 (PBST, 0.1 % v/v 
Tween 20) overnight at 4 ˚C. The membrane was then washed with PBST (3 × 10 min) and 
incubated with 1:10000 horseradish peroxidase (HRP)-streptavidin in 3 % (w/v) BSA-PBST for 
1 h at 22 ˚C. The membrane was then washed with PBST (3 × 10 min) and immunodetection 
was performed using ECL Plus chemiluminescence reagents (Perkin-Elmer, USA), and 
detected by a ChemiDoc XRS (BioRad, USA). 
 
2.3.5.2 S-Glutathionylated proteins 
Membranes were blocked for 1 h at 22 ˚C in 3 % (w/v) BSA in PBST containing 2.5 mM NEM 
(to alkylate any thiol contaminates present in the BSA solution). Membranes were incubated 
overnight at 4 ˚C with 1:1000 anti-GSH IgG (ViroGen) in PBST. Prior to washing with PBST (3 
× 10 min), and incubation with 1:1000 anti-mouse rabbit IgG (Cell Signalling) in 3 % BSA (w/v) 
in PBST. Finally, the membranes were washed with PBST (3 × 10 min) before 
immunodetection was performed using ECL Plus chemiluminescence reagents (Perkin-Elmer, 
USA), and detected by a ChemiDoc XRS (BioRad, USA). 
 
2.3.5.3 Housekeeping proteins 
β-actin, GAPDH, trisephosphate isomerase, fructose-bisphosphate aldolase and COX-4 
antibodies were used to determine the protein loading in experiments involving DCP-Bio1 
(Section 2.3.3.4). PVDF membranes were incubated with their respective loading control 
antibody at 1:1500 in 3 % (w/v) BSA-PBST for 1 h at 22 ˚C. The PVDF membranes were then 
washed with PBST (3 × 10 min), then incubated with 1:1000 anti-mouse rabbit IgG (Cell 
Signalling) in 3 % BSA (w/v) in PBST. The membrane was then washed with npH2O and dried 
before being immunodetection was performed using ECL Plus chemiluminescence reagent 
(Perkin-Elmer, USA), and detected by a ChemiDoc XRS (BioRad, USA). 
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2.3.5.4 Protein staining of membranes 
Protein staining of the PVDF membranes was carried out to confirm equal protein loading. 
Membranes were incubated with 0.05% (w/v) Coomassie R-250 (Sigma-Aldrich) in 
isopropanol/acetic acid/npH2O (50:20:30) for 2 h. The membrane was then destained for 1 
h in isopropanol/acetic acid/npH2O (13:10:77), and washed with npH2O, dried, before being 
immunodetection was performed using ECL Plus chemiluminescence reagents (Perkin-Elmer, 
USA), and detected by a ChemiDoc XRS (BioRad, USA). 
 
2.3.5.4.1 Determining band density and analysis 
After gel or PVDF membrane imaging was performed, the detected bands were analysed 
using Image J software. The images were opened in the software and the bands were 
selected using the “Select Lane Tool” (Figure 2.2A). The image was then processed and the 
band intensities were plotted, with each lane being plotted on separate graphs (peaks display 
each bands intensity within a specific lane) (Figure 2.2B). To integrate the peaks, the “Line 
Tool” was used to create a rolling ball integration (Figure 2.2C), which was done separately 
for each protein lane. Finally, the “Wand Tool” was used to determine the area under each 
peak of a lane (Figure 2.2D, example of Lane 1), which was then summed to give the total 
density of detected product in each lane, which was expressed as Area (Pixels). 
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Figure 2.2: Using Image J to analyse protein band densities. 
An example of protein density analysis using Image J. The scanned gel or membrane with 
detectable proteins was scanned and the image is loaded into the program. (A) An example 
of a typical scanned gel with Lane 1; 0 µM HOSCN, Lane 2; 50 µM HOSCN and Lane 3; 100 µM 
HOSCN being selected using the lane selection tool. (B) An intensity plot of the selected lanes 
(numbers correspond with lanes). (C) Peaks after using a rolling ball method of integration. 
(D) Using the “Wand Tool” the area of the peaks is determined (example of Lane 1 results). 
 
2.3.6 Seahorse XF24 extracellular flux assays 
Extracellular flux analysers probe energy producing pathways of the cell in real time. The 
XF24 analyser determines oxygen consumption rates (OCR) and extracellular acidification 
rates (ECAR) in cellular extracellular media to determine the functions of oxidative 
phosphorylation and glycolysis. The analyser measures OCR and ECAR by isolating small 
volumes of media above a cellular monolayer. Oxidative phosphorylation and glycolysis 
cause almost instantaneous and measureable changes to the dissolved oxygen and free 
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protons in the media and it is these changes that allow for the determination of respiratory 
and glycolytic activity of cells. 
 
2.3.6.1 Plate and cartridge preparation 
To maintain cell adhesion during the flux assay, the XF24-well cell plate was prepared with 
BD Cell-Tak adhesive (BD Biosciences). The Cell-Tak adhesive was added to the XF24 plate 
(0.28 cm2/well) at a density of 3.5 µg/cm2 in NaHCO3. Cell-Tak (20 µL) was added to each well 
and the plate was left for 30 min at 22 ˚C in a sterile environment. The Cell-Tak solution was 
removed and 300 µL npH2O was added to the plate and it was left for 5 min at 22 ˚C. The 
npH2O was then removed and the plate was left to dry in a sterile environment for 30 min at 
22 ˚C. Once dry, the plate could be stored for up to 7 days at 4 ˚C. 
Prior to running the Seahorse XF24, the XF24 probes on the cartridge were rehydrated with 
1 mL XF calibrant solution (Seahorse Bioscience, USA) and left to incubate in a CO2-free 
environment overnight at 37 ˚C (Figure 2.3). 
 
Figure 2.3: XF24 probe cartridge and cell culture plate. 
A profile view of the XF24 probe cartridge (green) containing the wells to place inhibitors, and 
the XF24 cell culture plate which was coated with Cell-Tak adhesive and plated with J774A.1 
macrophages. 
 
2.3.6.2 Preparation of cells 
The media was removed from the J774A.1 cells in 175 cm2 flasks and the cells were washed 
3 times with HBSS before the media was replaced with XF base medium (Seahorse 
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Bioscience, USA), containing 2 mM L-glutamine, 40 mM sodium pyruvate and 10 mM glucose 
(glucose was excluded if the glycolysis assay was to be performed). The cells were then 
scraped from the flask and a small volume (10 µL) of cell suspension was removed for 
counting in the presence of 0.2% (w/v) trypan blue (10 µL) to exclude dead cells. Cells were 
then centrifuged in an Allegra X-15R centrifuge (Beckman Coulter) at 400 g for 5 min at 22 
˚C to form a cell pellet. The pellet was then resuspended in the XF base medium and the cells 
were plated on the XF24 plate at 7.5 × 104 cells/well. Cells were excluded from 4 wells on the 
XF24 plate as they served as background wells (as per the manufacturer’s instruction). The 
plate was then left to incubate in a CO2-free incubator at 37 ˚C for 45 min. 
 
2.3.6.3 Baseline Glycolysis 
Before treating the cells with oxidant, the rehydrated probe cartridge was prepared with 100 
mM glucose (50 µL) pipetted into PORT A (Figure 2.4A), to be injected during the stress test. 
The rehydrated probe cartridge was then placed into the Seahorse XF analyser to undergo a 
15 min calibration. The cells (7.5 × 104 cells/well) were then treated with HOSCN (10, 25, 50, 
100 µM) or a pH 6.6 potassium phosphate buffer control in the base medium (no glucose) 
(final volume = 450 µL) and the cell plate was placed directly into the XF24 analyser. 
Extracellular acidification rate (ECAR) was monitored over a period of 13 cycles (Equilibrate, 
Loop (3 ×), Shake (3 min), Wait (3 min), Measure (3 min), End Loop, Inject PORT A, Loop (10 
×), Shake (3 min), Wait (3 min), Measure (3 min), End Loop). After the experiment had 
concluded the cells were removed from the analyser, media on the cells was removed and 
the cells were lysed in 25 µL RIPA buffer and glycolytic activity was normalised to cell protein 
after quantification using the DC Lowry protein assay (Section 2.3.12.3). 
 
2.3.6.4 Glycolysis stress test 
After incubation in the CO2-free incubator at 37 ˚C for 45 min, the cells were treated with 
HOSCN (10, 25, 50, 100 µM) or a pH 6.6 potassium phosphate buffer control in the base 
medium (no glucose) (final volume = 300 µL) for 1 h at 22 ˚C. While the cells were being 
treated, the rehydrated probe cartridge was prepared with the glycolysis inhibitors to be 
injected during the stress test. Glucose (50 µL, 100 mM) was pipetted into PORT A, 
Oligomycin (50 µL, 13.5 µM) was pipetted into PORT B and 2-deoxyglucose (50 µL, 1 M) was 
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pipetted into PORT C (Figure 2.4B). The cartridge was then placed into the Seahorse XF24 
analyser to undergo a 15 min calibration. After treatment, the cell plate was placed into the 
XF24 analyser and the glycolysis stress test was performed. The experimental protocol to 
observe ECAR was setup in the following order: Equilibrate, Loop (3 ×), Shake (3 min), Wait 
(3 min), Measure (3 min), End Loop, Inject PORT A, Loop (3 ×), Shake (3 min), Wait (3 min), 
Measure (3 min), End Loop, Inject PORT B, Loop (3 ×), Shake (3 min), Wait (3 min), Measure 
(3 min), End Loop, Inject PORT C, Loop (3 ×), Shake (3 min), Wait (3 min), Measure (3 min), 
End Loop. After the experiment had concluded, the cells were removed from the analyser, 
media on the cells was removed and the cells were lysed in 25 µL RIPA buffer and glycolytic 
activity was normalised to cell protein after quantification using the DC Lowry protein assay 
(Section 2.3.12.3). 
 
 
Figure 2.4: XF24 probe cartridge port layout for baseline glycolysis and glycolysis stress test 
experiments. 
 
2.3.6.5 Baseline mitochondrial respiration 
Before treating the cells with oxidant, the rehydrated probe cartridge was prepared by 
placing it in the Seahorse XF24 analyser to undergo a 15 min calibration. The cells were 
treated with HOSCN (50, 75, 100, 150 µM) or a pH 6.6 potassium phosphate buffer control 
in the base medium (final volume = 500 µL) and the cell plate was placed directly into the 
XF24 analyser and baseline oxygen consumption rate (OCR) was monitored over a period of 
10 cycles (Equilibrate, Loop (10 x) Shake (3 min), Wait (3 min), Measure (3 min), End Loop). 
After the experiment had concluded the cells were removed from the analyser, media on the 
cells was removed and the cells were lysed in 25 µL RIPA buffer and glycolytic activity was 
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normalised to cell protein after quantification using the DC Lowry protein assay (Section 
2.3.12.3). 
 
2.3.6.6 Mitochondrial stress test 
After incubation, the cells were treated with HOSCN or a pH 6.6 potassium phosphate buffer 
control in the base medium (final volume = 500 µL) for 1 h at 22 ˚C. While the cells were 
being treated, the cartridge was prepared with the mitochondrial inhibitors to be injected 
during the stress test. Oligomycin (55 µL, 15 µM) was pipetted into PORT A of the cartridge, 
FCCP (61 µL, 5 µM) was pipetted into PORT B and a cocktail of antimycin A (5 µM) and 
rotenone (5 µM) (68 µL) was pipetted into PORT C (Figure 2.5). The cartridge was then placed 
into the Seahorse XF24 analyser to calibrate. After treatment, the cell plate was then placed 
into the XF24 analyser and the mitochondrial stress test was performed. The experimental 
protocol to observe OCR was setup in the following order: Equilibrate, Loop (3 ×), Shake (3 
min), Wait (3 min), Measure (3 min), End Loop, Inject PORT A, Loop (3 ×), Shake (3 min), Wait 
(3 min), Measure (3 min), End Loop, Inject PORT B, Loop (3 ×), Shake (3 min), Wait (3 min), 
Measure (3 min), End Loop, Inject PORT C, Loop (3 ×), Shake (3 min), Wait (3 min), Measure 
(3 min), End Loop. After the experiment had concluded the cells were removed from the 
analyser, media on the cells was removed and the cells were lysed in 25 µL RIPA buffer and 
metabolic activity was normalised to cell protein after quantification using the DC Lowry 
protein assay (Section 2.3.12.3). 
 
Figure 2.5: XF24 probe cartridge port layout for the mitochondrial stress test experiment. 
 
 54 
 
2.3.7 Determination of mitochondrial membrane potential 
JC-1 (Life Technologies) is a membrane permeable dye that exhibits potential-dependent 
accumulation in the mitochondria. In the mitochondria JC-1 becomes a red fluorescent J-
aggregate which can leak out into the cytosol with changes in membrane potential, where 
the aggregates are lost and JC-1 fluoresces green [331, 332]. This ability allows for the 
determination of mitochondrial membrane potential after the treatment of cells with 
oxidant. JC-1 experiences an emission shift from green (λem = 529 nm) in the cytosol to red 
(λem = 590 nm) in the mitochondria due to the formation of these J-aggregates. Therefore, 
mitochondrial depolarisation is indicated by a decrease in the red/green fluorescence 
intensity ratio. After oxidant treatment, the media was removed from the cells and they were 
washed twice with HBSS, before adding 1 mL of HBSS to each well of cells, and scraping them 
from the plate. Pipetting was then performed to ensure that the cells were mixed 
homogeneously throughout the HBSS. The cells were pipetted into flow cytometry tubes and 
labelled with 2 µM JC-1 and left to incubate for 15 min in an incubator of humidified 5% CO2 
at 37 ˚C. Positive controls were treated with 5 µM of the mitochondrial uncoupler, CCCP, for 
10 min in an incubator of humidified 5% CO2 at 37 ˚ C. When complete the cells were analysed 
using a BD flow cytometer scanning both the emission shift from 590 nm to 530 nm, 
indicating a leak of the JC-1 from inside to mitochondria (red) to the cytosol (green). This leak 
is viewed as a percentage of the total counts (10, 00 counts), that is then expressed as a ratio 
(red/green), with a decrease in the ratio indicating an increase in the permeability of the 
mitochondrial permeability transition pore (MPTP). 
 
 
 
2.3.8 ATP assays 
Intracellular adenosine triphosphate (ATP) is a marker for cell viability as ATP is required by 
and present in all metabolically active cells [333]. The concentration of ATP declines rapidly 
in cells undergoing failure in the mechanisms that synthesise ATP, such as glycolysis or 
oxidative phosphorylation. The ATPlite assay (Perkin Elmer) is based on the production of 
white light via the reaction between ATP, luciferase and D-luciferin (Reaction 2.2). 
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ATP + D-luciferin + O2                        ADP + PPi + CO2 + oxyluciferin + light          Reaction 2.2 
 
Cells (1 × 106 cells/well) were treated with HOSCN (0, 25, 50, 75, 100, 150 and 200 µM) for 1 
h at 22 ˚ C. After oxidant treatment, the oxidant was removed and the cells were washed with 
HBSS 3 times. 1 mL of HBSS was pipetted onto the cells and they were scraped from the wells 
of the 12-well culture plate before pipetting 100 µL of the cell suspension into a 96-well 
white-walled plate. Mammalian cell lysis solution (50 µL) was added to the wells containing 
the cell suspension and the plate was shaken on an orbital shaker for 5 min at 22 ˚C. After 
shaking, 50 µL of the substrate solution was added to the wells and the plate was shaken 
again on the orbital shaker for 5 min at 22 ˚C. Finally, the plate was removed from the shaker 
and incubated in the dark for 10 min at 22 ˚C before the luminescence was recorded at 570 
nm (10 sec integration) using a SpectraMax L luminescence plate reader (SpectraMax). ATP 
concentration was determined using ATP standards that were included with the ATPlite 
luminescence ATP detection kit (Perkin Elmer). The results were normalised to cellular 
protein concentration using a BCA protein assay to quantify protein in the lysate from the 
cell suspensions (Section 2.3.12.2). 
 
2.3.9 Lactate dehydrogenase assays 
Lactate dehydrogenase (LDH) is a ubiquitous cytoplasmic protein that catalyses the reduction 
of pyruvate to lactate, using NADH as a co-factor. Viable cells are able to prevent the diffusion 
of LDH into the extracellular milieu, therefore, the LDH assay is a reliable measure of cell 
viability as a loss in viability is correlated with LDH release into the media.  
 
Pyruvate + NADH  L-Lactate + NAD+  
Reaction 2.3: The conversion of pyruvate to lactate by lactate dehydrogenase using NADH 
as a co-factor.  
 
Luciferase 
Mg2+ 
M 
M 
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Thus the extent of cell lysis can be quantified by measuring LDH activity in the media as a 
proportion of the total LDH activity (intracellular and extracellular). After oxidant treatment, 
the media on the cells is removed and kept on ice. Then 1 mL of npH2O is added to the cells, 
they are lysed using a syringe plunger and left to incubate for 20 min at 4 ˚ C. After incubation, 
10 µL of sample (media and lysate) are added into separate wells on a 96-well plate along 
with 200 µL of the reaction buffer (0.15 mg/mL NADH and 2.5 mM sodium pyruvate in PBS). 
The plate is mixed briefly and the absorbance is recorded at 340 nm every 5 min for 7 cycles 
on an M2e plate reader (SpectraMax) to determine the rate of change of NADH absorbance 
as a measure of LDH activity (Reaction 2.3). The cellular viability is then determined using 
Equation 1. 
 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
∆ 𝐼𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐿𝐷𝐻
∆ 𝐼𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐿𝐷𝐻 + ∆ 𝐸𝑥𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐿𝐷𝐻
 × 100 
Equation 1: Lactate dehydrogenase viability equation. 
 
2.3.10 Lactate assays 
Lactate is an end product of glycolysis, which is released into the extracellular environment; 
its levels are directly correlated with intracellular glycolytic activity [334, 335]. The glycolysis 
cell-based assay kit (Cayman) allows for the determination of lactate concentration in the 
extracellular media of cells in culture. The cells (1 × 106 cells/well in a 12-well plate) were 
treated with HOSCN (0, 10, 25, 50 and 100 µM) as well as decomposed HOSCN (dHOSCN) for 
1 h at 22 ˚C. After treatment, the cell plate is centrifuged at 1000 g for 5 min before 10 µL of 
the media on top of the cells is removed and pipetted into the well of a 96-well plate. Next, 
90 µL of assay buffer is pipetted into the well containing the sample and finally 100 µL of the 
reaction solution is pipetted into each well. The plate was then incubated on a plate shaker 
for 30 min at 22 ˚C before absorbance was read at 490 nm on an M2e plate reader 
(SpectraMax). The lactate concentration was determined using L-lactate standards included 
in the kit (0 – 1 mM). 
For further time points, all the media above the cells was removed and replaced with HBSS 
before the cells were incubated in a humidified 5% CO2 environment at 37 ˚C for a further 1 
h. At the end of the second hour, 10 µL of the media on top of the cells was removed and 
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pipetted into the well of a new 96-well plate, where the assay was performed as described 
above. 
 
2.3.11 Glucose uptake assay 
Glucose uptake is a process achieved by the action of glucose transporters, which move 
glucose down a concentration gradient. This is a highly regulated and dynamic process, which 
is dictated by environmental conditions [336]. These experiments were performed to 
determine whether the effect of HOSCN on glycolysis was influenced by changes to glucose 
uptake into the cell. 
 
2.3.11.1 Plate reader assay 
For the plate reader assay, cells were plated directly into clear bottom 12-well plates (1 × 106 
cells/well) in 1 mL DMEM and left to incubate overnight in an incubator of humidified 5% 
CO2 at 37 ˚C. The next day the media in the plate was aspirated and the cells washed with 
PBS (glucose-free) twice before being treated with 1 mL HOSCN (0, 25, 50, 100, 200 µM) 
supplemented with 500 µM 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose 
(2-NBDG) in PBS for 1 h at 22 ˚C. Cells were also treated with 50 µM Apigenin, which is a 
flavonoid that inhibits glucose uptake, and supplemented with 500 µM 2-NBDG in 1 mL PBS 
for 20 min at 22 ˚C as a positive control. The plate was then centrifuged for 5 min at 400 g 
and the PBS was aspirated. The cells were washed twice with 500 µL cell-based assay media 
(item no. 10009322, Cayman chemical), being careful not to disturb the cells. The assay 
media was aspirated once more before being replaced with 500 µL of cell-based assay media 
and analysis using the M2e plate reader (SpectraMax) (λex = 485 nm, λem = 535 nm centre 
focus). 
 
2.3.11.2 Fluorescence microscopy 
After plating and overnight incubation (1 × 106 cells/well) (as Section 2.3.11.1), cells were 
washed with PBS (glucose-free) twice and then treated with 1 mL HOSCN (0, 50, 100 µM) 
supplemented with 500 µM 2-NBDG in PBS for 1 h at 22 ˚C. Cells were also treated with 50 
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µM Apigenin supplemented with 500 µM 2-NBDG in PBS for 20 min at 22 ˚C served as a 
positive control. The plate was then centrifuged for 5 min at 400 g and the media was 
aspirated. The cells were washed twice with 1 mL cell-based assay media as above (Section 
2.3.11.1). The assay media was aspirated once more, before being replaced with 500 µL of 
cell-based assay media and anlysis using a fluorescent microscope (λex = 485 nm, λem = 535 
nm). 
 
2.3.12 Protein concentration assays 
2.3.12.1 Bradford protein assay 
The Bradford protein assay was used to determine the protein concentration in samples 
containing IAF to be separated by SDS-PAGE, as it is compatible with the various components 
present in the cell lysis buffer (with the exception of samples treated with DAz-2 or DCP-Bio-
1, the BCA assay was used in this case). The Bradford assay is based on the direct binding of 
Coomassie brilliant blue G-250 dye (CBBG) to proteins at Arg, Trp, Tyr, His, and Phe residues 
[337, 338]. Anionic CBBG binds to these residues producing an absorbance maximum at 595 
nm, whilst the free dye in solution has an absorbance maximum at 470 nm. The assay 
measures the CBBG complex with the protein, which results in an absorption peak shift at 
595 nm.  
The Bradford reagent solution (BioRad) was diluted 1:5 in npH2O, and passed through filter 
paper to remove insoluble particles of dye prior to use. The assay was performed by the 
addition of 200 µL of the Bradford reagent to 10 µL of protein sample or standard on a 96-
well plate, in triplicate. Solutions were mixed by gentle shaking, followed by 5 min incubation 
at 22 ˚C. The absorbance was recorded at 595 nm on an M2e plate reader (SpectraMax), and 
the protein concentration was determined by the inclusion of protein standards prepared 
with BSA (0.05 – 1.0 mg mL-1). 
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2.3.12.2 Bicinchoninic acid protein assay 
Cellular protein concentration was measured using a Bicinchoninic acid (BCA) assay. The BCA 
assay measures the formation of Cu+ from Cu2+ by the Biuret complex in alkaline solutions of 
proteins using BCA, which has a strong absorbance at 562 nm [339, 340]. The BCA assay 
reagent was prepared by mixing BCA solution A (Pierce, 0.1 g sodium bicinchoninate, 2.0 g 
Na2CO3·H2O, 0.16 g sodium tartrate, 0.4 g NaOH, 0.95 g NaHCO3 made up to 100 mL) and 4% 
CuSO4 (w/v) in a 50:1 ratio. 200 µL of the BCA working reagent was mixed with 10 µL of 
samples and standards, on a 96-well plate, in triplicate. Solutions were mixed by gently 
shaking, followed by a 30 min incubation at 60 ˚C. The absorbance was recorded at 562 nm 
on an M2e plate reader (SpectraMax), and the protein concentration was determined by the 
inclusion of protein standards prepared with BSA (0.05 – 1.0 mg mL-1). 
 
2.3.12.3 DC Lowry protein assay 
The Lowry DC assay (BioRad) was used to measure protein content within the cell 
populations that had undergone the Seahorse XF extracellular flux assay. It was chosen as it 
was a method compatible with the lysis buffer used and allowed for the quick determination 
of protein concentration without the need for incubation at 60 ˚C. The reaction measures 
the formation of Cu+ by the Biuret complex, the reaction of Cu2+ with peptide bonds in 
alkaline solutions produces a colour change which can be measured at 750 nm [341]. The DC 
Lowry working reagent was prepared by mixing solution A (alkaline copper taltrate) and 
solution S (surfactant solution) in a 49:1 ratio. 125 µL of the A+S solution was added to 25 µL 
of the cell lysate in the XF24 plate and mixed, then 1 mL of solution B (Folin reagent) was 
added. This solution was then mixed thoroughly on an orbital shaker and incubated for 15 
min at 22 ˚C. 200 µL of sample was then added to a 96-well plate before the absorbance was 
recorded at 750 nm on a M2e plate reader (SpectraMax). The protein concentration was 
determined by the inclusion of protein standards prepared with BSA (0.1 – 2.0 mg mL-1). 
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2.3.13 Statistical analysis 
Statistical analyses were performed to compare the effect of oxidant treatment on J774A.1 
cells, cellular enzymes and cell function versus the untreated control. All analyses were 
carried out using one-way ANOVA with a Tukey’s post-hoc test, two-way ANOVA was used 
to compare multiple treatment conditions or differences over time. All statistical analyses 
were performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, USA), with p < 
0.05 taken as significant. Details of the significance or changes to statistical methods for each 
experiment are outlined where relevant. 
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3 The Effect of Hypohalous Acids on Cellular Protein Thiols 
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3.1 Introduction 
The production of the hypohalous acids, HOSCN and HOCl is catalysed by the peroxidase 
enzymes MPO, LPO and EPO, which are all important elements of the human innate immune 
system [11, 342-344]. HOCl is a chemical that is primarily involved in bacterial cell killing, 
which has the ability to cause cell lysis in a wide number of different cell types [180, 184]. 
HOCl is not particularly specific in respect to the targets that it oxidises, reacting readily with 
most biological molecules, particularly proteins, owing to rapid rate constants for reaction 
with many amino acids, including methionine, cysteine, histidine, tryptophan and lysine [96]. 
HOCl can also react rapidly with a range of other substrates including DNA, lipids or 
plasmalogens to form various chlorinated and oxidised products [143, 153-155]. Thus, HOCl 
can cause wide spread damage upon exposure to cells [66, 70, 183, 324, 345]. In contrast, 
HOSCN is a bacteriostatic agent, and it is reported that rather than causing cell death, HOSCN 
inhibits bacterial cell growth and proliferation [197, 199]. This action is attributed to the 
ability of HOSCN to almost exclusively target protein thiols contained on the cysteine 
residues of various proteins [95, 98]. It has been demonstrated that thiol proteins essential 
to glycolysis within bacteria are key targets [198-200, 274]. HOSCN forms reversible oxidised 
cysteine products on these proteins including sulfenyl products, disulfides and mixed 
disulfides, which can be reduced by various mechanisms to restore function and permit 
bacterial cell growth [56, 199]. 
HOCl also reacts readily with thiols, with a higher rate constant that reported for HOSCN with 
cysteine residues (HOCl: k = 3 × 107 M-1 s-1 compared to HOSCN: k = ca. 7.8 × 104 M-1 s-1) [96, 
98]. The reaction of thiols with either HOCl or HOSCN yields a sulfenyl halide (RS-X, where X= 
Cl or SCN) [101, 102]. With HOSCN, this results in the formation of a sulfenyl thiocyanate, 
which can then be hydrolysed to a sulfenic acid (RS-OH) or react with another cysteine to 
form a disulfide bridge (RS-SR’), both of which are reversible species that can be reduced to 
the original thiol [62]. When thiols are exposed to HOCl, which is a stronger oxidising agent, 
the resulting sulfenyl chloride (RS-Cl) can then be further oxidised to higher oxyacid products 
and irreversibly oxidised products, such as sulfinic (RS-O2H) and sulfonic acids (RS-R3H) [346]. 
The formation of reversibly oxidised sulfur-species within a cell can be important, as oxidant-
induced damage can be potentially reversed, thereby avoiding permanent enzyme 
inactivation [56]. Furthermore, these modifications are critical in redox signalling processes 
[347, 348]. The repair of HOSCN-modified protein modifications resulting in the restoration 
of enzyme function has been reported on isolated proteins, including creatine kinase (CK) 
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and GAPDH, after HOSCN exposure with subsequent reduction with dithiothreitol (DTT) 
[201]. Direct evidence for repair of thiol modifications within mammalian cells is rather 
limited, but is known to occur in bacteria [56, 199]. The formation of higher cysteine 
oxyacids, such as those formed upon HOCl treatment, can lead to irreversible enzyme 
activation and the failure of essential redox switches within the cell [9, 109, 349], which has 
been postulated to be a cause of cell death [162, 180, 187]. Targeting of critical thiol proteins 
has been proposed to be the cause for the inhibition of various cellular processes, though 
very few studies have reported or characterised the post-translational modifications induced 
by HOSCN compared to HOCl within cells. The specificity of HOSCN for thiols has been shown 
to cause more damage to susceptible sites than the non-specific reactions of HOCl [84, 91]. 
However, whether sulfenic acids and other reversible thiol products are also formed in cells 
exposed to HOCl is not well established. Comparative studies of thiol oxidation on proteins 
in cells exposed to HOCl and HOSCN have shown different results, which are dependent on 
the cell type. With macrophages, a greater extent of thiol loss was seen with HOSCN, 
whereas in endothelial cells, HOCl induced a greater loss in the thiol concentration under 
analogous reaction conditions [91, 185]. 
 
3.2 Aim 
The aim of the studies in this Chapter is to assess the ability of HOSCN and HOCl to target 
protein thiols, and form reversible oxidation products in J774A.1 murine macrophages, using 
a thiol specific probe to assess reversible modifications. The nature of the reversible 
oxidation products formed in each case will be examined using a Western blotting approach 
with the sulfenic acid probes DAz-2 and DCP-Bio1, and an antibody raised against 
glutathionylated protein. The formation of reversible cysteine oxyforms in the mitochondria 
was also studied using a mitochondrial isolation kit to fractionate mitochondrial and cytosolic 
proteins.  
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3.3 Results 
3.3.1 HOSCN and HOCl affect intracellular thiol concentrations 
Initial studies were performed to explore whether there were differences in the extent of 
total thiol loss on exposure of J774A.1 murine macrophages to HOCl and HOSCN, as previous 
studies have shown that thiol-dependent enzymes can be readily inactivated by these 
oxidants [201].  J774A.1 cells (1 × 106 cells) were treated with HOSCN and HOCl (0 – 100 µM) 
for 1 h at 22 ˚C. These conditions were selected as a result of data in the literature showing 
that cells exposed to concentrations ≤ 200 µM HOSCN for 1 h showed very little cell lysis [91] 
but a decrease in enzyme activity and thiol loss is noted [201]. After treatment, intracellular 
thiol concentrations were determined with a fluorescence assay using ThioGlo-1. ThioGlo-1 
is a maleimide derivative that contains a double bond that reacts readily with the thiol group 
of cysteine, which are targets of both HOSCN and HOCl oxidation, resulting in a change in 
fluorescence [324, 350]. This method is superior to other methods, such as the DTNB (5,5'-
dithiobis-(2-nitrobenzoic acid)) assay, where the disulfide bond of the DTNB is cleaved by a 
thiol to give TNB-, which has been performed previously on this cell type, as it is more 
sensitive and there is no confounding reaction of the oxidants with ThioGlo-1 in contrast to 
TNB [324, 350].  ThioGlo-1 is added to the cell lysate after the cells were oxidant-treated, 
washed and lysed in npH2O, and the loss of thiols in the samples is determined via a 
proportional loss in ThioGlo-1 binding to available thiols. The concentration of thiols within 
the samples is determined by comparing the sample fluorescence against a GSH standard 
curve (0 – 10 µM).  
Treatment of J774A.1 macrophages with HOSCN resulted in a dose-dependent decrease in 
the intracellular thiol concentration (Figure 3.1). The result was significant at concentrations 
above 50 µM HOSCN (Figure 3.1), while at 100 µM the effect begins to plateau, indicating 
there are thiols inaccessible or unreactive to HOSCN. In contrast, when the cells were treated 
with HOCl, no significant reduction in the concentration of intracellular thiols was observed 
unless a dose greater than 50 µM was employed. When the cells were treated with 100 µM 
HOCl, there was a decrease in the intracellular thiol concentration that was comparable to 
the 50 µM HOSCN treatment. In each case, the thiol concentration was normalised to protein 
concentration, to account for any thiol loss due to lysis. To confirm that the change in 
fluorescence was reflecting thiol concentration rather than a reaction of ThioGlo-1 with 
other intracellular targets to cause an artifactual increase in fluorescence, the cells were 
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treated with N-ethylmaleimide (NEM, 1 mM) prior to adding ThioGlo-1. NEM is an alkene, 
Michael acceptor that reacts with nucleophiles, such as thiols, producing a strong, almost 
irreversible C-S bond. Blocking the thiols in the samples with NEM prevents a reaction of the 
thiols with ThioGlo-1, allowing for the determination of background or non-specific 
fluorescence. 
 The results show that upon treatment with NEM, the ThioGlo-1 fluorescence is dramatically 
decreased, consistent with ThioGlo-1 reacting primarily with intracellular thiols. The 
difference in intracellular thiol concentrations after treatment with HOSCN or HOCl was then 
extended to examine the nature of the oxidation products formed, and whether the 
oxidation and subsequent thiol loss could be reversed. 
 
 
Figure 3.1: HOSCN and HOCl are able to oxidise intracellular thiols in J774A.1 cells. 
Loss of intracellular thiols by HOSCN (black bars) or HOCl (grey bars) occurs in a dose-
dependent manner. J774A.1 (1 × 106) cells were treated with HOSCN or HOCl (0 – 100 µM) for 
1 h at 22 ˚C. J774A.1 cells were also treated with NEM (1 mM) for 15 min instead of oxidant 
before the addition of ThioGlo-1, to probe for artifactual ThioGlo-1 fluorescence, due to non-
specific binding. Thiol concentrations were determined by fluorescence spectroscopy at λex = 
360 nm and λem = 530 nm. Values of the results are the mean ± S.E.M (n = 3). *** and **** 
show a significant (p < 0.001 and 0.0001, respectively) decrease compared to the respective 
non-treated controls. ^^^ shows a significant (p < 0.001) difference between the oxidants at 
the same concentration by Repeated Measures two-way ANOVA with a post-hoc Tukey’s test. 
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3.3.2 Formation of reversible protein thiol modifications by HOSCN and HOCl 
This study was performed to determine whether the intracellular oxidation products of 
HOSCN or HOCl formed on protein thiols are reversible. J774A.1 cells were treated with HOCl 
or HOSCN (0 – 100 µM) prior to washing to remove any residual oxidant and treatment with 
NEM (100 mM) to block any of the thiols that did not become oxidised (i.e. reduced thiols). 
The samples were then treated with DTT (1 mM) to reduce any reversibly oxidised thiols back 
to their original state. Finally, samples were treated with the fluorescent IAF probe (80 mM) 
to alkylate the newly reduced thiol groups. The cell protein samples were then separated 
using SDS-PAGE. In this case, an increase in IAF fluorescence is consistent with the production 
of reversible thiol products, which could include, but are not limited to, disulfide bridges, 
sulfenic acids and S-glutathionylated adducts. 
Results show that exposure of the cells to 50 µM HOSCN results in the formation of reversible 
oxidation products upon treatment for 1 h at 22 ˚C, shown by an increase in IAF staining 
intensity (Figure 3.2A). This increase in the formation of reversible cysteine oxidation 
products is apparent at both the concentrations of HOSCN used (50 and 100 µM) with the 
densitometry showing that the apparent density of the bands is almost double at the highest 
concentration of oxidant (Figure 3.2C). In the HOSCN treated samples proteins with 
molecular mass ca. 70, 65, 60 and 35 kDa were particularly sensitive to modification, as the 
densities of these protein bands contributed to the majority of the total pixel area, which 
was assessed using Image J. The protein content of each sample was visualised using the 
RuBPS stain (Figure 3.2B), which showed equal loading of sample across all the gel lanes 
(Figure 3.2D). Thus, the increase in IAF staining is consistent with reversible thiol modification 
rather than increased protein loading on the gel. 
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Figure 3.2: HOSCN and HOCl both promote the formation of reversible oxidation products 
on protein cysteines.  
J774A.1 (1 × 106 cells mL-1) cells were treated with HOSCN or HOCl (0 – 100 µM) for 1 h at 22 
˚C, blocked with NEM, reduced with DTT and probed with IAF before the proteins separated 
via 1D SDS-PAGE (4-12%). (A) Protein cysteines probed with the fluorescent thiol probe IAF, 
with increases in intensity indicating an increase in the formation of reversible oxidation 
products when scanned at λex = 488 nm and λem = 530 nm on the PharosFX system. (B) The 
gel is treated with the protein stain RuBPS to ensure equal protein loading by scanning the 
gel in the PharosFX system using λex = 532 nm and λem = 605 nm lines. (C) The densitometry 
of the IAF bands for both HOSCN (black bars) and HOCl (grey bars) treated samples and (D) 
the densitometry of the RuBPS stained bands. The images are representative of 3 separate 
experiments. Values of the results are the mean ± S.E.M (n = 3). **, *** and **** show a 
significant (p < 0.01, 0.001 and 0.0001, respectively) increase compared to respective controls 
by Repeated Measures one-way ANOVA with a post-hoc Tukey’s test. 
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In contrast with HOCl, a less significant increase in IAF staining was observed, and the change 
in IAF fluorescence was not as marked as with HOSCN. This is consistent with a decreased 
extent of formation of reversible cysteine oxidation products (Figure 3.2A), and supports the 
reported differences in the chemistry and selectivity of these oxidants [49, 95]. Again, the 
difference in the formation of reversible thiol products is not a reflection of unequal loading 
of the protein samples, seen by RuBPS staining (Figure 3.2B & D), with densitometry 
performed using Image J software. 
 
3.3.3 HOSCN, HOCl and the formation of protein sulfenic acids in J774A.1 
macrophages 
The formation of sulfenic acids has been demonstrated in J774A.1 macrophages after HOSCN 
treatment [201], but it is not clear whether these species are also formed in cells exposed to 
HOCl, which may be expected in light of the above finding showing some evidence for 
reversible thiol modification with IAF. To address this, additional studies were performed to 
examine the nature of the reversible modifications using the chemical probe DAz-2, a sulfenic 
acid specific dimedone containing molecule that contains an azido group, allowing 
conjugation to phosphine-biotin (p-biotin), as the phosphine is reactive towards azido groups 
(Staudinger ligation, click reaction) [328, 351]. Using DAz-2 and p-biotin allows for the 
detection of sulfenic acid formation using streptavidin-HRP to visualise the resulting 
biotinylated proteins. Prior to the exposure of J774A.1 cells to HOSCN, cells were treated 
with DAz-2 (500 µM) in DMSO (1% v/v) or a vehicle control of DMSO (1% v/v) in DMEM for 1 
h at 37 ˚C. Cells (1 × 106 cells mL-1) were then washed and treated with HOSCN or HOCl (0 – 
150 µM) for 1 h at 22 ˚C before being lysed in npH2O. The lysate was then incubated with p-
Biotin to biotinylate any protein-bound DAz-2 (Figure 3.3) and the proteins were separated 
using SDS-PAGE and transferred to a PVDF membrane. The membrane was incubated with 
streptavidin-HRP and the protein bands visualised using ECL. 
Under these conditions, evidence was obtained for the formation of sulfenic acids in 
macrophages upon treatment with concentrations above 50 µM of HOSCN (Figure 3.4A). The 
band density of biotinylated proteins was determined using Image J, where it was apparent 
that there was more than a doubling in the average total density between the control and 
the 150 µM HOSCN treatment group (Figure 3.5A) (red arrows indicate proteins that had 
more than a 100% increase in density between the control and 150 µM treatment groups). 
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These data are consistent with previous studies with isolated proteins and in cells [201]. 
There was a significant increase in the formation of cellular protein sulfenic acids at all the 
concentrations of HOSCN tested. After visualisation of sulfenic acid formation with 
streptavidin-HRP and ECL, the blots were stained with Coomassie R-250 to ensure equal 
protein loading across all samples (Figure 3.4C). Image J was used to measure the density of 
the protein bands and no change was observed in Coomassie staining, indicating equal 
protein loading (Figure 3.5B). 
 
 
Figure 3.3: DAz-2 as a tag for sulfenic acid production in cells. 
The figure outlines the steps taken to tag sulfenic acids with DAz-2, and the subsequent 
addition of p-biotin via a Staudinger ligation to form a complex that can be visualised using 
a Western blotting method and ECL.  
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Figure 3.4: HOSCN promotes the formation of sulfenic acids on protein cysteine residues, 
while HOCl does not, following treatment of J774A.1 cells. 
J774A.1 cells (1 x 106 cells mL-1) were pre-treated with DAz-2 (500 µM) or DMSO (1% v/v) for 
1 h at 37 ˚ C prior to the addition of (A) HOSCN or (B) HOCl (0 – 150 µM) and further incubation 
for 1 h at 22 ˚C. Cells were then lysed, and Staudinger ligation was carried out with p-Biotin 
(200 µM) and DTT (5 mM) for 2 h at 37 ˚C. The reaction was quenched and proteins were 
separated via 1D SDS-PAGE (4-12%). Proteins were transferred to PVDF membranes and 
biotinylated proteins were detected by Western blotting with HRP-streptavidin. Coomassie R-
250 was used to determine equal protein loading on both (C) HOSCN and (D) HOCl - treated 
samples. The images are representative of 3 separate experiments. Red arrows indicate 
bands that had more than a doubling in density between the control and 150 µM treatment 
groups. 
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Figure 3.5: Changes in the band density of Daz-2 reactive sulfenic acid protein-residues. 
Densitometry analysis of the membranes was performed using ImageJ. (A) Density of the 
biotinylated bands detected via Western blot after DAz-2 derivitisation shows that HOSCN 
causes an increase in the formation in protein sulfenic acids as determined by an increase in 
biotinylated proteins. HOCl shows a trend towards increase but no significance was 
determined. (B) Density of the Coomassie R-250 stained protein bands shows no significant 
difference in the density of bands across all samples, indicating an equal load of proteins 
across all samples tested. Values of the results are the mean ± S.E.M (n = 3). **** shows a 
significant (p < 0.0001) increase when compared to the control by Repeated Measures one-
way ANOVA with a post-hoc Tukey’s test. 
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In contrast, HOCl had a different effect on the cells, as the formation of sulfenic acids on 
cellular protein was not observed (Figure 3.4B). Thus, in this case, the formation of sulfenic 
acids was below the detection limit, with no statistical difference in the density between the 
control or the highest concentration of HOCl used (150 µM) (Figure 3.5A). After probing for 
biotinylated proteins, the membranes were again stained with Coomassie R-250 to 
determine protein loading (Figure 3.4C & D). The analysis of the band density showed that 
there was no statistical difference between the density of any of the protein bands (Figure 
3.5B), indicating that the lack of sulfenic acid formation was not a result of reduced or 
unequal protein loading. 
In the vehicle control treated samples (DMSO) (Figure 3.4A & B), there were only a few visible 
bands, with 2 prominent bands at ca. 70 and 120 kDa. This is attributed to proteins that are 
already biotinylated within the cell, that are not related to sulfenic acid formation. This is 
further supported by the observation that the band density in the DMSO treated samples 
remains constant, indicating that protein biotinylation in this case, occurs independently 
from HOSCN treatments (Figure 3.5A). 
In summary, exposure of J774A.1 cells to HOSCN but not HOCl induces the formation of 
sulfenic acids on protein residues. Various bands within the HOSCN treated samples 
exhibited increases in sulfenic acid formation (shown by red arrows in Figure 3.4A) which 
suggests that HOSCN may exhibit specificity for particular cellular proteins or that particular 
proteins may be susceptible to sulfenic acid formation via HOSCN oxidation.  
 
3.3.4 HOSCN and the formation of S-glutathionylated proteins in J774A.1 
macrophages 
Sulfenic acids are highly reactive and unstable intermediates that can react with other 
cysteine residues to form disulfides or mixed disulfides [352, 353].  The reaction of a protein-
bound sulfenic acid with a molecule of GSH can lead to the formation of a particular type of 
mixed disulfide, an S-glutathionylated protein disulfide (PSSG). In recent years PSSG have 
been increasingly implicated in various cellular pathways and modification of protein 
function, including the protection of cysteine residues from over-oxidation into the higher, 
non-reversible oxyacids such as sulfinic and sulfonic acids [348, 354-356]. 
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The formation of PSSG residues within J774A.1 cells after treatment with HOSCN or HOCl for 
1 h at 22 ˚C was determined using an anti-GSH antibody (ViroGen, [357]). Due to the 
instability of the PSSG adducts, the cells were kept on ice, to reduce PSSG decomposition 
with an excess of NEM present throughout the entire experiment [358]. By alkylating any 
reduced thiols it was ensured that any thiols that were not originally oxidised during HOSCN 
or HOCl treatment would not become oxidised during further processing steps. To do this, 
after treatment the cells were lysed under alkylating conditions using NEM (100 mM) and 
the proteins were resuspended in LDS buffer containing NEM (100 mM). SDS-PAGE was also 
run under non-reducing conditions with running buffer containing NEM (100 mM). Results 
show that the samples treated with HOSCN show a consistent increase in PSSG formation in 
3 separate experiments (Figure 3.6C), particularly in the bands located at ca. 40 kDa and 
another at 250 kDa (red arrows), after protein band density is analysed using Image J. 
Samples treated with HOCl also exhibited an increase in PSSG formation, in a similar fashion 
to the PSSG formation in HOSCN treated samples. In this case, the PSSG formation but tended 
to be more variable over the 3 independent experiments (Figure 3.6C). Protein bands which 
exhibited consistent increases in PSSG were proteins located at ca. 40, 90, 150 and 250 kDa 
(Figure 3.6A), indicating that HOCl may exhibit specificity for these particular proteins. With 
both HOSCN and HOCl, an increase in PSSG formation on cellular proteins only became 
significant at the highest treatment concentration (200 µM), primarily due to the high 
amount of PSSG observed in the control samples of both treatments. In most cases, the 
bands present in non-treated controls increased in intensity with increasing oxidant 
concentrations, while in others, very little, to no increase was observed. When the blots were 
stained with Coomassie R-250 (Figure 3.6B), no change was observed in the amount of 
protein loaded in each lane as indicated by the constant density across all the samples when 
analysed using ImageJ (Figure 3.6D). This demonstrates that the lack of consistency apparent 
on the PSSG blots is likely to be due to decomposition of the adducts rather than unequal 
loading of the protein sample. 
 
 74 
 
 
Figure 3.6: The formation of S-glutathionylated proteins in J774A.1 cells following 
treatment with HOSCN and HOCl. 
J774A.1 cells (1 x 106 cell mL-1) were treated with HOSCN or HOCl (0 – 200 µM) for 1 h at 22 
˚C, before being lysed in an NEM-containing buffer, and proteins were separated by 1D gel 
electrophoresis under non-reducing conditions in media containing 100 mM NEM before 
being transferred to a PVDF membrane. (A) Glutathionylated proteins were detected using 
an anti-GSH antibody before being imaged using ECL-HRP. (B) The PVDF membranes were 
stained with Coomassie R-250 and used to determine equal protein loading. The images are 
representative of 3 separate experiments. Using ImageJ, the density of the (C) anti-GSH 
probed blots and the (D) Coomassie R-250 stained blots were determined by analysing all the 
bands contained in each lane. Values of the results are the mean ± S.E.M (n = 3). * shows a 
significant (p < 0.05) increase when compared to the respective controls by Repeated 
Measures one-way ANOVA with a post-hoc Tukey’s test. Red arrows indicate proteins that 
showed consistent increases in density over the course of the 3 experiments. 
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It is not clear why PSSG adducts are so readily formed in the non-treated control wells, 
whereas little sulfenic acid formation or reversible thiol oxidation is seen in comparable 
conditions. This may reflect PSSG formation under basal conditions, which may play a role in 
cellular signaling and in redox regulation of protein functions [104, 359], This may also reflect 
a lack of specificity of the anti-GSH antibody.  
Due to the successful identification and formation of sulfenic acid adducts in the whole cell 
lysates after HOSCN treatment and a lack of consistency in the formation of PSSG after 
oxidant treatment, an experiment was devised to examine the susceptibility of cytosolic and 
mitochondrial proteins to sulfenic acid formation on HOSCN treatment. 
 
3.3.5 HOSCN causes the formation of protein-bound sulfenic acids in the cytosol 
and mitochondria 
3.3.5.1 Optimising protocols to detect sulfenic acid formation in mitochondria 
Using the sulfenic acid probe DAz-2 with p-biotin and Staudinger ligation, it was shown that 
the treatment of J774A.1 macrophage cells with HOSCN is able to generate protein sulfenic 
acids within the cells. Initial studies were performed to examine sulfenic acid formation on 
mitochondrial proteins by loading the cells with DAz-2, then treating the cells with HOSCN. 
After oxidant treatment, a mitochondrial isolation was performed, before the mitochondrial 
fraction was lysed and p-biotin was added, and a Staudinger ligation reaction performed. The 
mitochondrial proteins were then separated using SDS-PAGE and the proteins were 
transferred to a PVDF membrane where they were incubated with HRP-streptavidin and 
imaged with ECL. However, upon imaging, no biotinylated proteins (except for 2 bands at ca. 
70 and 100 kDa) were identified in any of the samples (Figure 3.7A), despite the identification 
of protein after staining the membranes with Coomassie R-250 (Figure 3.7B). This was 
attributed to the loss of the sulfenic acid adducts during the mitochondrial isolation 
procedure. 
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Figure 3.7: Using DAz-2 to identify sulfenic acid formation in J774A.1 mitochondria. 
J774A.1 cells (1 x 106 cells mL-1) were pre-treated with DAz-2 (500 µM) or DMSO (1% v/v) for 
1 h at 37 ˚C prior to the addition of HOSCN (0 – 200 µM) and further incubation for 1 h at 22 
˚C. Mitochondrial isolation was performed, and Staudinger ligation carried out with p-Biotin 
(200 µM) and DTT (5 mM) for 2 h at 37 ˚C. The reaction was quenched and mitochondrial 
proteins were separated via 1D SDS-PAGE (4-12%). (A) Proteins were transferred to PVDF 
membranes and biotinylated proteins were detected by Western blotting with HRP-
streptavidin and ECL. (B) Coomassie R-250 was used to determine equal protein loading and 
if protein was contained with mitochondrial samples. 
 
 After the unsuccessful result of the previous optimisation experiment, the cells were loaded 
with DAz-2 prior to HOSCN treatment and the p-biotin was added to the whole cells. After 
the Staudinger ligation, the mitochondria were isolated from the cells, and lysed before the 
proteins were separated using SDS-PAGE, transferred to a PVDF membrane and incubated 
with HRP-streptavidin and imaged with ECL. This was also unsuccessful, as no bands were 
detected, possibly because the p-biotin is more suited for use in lysates and not whole cells 
[360]. So another method was devised, which employed the use of a new sulfenic acid probe 
that did not require the need for Staudinger ligation to p-biotin, as the probe, called DCP-
Bio1, is already biotin-linked. To compare the reactivity of DCP-Bio1 and DAz-2, cells were 
loaded with DCP-Bio1 before HOSCN treatment and after oxidant treatment the cells were 
lysed and the proteins were separated using SDS-PAGE before being transferred to a PVDF 
membrane and incubation with streptavidin-HRP before imaging using ECL. The formation 
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of sulfenic acids in cells exposed to increasing concentrations of HOSCN using DCP-Bio1 was 
then compared to that seen using DAz-2. No difference in sulfenic acid detection was 
observed between the DCP-Bio1 (Figure 3.9A) or DAz-2 (Figure 3.9B). 
 
Figure 3.8: DCP-Bio1, a dimedone based sulfenic acid probe that contains a cleavable biotin 
tag. 
 
 
Figure 3.9: A comparison of the sulfenic acid probes DCP-Bio1 and DAz-2 in whole cell 
lysates 
J774A.1 cells (1 x 106 cells mL-1) were pre-treated with (A) DCP-Bio1 (500 µM) or (B) DAz-2 
(500 µM) for 1 h at 37 ˚C prior to the addition of HOSCN (0 – 200 µM) and further incubation 
for 1 h at 22 ˚C. Cells were then lysed, and Staudinger ligation was carried out with p-Biotin 
(200 µM) and DTT (5 mM) for 2 h at 37 ˚C on the cells treated with the DAz-2 probe. The 
reaction was quenched and proteins were separated via 1D SDS-PAGE (4-12%). Proteins were 
transferred to PVDF membranes and biotinylated proteins were detected by Western blotting 
with HRP-streptavidin. 
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To determine whether sulfenic acids are formed on mitochondrial proteins in J774A.1 cells, 
the cells were loaded with DCP-Bio1, then treated with HOSCN before the mitochondria were 
isolated from the cytosolic fraction using a mammalian mitochondria isolation kit (Thermo 
Fisher). The mitochondria were lysed in mitochondrial lysis buffer and both the 
mitochondrial and cytosolic proteins were separated using SDS-PAGE. After electrophoresis 
the proteins were transferred to a PVDF membrane, and the membranes were incubated 
with HRP-streptavidin and imaged using ECL. 
On separation of the cytosolic and mitochondrial fractions, it was shown that the cytosolic 
fraction gave results were similar to the results of the experiment with whole cell lysates 
(Figure 3.9A) but fewer bands were apparent when compared to the results of the DAz-2 or 
DCP-Bio1 probe with whole cell lysates. Treatment of the cells with HOSCN results in an 
increase in the formation of sulfenic acid adducts on proteins within the cytosol (Figure 
3.10A), which is consistent with the results of the DAz-2 probing experiment. After imaging, 
the membrane was stripped and re-probed for β-actin and COX-4, which both act as a loading 
control and a means to determine mitochondrial contaminants in the cytosolic fractions 
(Figure 3.10A). Using ImageJ, analysis of the cytosolic fraction showed that the intensity of 
biotinylation increases by approximately 3-fold between 0 – 200 µM HOSCN treatments 
(Figure 3.11A), indicating an increase in biotinylation due to binding of the probe to sulfenic 
acids, formed by the increasing concentrations of HOSCN. Several bands within the cytosolic 
fraction became darker with increased oxidant treatment, such as bands located at ca. 100, 
ca. 160 kDa and ca. 37 kDa. After analysing the β-actin and COX-4 images using Image J, it 
was determined that equal protein was loaded between samples had no effect on the results 
(β-actin) (Figure 3.11E) and that there were no mitochondrial contaminants (COX-4) (Figure 
3.11). 
After HOSCN treatment, numerous proteins within the mitochondria are also oxidised to 
form sulfenic acids. Within non-treated, control samples, very few protein sulfenic acid 
residues are observed; whereas an increase in sulfenic acid production within the 
mitochondria is apparent with increasing concentrations of HOSCN (Figure 3.10B). The 
results also indicate that various proteins within the mitochondria (marked with red arrows) 
showed larger increases in sulfenic acid formation than others, indicating that there is 
possible protein-specific sulfenic acid formation in the mitochondria on exposure of cells to 
HOSCN. After analysing all the bands within each lane, using Image J, a trend towards an 
increase in protein sulfenic acid formation is identified in all the treated samples, which is 
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statistically significant at the 200 µM HOSCN treatment (Figure 3.11B). After imaging, the 
membrane was stripped and blotted for COX-4 and β-actin (Figure 3.10B). Data showed no 
variation in COX-4 intensity (Figure 3.11D), indicating that the results are not due to changes 
in protein loading. Within the mitochondrial fraction there was some β-actin recognition 
(Figure 3.11F), which may be an artifact of the mitochondrial isolation preparation or show 
residual cytosolic proteins in the mitochondrial preparation. However, the levels of β-actin 
in the mitochondria are very low compared to the cytosolic fraction, and the pattern of bands 
in the 2 fractions are quite different (red arrows; proteins with the largest increase in sulfenic 
acid formation), suggesting that different proteins are being oxidised by HOSCN in each case. 
This is consistent with the mitochondrial fraction containing primarily mitochondrial 
proteins, and the cytosol composed of cytosolic proteins. 
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Figure 3.10: HOSCN causes the formation of sulfenic acids in both the cytosol and 
mitochondria of J774A.1 cells after treatment. 
J774A.1 cells (1 x 106 cells mL-1) were pre-treated with DCP-Bio1 (500 µM) or DMSO (1% v/v) 
as the vehicle control (VC) for 1 h at 37 ˚C prior to the addition of HOSCN (0 – 200 µM) before 
further incubation for 1 h at 22 ˚C. The (A) cytosol and (B) mitochondrial fractions were 
prepared using the mammalian mitochondrial isolation kit (Thermo Fisher Scientific) before 
the proteins were separated via 1D SDS-PAGE (4-12%). Proteins were transferred to PVDF 
membranes and biotinylated proteins detected by Western blotting with HRP-streptavidin. 
After imaging, the membranes were stripped before being probed with the loading control 
antibodies, COX-4 for mitochondrial protein detection and β-actin for cytosolic protein 
detection. The images are a representative of 3 separate experiments. Red arrows indicate 
bands that had more than a doubling in density between the control and 200 µM treatment 
groups. 
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Figure 3.11: Changes in the band density of DCP-Bio1 reactive sulfenic acid protein-
residues. 
Densitometry analysis of the membranes was performed using ImageJ, analysing each band 
in every lane. Density of the biotinylated bands was detected via Western blot after DCP-Bio1 
derivitisation in the (A) cytosol and (B) mitochondria after treatment with HOSCN (0 – 200 
µM) or DMSO (VC).  After imaging each membrane was probed for loading controls of COX-4 
(C & D) or β-actin (E & F). Values of the results are the mean ± S.E.M (n = 3). *, ** shows a 
significant (p < 0.05 or 0.01, respectively) increase when compared to the control by Repeated 
Measures one-way ANOVA with a post-hoc Tukey’s test. 
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3.4 Discussion 
This Chapter examined the extent and pattern of reactivity of HOCl and HOSCN with 
intracellular thiols and the nature of the reversible protein thiol modifications. Exposure of 
J774A.1 macrophages to HOCl and HOSCN resulted in changes to intracellular thiol 
concentrations, with HOSCN reducing the intracellular thiol concentration to a greater extent 
than HOCl. The nature of the oxidised products of HOCl and HOSCN-induced protein thiol 
oxidation was probed using SDS-PAGE and Western blotting methods. The results indicate 
that HOCl and HOSCN are able to form reversible thiol oxidation products, though HOSCN 
was able to do this to a greater extent under analogous conditions. Evidence was obtained 
for the formation of sulfenic acids and S-glutathionylated adducts. In each case, a greater 
extent of product was seen with HOSCN compared to HOCl. It was also shown that HOSCN 
targeted both cytosolic and mitochondrial proteins on exposure to the cells, with sulfenic 
acids seen in each case following fractionation. 
Exposure of J774A.1 cells to HOSCN results in a decrease in intracellular thiols in a dose-
dependent manner. The decrease in thiols seen with HOSCN was greater than that seen in 
corresponding experiments with HOCl. This is attributed to the difference in selectivity 
between HOSCN and HOCl [49]. HOSCN reacts almost exclusively with protein thiols and low-
molecular mass thiols such as GSH, whereas HOCl reacts with a wide range of biological 
targets [49, 91, 95, 96, 98, 345]. Thus, although HOSCN reacts with protein thiols at a rate in 
the range of 1 × 104 – 7.6 × 104 M−1 s−1, and with GSH at a rate of 2.5 × 104 M−1 s−1 at pH 7.4 
[98], which is slower than the reaction of  HOCl with thiols (k = 3 × 107 M−1 s−1) [96] the limited 
reactivity of HOSCN with other cellular targets means a greater loss in thiols is seen. These 
results compare well with previous studies reporting a greater targeting of HOSCN for thiols 
compared to HOCl in macrophages. For example, Lloyd et al. [91] reported that after 15 min 
oxidant treatment HOSCN reduced the intracellular GSH concentration to a greater extent 
than HOCl. HOSCN also oxidised protein thiols in J774A.1 macrophages to a greater extent 
than HOCl, as observed by a decrease in the binding of the IAF, indicating a reduced 
availability of free thiols. The ability of HOSCN to oxidise thiols in cellular models has been 
studied extensively in the past decade. One study, comparing the thiol oxidising abilities of 
HOSCN and HOCl showed that the selectivity of HOSCN for thiols led to an increased 
inactivation of membrane ATPases, and HOSCN could be up to 1000 times more efficient 
than HOCl at inhibiting ATPases [84]. It has also been shown that both HOCl and HOSCN could 
cause thiol loss in yeast alcohol dehydrogenase. Both oxidants caused protein thiol loss, but 
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it occurred at lower concentrations in samples treated with HOSCN compared to HOCl, most 
likely due to the differences in the number of targets between HOSCN and HOCl [361]. 
Similarly, HOSCN has been shown to oxidise free cysteines on LDL-apoB100 with greater 
efficiency than HOCl during a 30 min exposure [142]. 
Conversely, studies have shown that during a 15 min exposure to varying concentrations of 
HOSCN or HOCl, HOCl consistently depleted intracellular thiols and GSH with greater 
efficiency [185] in human coronary artery endothelial cells (HCAECs), though this may be due 
to reduced uptake of HOSCN into HCAEC’s, as a slower rate of oxidant consumption is seen 
in this case. These data agree with previous studies of HOCl with HCAECs [362] and HUVECs 
[363], where depletion of thiols occur at low oxidant concentrations. There are other 
examples where HOCl depletes thiols to a similar or greater extent as HOSCN. When 
comparing the effect of HOSCN and HOCl on sarcoplasmic reticulum samples from rat hind-
limb skeletal muscles, Cook et al. found no difference between HOCl or HOSCN induced thiol 
loss at 100 µM after 2 h treatments [170].   
The results show that HOSCN causes the formation of more reversible thiol oxidation adducts 
than HOCl.  Results indicate that a majority of the oxidation occurs at 50 µM HOSCN as an 
increase in staining is observed, but this response is seen to plateau at 100 µM HOSCN (Figure 
3.2C), indicating that many of the reversible cysteine adducts are formed at lower HOSCN 
concentrations. The formation of reversible oxidative species by HOCl is less obvious (Figure 
3.2A), as there seems to be less difference between the treatment groups. These results can 
be rationalised on the basis of the difference in chemistry between HOCl and HOSCN [49]. 
When thiols are exposed to stronger oxidising agents, such as HOCl, the sulfenyl chloride (RS-
Cl) can be further oxidised to higher oxyacid products, such as sulfinic and sulfonic acids 
which are not readily reduced [108, 364]. The ability of HOCl to oxidise thiol proteins has 
been shown to be irreversible in cells and shown to occur on thiols on various proteins 
including GAPDH, PTPs and caspases, leading to enzyme inactivation or attenuation [91, 179, 
181, 187]. Conversely, HOSCN is a weaker acid, and upon exposure to thiols can cause the 
formation of sulfenyl thiocyanate products, which can be hydrolysed to reversible products 
such as sulfenic acids [201].  
This difference between HOCl and HOSCN is reflected in the formation of cellular sulfenic 
acids, with treatment of cells with HOSCN, but not HOCl, leading to the formation of sulfenic 
acids at all concentrations tested (Figure 3.4A). Cells treated with HOCl did not elicit a similar 
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response, with no significant increase in sulfenic acid formation noted at any of the 
concentrations tested (0 – 150 µM).  
Many proteins have been identified as candidates for sulfenic acid formation (e.g. c-Jun, 
GAPDH) and the formation of sulfenic acids has been hypothesised to be a redox sensitive 
biochemical switch [364, 365]. The  formation of sulfenic acids by HOSCN has also been 
shown to occur on the glycolysis-related enzymes GAPDH and CK, which results in a loss of 
activity [201]. Other studies have shown that  various proteins involved in DNA repair, 
metabolism, nuclear transport, protein homeostasis and protein synthesis, redox 
homeostasis, signaling and cellular transport contain sulfenic acids in HeLa cells [328]. 
Another study showed the formation of sulfenic acids on Yap1, a transcriptional co-activator 
with proliferative and oncogenic activity, following exposure to H2O2 [366].  Studies have 
shown that the formation of sulfenic acids have effects on various proteins, such as 
phosphatases, including PTP-1B [367, 368], a protein involved in metabolism. The formation 
of sulfenic acids is crucial towards PTP-1B activity; oxidation of Cys215 to sulfenic acid 
prevents irreversible over-oxidation, indicating that sulfenic acids regulate PTP-1B activity. 
Previous studies have shown that HOSCN can inactivate PTPs which can result in the 
perturbation of the phosphorylation of MAPK proteins [179]. In light of the data in this Thesis, 
this may occur via the formation of sulfenic acids.  
Protein S-glutathionylation is a cysteine specific post-translational modification that is 
stimulated by oxidative stress [106]. Not all thiols are equally susceptible to S-
glutathionylation, but this modification can occur via reaction of sulfenic acids and GSH, and 
requires thiol accessibility and a cationic environment for the reaction to occur, which can 
play an important role in protein function [355, 369, 370]. Treatment of the J774A.1 cells 
with HOSCN and HOCl led to an increase in PSSG formation, though the formation of these 
species was inconsistent throughout 3 separate experiments and there were large amounts 
of PSSG detected in the control lanes.  
The lack of reproducible protein S-glutathionylated products could be explained by the very 
strict and specific conditions required for S-glutathionylation to occur [371]. The cysteines 
need to be accessible for glutathionylation to occur; the environment requires cationic 
conditions as acidic environments will inhibit glutathionylation [106, 357, 359]. The addition 
of HOSCN or HOCl to the cells may therefore perturb the conditions required for 
glutathionylation to occur. The formation of PSSG adducts in cells exposed to HOSCN helps 
rationalise data from a previously published study, where HOSCN led to a loss in intracellular 
 85 
 
GSH concentration, but this loss could not be accounted for by GSSG formation within 
J774A.1 cells [91]. In contrast, in isolated systems, GSSG is the only product formed on 
reaction of GSH with HOSCN [98]. This disparity may be explained by the formation of PSSG 
adducts on exposure of cells to HOSCN. 
Formation of PSSG adducts after HOCl treatment of the cells was unexpected, as HOCl is a 
strong oxidant, and is perhaps more likely to oxidise protein thiols to sulfinic or sulfonic 
derivatives, which are irreversible and do not allow for the formation of PSSG. The formation 
of sulfinic or sulfonic acids on exposure of cells to HOCl could cause protein misfolding and 
aggregation [372], which may allow for the formation of PSSG adducts. After HOCl oxidation 
and the induction of protein misfolding, new neighbouring amino acids would play a greater 
effect on the environment of the cysteine residue. One possibility being a change in the pKa 
of the environment surrounding the cysteine residue, the change in protein structure may 
affect S-glutathionylation via a loss in hydrogen-bonding between cysteine residues and 
residues such as serine and histidine, which would decrease the pKa and allow PSSG 
formation [369]. Previous data has shown that extensive modification of cysteine residues 
can affect protein function and structure [373, 374], so if oxidation of proteins by HOCl yields 
changes in protein structure, this may affect the formation of protein S-glutathionylated 
species, but no previous data exists in relation to the formation of PSSG in response to HOCl, 
or indeed HOSCN. 
The formation of PSSG in the control samples suggests that PSSG adducts are used in J774A.1 
cellular signaling and redox regulation [104, 359], which may be perturbed on formation of 
PSSG in response to HOSCN and HOCl treatment. In response, the formation of the PSSG 
adducts is most likely a defensive mechanism, to prevent the over-oxidation of cysteine 
residues [106] in highly oxidative environments. But the formation of PSSG adducts, while 
protecting the cysteine residues from over oxidation, can lead to perturbation of protein 
function, and if the thiol is critical to protein function, the PSSG adduct will render the protein 
totally inactive [375-378].  
However, the lack of reproducibility in this experiment is a limitation of this study, which 
could be a result of adducts being lost due to decomposition during the protocol. Moreover, 
the extensive glutathionylation in the non-treated controls could reflect a lack of specificity 
of the antibody used. Another method which could be employed to observe protein S-
glutathionylation would involve using the thiol probe IAF, with use of glutaredoxin to remove 
GSH from the proteins, and a comparison between the IAF/DTT blot and the IAF/glutaredoxin 
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blot would allow for the visualisation of PSSG adduct formation in response to HOSCN or 
HOCl. 
The reactivity of mitochondrial proteins with HOSCN was examined using DCP-Bio1 which 
gave comparable data to the DAz-2 experiment performed in whole cell lysates. The 
mitochondrial samples also showed increases in protein sulfenic acid formation in response 
to HOSCN treatment, consistent with the targeting of mitochondria by HOSCN.  
The mitochondria would be a viable target for HOSCN, as previous data has shown that 
HOSCN can influence mitochondrial membrane potential in HCAECs [185] and the 
mitochondria contain numerous thiol containing proteins, especially those involved in the 
tricarboxylic acid (TCA) cycle and the electron transport chain (ETC). Proteins including 
aconitase 2, NADH dehydrogenase (Complex I), succinate dehydrogenase (Complex II) and 
cytochrome c — oxidoreductase (Complex III), all of which contain numerous Fe-S clusters, 
are viable targets of HOSCN-induced sulfenic acid formation [207-212]. Other proteins 
include ATP synthase (Complex V), which contains crucial thiol residues and voltage-
dependent anion channel 1 (VDAC-1), which is located on the outer mitochondrial 
membrane and contains transmembrane cysteine residues. In both cases the cysteines are 
critical for protein function [213, 215]. Furthermore, caspase 3, which is a mitochondrial 
protein, has also been shown to be inhibited by HOSCN in HUVECs, which inhibited apoptosis, 
even in the presence of apoptotic stimuli [92]. Another report hypothesised that HOSCN was 
interacting with the mitochondria of J774A.1 macrophages by inducing a caspase-
independent apoptotic pathway [91]. All of the proteins mentioned contain crucial cysteine 
residues that can possibly be oxidised by HOSCN, and the formation of sulfenic acids on these 
proteins could cause changes in protein conformation, inhibiting their activity, which would 
cause an inhibition of cellular proliferation and growth, much in the same way HOSCN affects 
bacterial cell growth and proliferation [198, 200, 379].  
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3.5 Summary 
The studies in this Chapter have shown that HOSCN and HOCl can reduce the concentration 
of intracellular free thiols in J774A.1 cells by oxidising cysteine residues contained on 
proteins. The results show that both oxidants can cause reversible thiol modifications, but 
HOSCN is more potent. HOSCN, and not HOCl is able to cause the formation of sulfenic acids 
within the cell, and HOSCN is able to form these adducts within both the cytosol and the 
mitochondria. The formation of S-glutathionylated adducts was also investigated, and both 
oxidants were able to induce the formation of PSSG on cellular proteins, though HOSCN was 
more efficient. These data suggest that HOSCN may play a role in perturbing cellular 
homeostasis and protein-redox regulation. Further studies in this Thesis will investigate the 
functional consequences of HOSCN-induced thiol targeting of cytosolic and mitochondrial 
proteins by assessing changes that occur to glycolysis and oxidative phosphorylation in 
J774A.1 macrophages in response to HOSCN treatment. 
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4 The Effect of Hypothiocyanous Acid on Glycolysis 
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4.1 Introduction 
The action of HOSCN, in a cellular setting, is primarily attributed to the oxidation of protein 
and low-molecular mass thiols [49, 95]. It was shown that exposure of J774A.1 cells to HOSCN 
results in the formation of reversible thiol oxidation products, including sulfenic acids, which 
may act as regulators of protein redox status and redox homeostasis. The formation of 
protein sulfenic acids has been reported previously, in both mammalian and bacterial cells, 
with the latter exposed to HOSCN via its production by the LPO system, which is present in 
milk and other biological fluids [11]. 
It was first hypothesised that the bactericidal activity of milk was due to agents termed 
“oxidising enzymes”, as heat treatment inhibited the activity of these enzymes, later 
recognised as peroxidases, which in turn diminished the bactericidal effects [194, 195]. It was 
then determined that the peroxidases themselves had little direct effect on the bactericidal 
properties of milk; rather, other components, including the substrates thiocyanate (SCN-) 
and hydrogen peroxide (H2O2) play a critical role. LPO catalyses the reaction between H2O2 
and SCN- to form HOSCN, which is the critical component in the antimicrobial action of this 
system [380].  In milk and similarly, the oral cavity, the requirement for H2O2 in the LPO (or 
SPO)/SCN-/H2O2 system is met by bacterial metabolism [196], as the addition of catalase is 
able to prevent the system’s ability to inhibit the growth of Streptococcus cremoris (strain 
972) in milk or Lactobacillus acidophilus in saliva [196]. Data has shown that stationary phase 
Streptococcus mutans incubated with LPO/SCN- had glucose utilisation inhibited by up to 
90%, and if cells released H2O2 as a result of metabolism, into the media, which contained 
LPO and SCN-, glucose utilisation was inversely proportional to the amount of H2O2 released 
indicating that the LPO/H2O2/SCN- system is more bactericidal than H2O2 alone, due to the 
production of HOSCN [197, 198].   
The product of the LPO-catalysed oxidation of SCN- was also found to inhibit glycolysis in 
other studies with strain 972 Streptococci after a 30 min treatment at 30 C [199]. Analysis 
of the glycolytic enzymes revealed that hexokinase, aldolase and glucose 6-phosphate 
dehydrogenase were all inhibited to some degree [199]. The removal of LPO/SCN-/H2O2 from 
the Streptococci led to the restoration of enzyme activity, consistent with the reversible 
nature of HOSCN-induced oxidation. In related studies, growth inhibition of the bacteria was 
hypothesised to occur via the incorporation of a product from the LPO/SCN-/H2O2 system 
into thiols of proteins involved in cell growth, glycolysis and glucose transport, removing 
these proteins from the functional pool [200]. A study investigating the action of HOSCN in 
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mammalian cells has shown that HOSCN can target GAPDH in HCAECs, and GAPDH and CK in 
J774A.1 macrophages, both important proteins involved in glucose metabolism, resulting in 
a loss of enzymatic activity, indicating that HOSCN can also oxidise non-bacterial proteins, 
influencing their activity [92, 185, 201]. 
However, the consequences of the perturbation of GAPDH activity, and potentially other 
metabolic enzymes, by HOSCN have not been studied in detail. During inflammatory 
conditions, where neutrophil activation leads to the increased production of MPO-derived 
oxidants, this may be an important pathway to cell dysfunction. This is particularly important 
to smokers who are at an increased risk of developing inflammatory diseases, including 
cardiovascular diseases and stroke, and have elevated plasma SCN-, hence producing greater 
yields of HOSCN [83, 304, 381]. 
The study performed in this Chapter will determine whether HOSCN-induced oxidation of 
protein thiols influences glycolysis in J774A.1 macrophages, as predicted on account of the 
known targeting of GAPDH, and the effects of this oxidant on glycolysis in bacterial cells. 
 
4.2 Aims 
The aim of the studies presented in this Chapter is determine whether HOSCN perturbs the 
metabolism of glucose in J774A.1 macrophages, resulting in decreased energy production 
using a series of functional glycolysis assays. Whether the effect of HOSCN on the cellular 
glycolytic pathways occurs in a reversible manner will also be assessed. 
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4.3 Results 
4.3.1 HOSCN targets glycolytic enzymes 
It has been shown previously that HOSCN targets glycolytic enzymes in different cell types 
[56, 199, 379]. Evidence has been presented for sulfenic acid formation on GAPDH and CK in 
macrophages exposed to HOSCN [201]. In addition, a proteomic analysis to measure 
reversible thiol modification indicated that fructose-bisphosphate aldolase and triose-
phosphate isomerase (TPI) are also targets of HOSCN (Tessa Barrett, PhD Thesis, 2012). Initial 
studies were performed to examine whether sulfenic acids were formed on key glycolytic 
enzymes within cells after exposure to HOSCN. J774A.1 cells (1 × 106 cells) were treated with 
DCP-Bio1 for 1 h at 37 ˚C before being treated HOSCN (0 – 200 µM) for 1 h at 22 ˚C. After the 
mitochondrial isolation, the cytosolic fraction was sampled and the proteins were separated 
using SDS-PAGE. The proteins were transferred to membranes and were probed with anti-
GAPDH, anti-aldolase or anti-TPI antibodies, before being incubated with streptavidin-HRP 
and imaged using ECL. 
 
Figure 4.1: Western blots identifying the location of glycolytic enzymes. 
J774A.1 cells (1 x 106 cells mL-1) were pre-treated with DCP-Bio1 (500 µM) or DMSO (1% v/v) 
(VC) for 1 h at 37 ˚C prior to the addition of HOSCN (0 – 200 µM) before further incubation 
for 1 h at 22 ˚C. Cells were then prepared and the cytosol was probed for (A) sulfenic acids (B) 
GAPDH, (C) fructose-bisphosphate aldolase or (D) TPI. These blots were then compared 
against the blots of DCP-Bio1 probed samples. Boxes indicate which bands lined up with 
bands from both the DCP-Bio1 probed cytosol samples. The images are a representative of 3 
separate experiments. 
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The results show that the molecular weight and position some of the bands in the DCP-Bio1 
blot align with the position of GAPDH, aldolase and TPI from this experiment (Figure 4.1).  
The data are consistent with previous studies using IAF and 2D SDS-PAGE to probe for 
reversible thiol modifications in J774A.1 cells exposed to HOSCN (Tessa Barrett, PhD Thesis, 
2012). As IAF does not identify the specific type of reversible modification, these results 
indicate that the reversible modifications previously identified are possibly sulfenic acids. 
There are various limitations to using Western blot analysis to identify proteins tagged with 
the DCP-Bio1 probe, and further analysis, such as LC-MS/MS, is required to fully characterise 
the identification of the DCP-Bio1 labelled proteins.  
Further studies were performed to determine whether HOSCN has a functional effect on 
glycolysis in J774A.1 macrophages. 
 
4.3.2 Determining the effect of HOSCN on glycolysis using the Seahorse XF 
analyser 
To determine the effect of HOSCN oxidation of the function of glycolysis in J774A.1 cells a 
Seahorse XF bioanalyser was used. The analyser can measure two variables, oxygen 
consumption rate (OCR), which is a measure of mitochondrial respiration, and extracellular 
acidification rate (ECAR), which is largely the result of the glycolytic pathway. Glycolysis is a 
process that causes the release of protons from the cell as a by-product. The release of 
protons from the cell causes the extracellular media to acidify, decreasing the pH, which can 
be analysed by the XF bioanalyser by isolating small volumes of the media directly above a 
cellular monolayer (ca. 100 – 200 microns) by solid state probes. By analysing the changes in 
pH above the cells, proton efflux from the cells can be determined, and by using specific 
inhibitors of mitochondrial respiration and glycolysis, the 2 processes can be directly 
measured. To properly determine glycolysis in cells, two prerequisites must be met, firstly; 
the cells must adhere in a monolayer to ensure an even release of protons from the sample 
into the media. Secondly; the cells must be in an environment of media that has no buffering 
capacity as to properly determine the flux of protons from the cell, as a change in the pH of 
the media must occur, if the media has a buffering capacity, glycolysis cannot be properly 
determined by this method. 
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Seahorse bioscience supplies a non-buffering DMEM media that also contains no glucose, L-
glutamine, sodium pyruvate or growth factors, which has been used in all of the glycolysis 
and mitochondrial analysis experiments in this Thesis and will be called “basal DMEM” 
throughout. 
A glycolytic stress test is performed by measuring the release of protons from the cell into 
the media. First, the glycolytic state of the cells in glucose-free media is recorded, then 
glucose (10 mM) is injected, activating the glycolytic pathway and the basal glycolytic state 
is recorded. After baseline glycolysis is recorded, oligomycin (1.5 µM) is injected; inhibiting 
mitochondrial ATP synthesis and this inhibition of ATP synthase induces the glycolytic 
capacity, an increase in the metabolism of glucose in an attempt to maintain ATP production. 
Finally, the hexokinase inhibitor 2-deoxyglucose (100 mM, 10 × excess compared to glucose) 
is injected, halting glycolysis and allowing for the quantification of non-glycolytic proton 
producing pathways. This reading is subtracted from all previous recordings, allowing for an 
accurate determination of glycolytic flux. From this point, the glycolytic reserve can be 
calculated, which is the difference between the glycolytic capacity and baseline glycolysis 
(Figure 4.2). 
 
4.3.2.1 Cell culture density 
Before performing the glycolytic stress test as a functional measure of glycolysis (Figure 4.2), 
an optimal cell number needed to be determined. The optimal cell number to be used was 
determined by finding a balance between a viable cell monolayer within each well of the 
plate and the required number of cells to cause a measurable change in ECAR (ca. 10 – 20 
mpH/min/mg protein). Because the plate is shaken between readings, the cells were plated 
to the wells (0.28 cm2/well) using Cell-Tak adhesive (3.5 µg/cm2), to ensure the cells remain 
attached to the plate.  
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Figure 4.2: The glycolytic stress test profile. 
The glycolytic stress test is made of 4 distinct parts. A no glucose glycolysis response, then the 
injection of 10 mM glucose allows recording of baseline glycolysis. After the baseline 
readings, 1.5 µM oligomycin is injected and the glycolytic capacity (maximum glycolysis) can 
be determined. 2-deoxyglucose (2-DG) is injected which inhibits hexokinase, halting 
glycolysis, allowing for the determination of background proton releasing processes to non-
glycolytic pathways. 
 
For this experiment, the cells were plated in basal DMEM containing 10 mM glucose (glucose 
is typically injected once the experiment has begun, but in this test a ‘no glucose reading’ 
was not needed), at varying cell densities, before being placed in the Seahorse XF analyser 
and baseline glycolysis was monitored for ca. 1 h. Results show that 2.5 × 104 cells and 5.0 × 
104 cells gave similar ECAR readings, both of which were below 10 mpH/min/mg protein 
(Figure 4.3). Cells plated at a density of 7.5 × 104 cells/well resulted in a steady and 
continuous signal for the duration of the experiment (ca. 17 mpH/min/mg protein), while 
cells at densities above this did not actually improve or increase the signal substantially. 
Instead, higher cell densities led to a decrease in ECAR throughout the experiment, upon 
further inspection, the cells had not formed a strong monolayer, which caused cells to be 
shaken off, confounding the analysis.  
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Figure 4.3: Optimisation of cell number used in the glycolytic stress test. 
J774A.1 cells were plated in XF24 cell culture plates at various densities 2.5 × 104 (), 5.0 × 
104 (), 7.5 × 104 (), 1.0 × 105 () and 1.25 × 105 () in basal DMEM containing 10 mM 
glucose. The cells were then left placed into the Seahorse bioanalyser and their baseline ECAR 
was measured for 7 cycles (ca. 1 h). The results indicate that 7.5 × 104/ well had the highest 
and most consistent measurements throughout. The results are the average of 1 experiment 
run with triplicate treatments ± S.E.M. 
 
4.3.2.2 Oligomycin injection concentration 
The next step was to optimise the concentration of the ATP synthase inhibitor, oligomycin. 
Oligomycin inhibits the formation of ATP by ATP synthase during oxidative phosphorylation; 
this causes the cells to respond by increasing their glycolytic activity to compensate [382, 
383], enabling the determination of the maximum glycolytic capacity of the cell to be 
determined. Two prerequisites were set to determine which concentration of oligomycin 
would be used; firstly, the response must be substantial compared to the baseline. Secondly, 
of the concentrations that are substantial, the lowest concentration of them would be 
chosen as high concentrations can be toxic [384]. 
J774A.1 cells were plated at a density of 7.5 × 104 cells/well before being placed in the 
Seahorse analyser and equilibrated for 10 min before baseline glycolysis (ECAR) was 
measured for 3 cycles. Oligomycin was then injected and the ECAR response was measured 
for another 3 cycles. The optimisation assay showed that low concentrations (0.5 µM and 
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1.0 µM) oligomycin did not induce an increase in the ECAR of J774A.1 cells (Figure 4.4), while 
higher concentrations (2.5 µM and 3.0 µM) of oligomycin led to unsteady and variable 
readings. The results indicated that both 1.5 µM and 2.0 µM oligomycin caused a doubling 
in the ECAR from baseline readings, and both caused very similar and steady responses, 
leading to the choice of 1.5 µM oligomycin being the concentration to be used for the stress 
test as it was the lower of the two. 
 
 
Figure 4.4: Oligomycin concentration optimisation using J774A.1 cells. 
J774A.1 cells (7.5 × 104 cells) were seeded into an XF24 cell culture plate and placed into the 
Seahorse XF bioanalyser where increasing concentrations 0.5 (), 1.0 (), 1.5 (), 2.0 (), 
2.5 () and 3.0 () µM of the ATP synthase inhibitor, oligomycin were injected and the ECAR 
response was recorded. The results are the average of 1 experiment run with triplicate 
treatments ± S.E.M. 
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4.3.3 HOSCN inhibits the glycolytic ability of J774A.1 macrophages 
The functional effect of HOSCN on the glycolytic activity of J774A.1 macrophages was 
examined initially using the Seahorse analyser to measure changes in ECAR on stimulation of 
cells with glucose. J774A.1 cells (7.5 × 104 cells) were treated with HOSCN (0 – 100 µM) in 
the XF24-well Seahorse plate in the presence of XF basal DMEM, which contained no glucose. 
Glucose is initially excluded from the media to determine the baseline measurement in the 
absence of glucose. After HOSCN treatment, the XF24 plate was placed into the Seahorse 
analyser to equilibrate, and then glycolytic activity was recorded by determining ECAR. 
Results indicate that HOSCN has a significant effect on the ECAR measurements following 
the injection of glucose into the media (Figure 4.5). In this experiment, the cells were 
exposed to HOSCN (0 – 100 µM) and immediately placed in the analyser, and changes in 
glycolysis were recorded for 13 cycles (ca. 1 h). Interestingly, it appears that the effect of 
HOSCN on glycolysis is almost immediate, as glycolysis is affected at the very first glucose 
positive recording, indicating the effects of HOSCN occur in the first ca. 20 min. Treatment 
with HOSCN has a dose-dependent inhibitory effect on ECAR measurements following 
injection of glucose to promote glycolysis, with untreated cells performing glycolysis 4 times 
more efficiently than cells treated with 100 µM HOSCN (Figure 4.5). This change in ECAR was 
only observed in the presence of active HOSCN, with no reduction in ECAR seen in 
experiments with decomposed HOSCN (dHOSCN). For the functional assays in this 
experiment, dHOSCN was employed to determine that the result observed was due to the 
oxidative ability of HOSCN and not due to the non-oxidative by-products of HOSCN 
decomposition, excess SCN- or a result of any buffer effect. 
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Figure 4.5: J774A.1 baseline glycolysis is affected by the oxidative ability of HOSCN 
Treatment of J774A.1 cells (7.5 × 104 cells) with 0 (), 10 (), 25 (), 50 (), 100 () µM 
HOSCN or decomposed HOSCN () for 1 h at 37 C led to the attenuation of baseline 
glycolysis.  Cells were treated with HOSCN and were immediately placed into the Seahorse 
analyser to be analysed for the duration of the treatment. Results show that under basal 
conditions (10 mM glucose injection only) glycolysis is clearly attenuated at even low levels 
of HOSCN exposure when compared against baseline wells. Results are the average of 3 
independent experiments ± S.E.M.  
 
 
After recording the baseline glycolytic activity of J774A.1 cells, the functional effect of HOSCN 
on glycolysis was examined in more detail by performing a glycolytic stress test. Cells (7.5 × 
104 cells) were treated with HOSCN (0 – 100 µM) or decomposed HOSCN for 1 h at 22  ̊C. 
After treatment, the cells were placed into the Seahorse analyser and the test was performed 
(Figure 4.6). The background ECAR readings were first recorded for 3 cycles in the absence 
of glucose before 10 mM glucose was injected into each well and baseline glycolysis was 
recorded. The baseline closely mirrors the results from the previous experiment (Figure 4.5), 
with increasing concentrations of HOSCN impairing the ability of the cells to perform 
glycolysis (Figure 4.6). 
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Figure 4.6: HOSCN affects the glycolytic profile of J774A.1 cells 
 Treatment of J774A.1 cells (7.5 × 104 cells) with 0 (), 10 (), 25 (), 50 (), 100 () µM 
HOSCN or decomposed HOSCN () for 1 h at 22 C led to the attenuation of the glycolytic 
profile of the cells, decreased basal glycolysis, glycolytic capacity and reserve. The cells were 
markedly affected by HOSCN treatment at all stages of glycolysis. Results are the average of 
3 independent experiments ± S.E.M. 
 
After baseline glycolysis was recorded, 1.5 µM oligomycin was injected into the media of the 
cells to measure glycolytic capacity (Figure 4.7B). Results indicate that HOSCN inhibits the 
glycolytic capacity of the cells, compared to that observed with non-treated control cells or 
cells exposed to dHOSCN. Thus, HOSCN leaves the cells unable to meet their bioenergetic 
needs, with increasing concentrations of HOSCN causing a decrease in the glycolytic capacity 
of the J774A.1 cells that was significant at every concentration tested. Results also indicate 
that cells treated with concentrations of ≥ 50 µM HOSCN are unable to increase glycolytic 
capacity in response to oligomycin, with the ECAR measurements of 50 and 100 µM HOSCN 
treated cells falling below their baseline glycolysis readings. 
After determining baseline glycolysis and glycolytic capacity, cellular glycolytic reserve was 
determined (Figure 4.7C). Glycolytic reserve is the difference between glycolytic capacity and 
baseline, and is measured after the injection of 2-deoxyglucose (100 mM), which is used to 
inhibit glycolysis, and confirm that changes to ECAR in the experiment are related to 
glycolysis, rather than background proton producing processes within the cell. The 
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measurement of glycolytic reserve, therefore acts as a determinant of glycolytic stress. 
Exposure of J774A.1 cells to HOSCN resulted in a dose-dependent decrease in glycolytic 
reserve which was significant at concentrations ≥ 25 µM HOSCN. These data indicate that 
HOSCN promotes a significant increase in glycolytic stress, which renders the cells unable to 
respond to the stress placed on the glycolytic pathway. Changes in baseline glycolysis, 
glycolytic capacity and glycolytic reserve were not observed in the analogous experiments 
with dHOSCN showing that the response is due to the oxidative ability of HOSCN and not due 
to any of the non-oxidative by-products of HOSCN decomposition.  
 
 
Figure 4.7: Changes in the glycolytic profile of J774A.1 cells exposed to HOSCN. 
Analysis of the glycolytic stress test performed on J774A.1 macrophages (7.5 × 104 cells/well) 
treated with HOSCN (0 – 100 µM) or decomposed HOSCN. (A) Baseline glycolysis, which 
describes the effect of HOSCN on basal glycolysis after the injection of 10 mM glucose. (B) 
The maximum glycolytic output is described by the glycolytic capacity, following the injection 
of oligomycin (1.5 µM). (C) Glycolytic reserve is the glycolytic capacity minus basal glycolysis, 
and it indicates that HOSCN causes ‘glycolytic stress’ at sub-pathological concentrations. All 
data are the average of 3 separate experiments ± S.E.M. Significance was defined using one-
way ANOVA with post-hoc Tukey’s multiple comparisons test (** = p <0.01, *** = p <0.001, 
**** = p <0.0001). 
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A limitation of this study was the requirement for incubation of the cells in non-buffered cell 
media rather than a balanced salt solution that has been used in previous experiments. 
HOSCN could react with media components which may influence its reactivity. For this 
reason, it was not possible to perform a direct comparison of HOSCN with HOCl, as HOCl 
reactivity was quenched by media components when tested (data not shown). Studies were 
therefore extended to examine the effect of HOSCN on glycolysis by measuring lactate 
release, an end-point measurement of glycolysis which allowed for the testing of cells in 
HBSS, and also provided a means of comparing the effects of HOSCN and HOCl. 
After analysing the results of the Seahorse assay, an experiment was devised to determine if 
the treatment of J774A.1 cells with HOSCN led to a decrease in the formation of glycolytic 
end-products, and if these end-products could be easily measured and correlated back to 
the data obtained by the glycolytic stress test. 
 
4.3.4 Extracellular release of lactate from J774A.1 macrophages is reduced by 
HOSCN 
Lactate is produced from the conversion of pyruvate via LDH and is considered an end-
product of glycolysis, which is released into the extracellular environment, with extracellular 
lactate levels being proportionally correlated to intracellular glycolytic activity [334]. A 
lactate assay was performed to determine if HOSCN exposure to J774A.1 macrophages led 
to a decrease in glycolytic end-products. J774A.1 cells (1 × 106 cells) were treated with HOSCN 
(0 – 100 µM) or decomposed HOSCN for 1 h at 22 ˚C, before removal of the oxidant solution, 
which was replaced with oxidant-free HBSS containing 10 mM glucose. The lactate 
concentration was measured in the supernatant at 1 and 2 h post treatment (Figure 4.8 & 
Figure 4.9). 
Exposure of cells to HOSCN for 1 h caused a significant decrease in the concentration of 
lactate secreted by the cells, with a significant decrease noted at the first treatment 
concentration (10 µM) (Figure 4.8A) and at further time points (Figure 4.8B & C). Treatment 
of cells with the decomposed HOSCN did not lead to a decrease in lactate release from 
J774A.1 cells, indicating that the loss is due to the oxidative action of HOSCN and not a 
decomposition by-product, with the results mirroring the basal ECAR measurements of the 
glycolytic baseline and stress test experiments.    
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Figure 4.8: HOSCN attenuates the extracellular release of lactate from J774A.1 cells. 
(A) Treatment of J774A.1 cells (1 × 106 cells) with HOSCN (0 – 100 µM) or decomposed HOSCN 
for 1 h at 22 C led to a decrease in lactate release. Cell media was replaced and cells 
incubated at 22 C for another (B) 1 h and (C) 2 h before lactate concentration was 
determined using an M2e plate reader reading absorbance at 490 nm. Values of the results 
are the mean ± S.E.M (n = 3). **, *** and **** show a significant (p < 0.01, 0.001 and 0.0001, 
respectively) decrease compared to respective controls by Repeated Measures one-way 
ANOVA with a post-hoc Tukey’s test. 
 
 
 
A second hypothesis was also tested, as data has shown that the removal of LPO/H2O2/SCN- 
from bacterial cultures led to the restoration of the glycolytic enzyme activity [200], 
indicating that HOSCN damage may be reversible. After measuring the lactate concentration 
in the extracellular media, the oxidant solution was removed and replaced with fresh HBSS 
(10 mM glucose). The cells were then left to metabolise the glucose in the media for another 
hour, to examine whether HOSCN-induced changes to lactate production is reversible. 
Results show that over the next 2 hours, the untreated cells and dHOSCN treated cells 
continued to release lactate into the media, at similar rate to that observed during the 
treatment time (Figure 4.8A). In the 1 h after treatment, there was a non-significant increase 
but still reduced extent of lactate release with the HOSCN-treated cells. During the second 
hour, non-treated and dHOSCN treated cells roughly doubled the concentration of lactate in 
the supernatant while cells treated with 10 and 25 µM HOSCN saw a significant, but still 
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reduced increase in extracellular lactate release compared to the treatment and 1 h post 
time points (Figure 4.9). Cells treated with ≥ 50 µM HOSCN saw no increases in the rate of 
lactate release over the 2 hours. These results indicate that treatment with 10 and 25 µM 
HOSCN may be reversible, though extent of reversibility is limited. 
 
 
Figure 4.9: Comparison of lactate release against time. 
Treatment of J774A.1 cells (1 × 106 cells) with HOSCN (0 – 100 µM) or decomposed HOSCN 
for 1 h at 22 C, comparing each concentration separately over the 3 h experiment. Results 
indicate that HOSCN induced damage can be repaired to a certain extent. Values of the results 
are the mean ± S.E.M (n = 3). *, **, *** and **** show a significant (p < 0.05, 0.01, 0.001 
and 0.0001, respectively) increase compared to respective time-points by Repeated Measures 
two-way ANOVA with a post-hoc Tukey’s test.  
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4.3.4.1 HOCl does not reduce the concentration of extracellular lactate 
An extracellular lactate assay was performed to determine if HOCl was able to inhibit lactate 
formation in J774A.1 cells and allow a comparison of the data to the results obtained after 
treating cells with HOSCN. 
J774A.1 cells were treated for 1 h with HOCl (0 – 100 µM) at 22 ˚C, before analysing, the 
extracellular media was tested for lactate. Results indicate that HOCl was unable to cause a 
reduction in the concentration of extracellular lactate at any of the concentrations tested 
(Figure 4.10), suggesting that HOCl, unlike HOSCN, is unable to inhibit glycolytic enzymes in 
J774A.1 cells. 
 
 
Figure 4.10: HOCl is unable to inhibit the release of lactate into the extracellular media. 
 J774A.1 cells (1 × 106 cells) were treated with HOCl (0 – 100 µM) for 1 h at 22 C before 
lactate concentration was determined using an M2e plate reader and reading absorbance at 
490 nm. HOCl did not induce a decrease in lactate release at any of the concentrations tested, 
indicating that HOCl does not play a part in the inhibition of glycolytic activity. Values of the 
results are the mean ± S.E.M (n = 3). Data were analysed using Repeated Measures one-way 
ANOVA with a post-hoc Tukey’s test. 
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4.3.4.2 Glucose uptake is unaffected by HOSCN treatment 
Experiments were performed to assess the effect of HOSCN on glucose uptake, which may 
also influence the capacity of the cells to undergo glycolysis. This is important because 
HOSCN may inactivate glucose transport proteins on the cell membrane; this has been 
reported previously in bacterial cells, including S. galactiae [385] Glucose uptake was 
measured using the fluorescent glucose analog, 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-
yl) amino]-D-glucose (2-NBDG). 
J774A.1 cells (1 × 106 cells mL-1) were treated with HOSCN (0 – 200 µM) in PBS (does not 
contain glucose) for 1 h at 22  ̊C or the glucose uptake inhibitor, apigenin (50 µM), for 20 min, 
while being supplemented with 500 µM 2-NBDG for 1 h. After treatment, the media was 
removed and replaced with PBS before being imaged using a fluorescence microscope. The 
results clearly show that non-treated control cells readily take up the fluorescent 2-NBDG, 
consistent with active glucose uptake. HOSCN has no effect on the uptake of 2-NBDG into 
J774A.1 cells at 50 and 100 µM while cells treated with the positive control, apigenin (50 
µM), had an observable reduction in 2-NBDG fluorescence indicating an inhibition of glucose 
uptake proteins. 
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Figure 4.11: HOSCN does not affect the ability of J774A.1 macrophages to uptake glucose. 
Representative images of cells exposed to HOSCN (0 – 100 µM) or the positive control, 
apigenin (50 µM), a flavonoid that inhibits glucose uptake. Images show that HOSCN has little 
to no effect on the fluorescence of 2-NBDG within the cell using a fluorescent microscope (λex 
= 485 nm, λem = 535 nm). Results indicate that glucose uptake is unaffected by HOSCN 
treatment while cells treated with apigenin show a marked decrease in intracellular 2-NBDG 
fluorescence, indicating an inhibition of glucose uptake. The results are representative of 1 
experiment with samples run in triplicate. 
 
 
A plate reader assay was also performed, to quantify the change in 2-NBDG fluorescence 
after HOSCN exposure of the J774A.1 cells. Cells (1 × 106 cells/well) were treated with HOSCN 
(0 – 200 µM) for 1 h or apigenin (50 µM) for 20 min at 22 ˚C in the presence of 500 µM 2-
NBDG in PBS. After treatment the cells were washed with PBS and the fluorescence was 
determined using an M2e plate reader at λex = 485 nm, λem = 535 nm. 
The results are consistent with the microscopy results, showing that HOSCN does not inhibit 
the ability of the cells to take up 2-NBDG at any of the concentrations tested (Figure 4.12). 
In contrast, apigenin caused a significant decrease in the ability of cells to uptake 2-NBDG. 
These data suggest that HOSCN plays no role in the inhibition of glucose uptake under the 
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conditions employed in this study. Thus, the effect of HOSCN on cellular glycolysis is 
attributed to the inhibition of glycolytic enzymes within the cytosol, rather than the oxidation 
of thiols or other modifications of membrane glucose transporters. However, it is important 
to confirm that extensive cell death is not responsible for the changes in glycolysis. 
 
 
Figure 4.12: HOSCN treatment has no effect on glucose uptake in J774A.1 cells exposed to 
2-NBDG. 
Cells (1×106 cells) were treated with HOSCN (0 – 200 µM) for 1 h or apigenin (50 µM) for 20 
min at 22 ˚C before the media was removed and replaced with PBS. In place of glucose, 2-
NBDG, a fluorescent glucose analogue was used to determine whether or not the cells are 
able to uptake glucose using a M2e plate reader (λex = 485 nm, λem = 535 nm). Results indicate 
that HOSCN does not have the ability to inhibit glucose uptake, while apigenin significantly 
reduced glucose uptake in J774A.1 cells. Values of the results are the mean ± S.E.M (n = 3). 
**** shows a significant (p < 0.0001) increase when compared to the control by Repeated 
Measures one-way ANOVA with a post-hoc Tukey’s test. 
 
Therefore, an experiment was performed to confirm that HOSCN did not perturb glycolysis 
via the induction of cell lysis and release of cellular contents into the media. 
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4.3.4.3 The inhibition of glycolysis is not due a decrease in cell viability 
Lactate dehydrogenase (LDH) catalyses the reversible reaction of pyruvate to lactate when 
oxygen is in short supply in the environment [386]. LDH release is commonly used as a test 
for cellular viability, as LDH activity can be readily measured in the extracellular milieu as 
cells lyse. Activity is measured following the addition of NADH and pyruvate, in excess, to 
ensure that the rate-limiting factor is LDH concentration. This assay was performed to 
confirm that the effect of HOSCN on glycolysis was not influenced by cellular lysis, as 
predicted on the basis of previously published data [91]. The experiment was performed 
under identical conditions to the Seahorse XF glycolysis stress test, except that cells were 
treated in HBSS, rather than the basal DMEM. Cells were treated with the same 
concentration of HOSCN used in the glycolytic stress test (0 – 100 µM) or decomposed 
HOSCN in HBSS for 1 h at 22 ˚C and for 2 h, with the second hour at 37 ˚C. 
Results of the LDH assay indicated that HOSCN did induce some cell lysis (20 % loss in 
viability) at the highest concentration of HOSCN used (100 µM) at the 1 h time point (Figure 
4.13A) with increases in the LDH activity apparent in the extracellular media, while little to 
no LDH activity was observed in the media of non-treated cells and cells treated with lower 
concentrations. At the 2 h time point, a greater degree of lysis was observed, which was 
significant on exposure of the cells to 50 and 100 µM HOSCN (Figure 4.13B). These results 
indicate that HOSCN-induced oxidation induces lysis at the higher treatment concentrations, 
while lysis did not occur in the samples treated with decomposed HOSCN, indicating that 
lysis is caused by the oxidative ability of HOSCN and not SCN- or a decomposition product of 
HOSCN (Figure 4.13A & B). These results indicate that the significant perturbation of 
glycolysis, seen at concentrations where no cell lysis is observed, is not due to a loss in cell 
viability. 
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Figure 4.13: Cell lysis and LDH release into the extracellular milieu is induced by HOSCN 
treatment. 
J774A.1 cells (1 × 106 cells) were treated with HOSCN (0 – 100 µM) or decomposed HOSCN 
for (A) 1 h or (B) 2 h at 22 C for the first hour and at 37 C for the second hour to emulate 
the conditions of the glycolysis assay. The activity of LDH was measured in the extracellular 
milieu and within the cells using an M2e plate reader, recording the absorbance at 340 nm 
every 5 min for 30 min, to determine the extent of cellular lysis. Values of the results are the 
mean ± S.E.M (n = 3). *** and **** show a significant (p < 0.001 and 0.0001, respectively) 
decrease compared to respective controls by Repeated Measures one-way ANOVA with a 
post-hoc Tukey’s test. 
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4.4 Discussion 
The results of this Chapter support the hypothesis that HOSCN targets glycolytic enzymes, 
causing an attenuation of glycolysis in J774A.1 cells. The Seahorse assay confirmed that the 
oxidative ability of HOSCN causes a decrease in the glycolytic capabilities of the 
macrophages. The results also indicate that the production of the glycolytic end-product, 
lactate, is reduced in HOSCN-treated cells. This was not observed in cells treated with HOCl, 
consistent with HOCl having less effect on glycolysis under the treatment conditions in this 
study. The results are consistent with the inhibitory effects of HOSCN on glycolysis being due 
to the targeting and inhibition of cytosolic glycolysis proteins, rather than the inactivation of 
glucose transport proteins or cell lysis. 
Aldolase, TPI together with GAPDH have been shown to be targeted by HOSCN in proteomic 
experiments (Tessa Barrett, PhD Thesis, 2012). These data are supported by the Western 
blots in this Chapter showing the co-migration of proteins labelled with the sulfenic acid 
probe, DCP-Bio1, with these glycolytic proteins following exposure of the cells to HOSCN. 
Aldolase converts fructose 1,6-bisphosphate into the triose phosphates, dihydroxyacetone 
phosphate and glyceraldehyde 3-phosphate, and has been shown previously to be partially 
inhibited in Streptococci cremoris 972 exposed to the LPO/H2O2/SCN- system for 30 min 
[199]. GAPDH catalyses the conversion of glyceraldehyde 3-phosphate to D-glycerate 1,3-
bisphosphate, and has been shown to be inhibited by HOSCN in both bacterial and 
mammalian cells [84, 92, 201]. These glycolytic enzymes span the end of the preparatory 
phase and the beginning of the pay-off phase of glycolysis (Scheme 4.1). Modification of 
these enzymes by HOSCN is likely to have impact on the extent of glycolysis and ATP levels 
in the cells, because of the locations of these proteins (aldolase, TPI and GAPDH) in the 
pathway, the cells will have consumed 2 ATP molecules in the preparatory phase to create 
fructose 1,6-bisphosphate. From this point, no further glycolysis is occurring in cells treated 
with HOSCN, as the enzymes required to form D-glycerate 1,3-bisphosphate are inhibited, 
which also means a loss in the net formation of 2 ATP molecules for the cell. 
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Scheme 4.1: The glycolytic pathway. 
Glycolysis is a highly conserved pathway involved in the production of ATP from glucose. The 
pathway consists of 10 steps and can be divided into 2 parts. The preparatory phase (blue); 
involves the use of 2 ATP molecules to break glucose down into glyceraldehyde 3-phosphate 
and the pay-off phase (green); where 4 ATP molecules are produced to net a total of 2 ATP 
molecules per molecule of glucose. Pyruvate, the glycolytic end-product can be converted to 
lactate by LDH and vice versa. G6P, glucose-6-phosphate; F6P, fructose-6-phosphate, PFK-1, 
phosphofructokinase-1; F1,6BP, fructose 1,6-bisphosphate; DHAP, dihydroxyacetone 
phosphate; GA3P, glyceraldehyde 3-phosphate; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; 1,3BPG, 1,3-bisphosphoglycerate; PGK, phosphoglycerate kinase; 3PG, 3-
phosphoglycerate; PSM, phosphoglycerate mutase; 2PG, 2-phosphoglycerate; PEP, 
phosphoenolpyruvate; LDH, lactate dehydrogenase. 
 
The ability of HOSCN to affect glycolysis in J774A.1 macrophages was examined using the 
Seahorse Extracellular Flux analyser. The analyser allows for the detection of changes in the 
pH of the extracellular milieu of cells. As cells undergo glycolysis, the surrounding media 
becomes increasingly acidic, which allows for the determination of glycolytic flux. Results 
indicated that HOSCN has a profound effect on the ability of J774A.1 cells to perform 
glycolysis, with low concentrations of the oxidant (25 µM) leading to a significant attenuation 
of glycolytic activity. These results were confirmed by determining the concentration of 
lactate released into the media by cells treated with HOSCN. It was shown that HOSCN 
inhibits the formation of lactate, a glycolytic end-product, in J774A.1 cells. The lactate assay 
also allowed for the determination of the effect of HOCl on glycolysis in J774A.1 cells, as the 
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experiment could be performed in a balanced salt solution rather than the basal DMEM 
required for use in the Seahorse assay, which immediately quenched the HOCl. In contrast 
to HOSCN, HOCl did not inhibit the formation of lactate in J774A.1 cells, indicating that HOCl 
does not attenuate glycolysis. 
Glucose transport in cells exposed to HOSCN was also interrogated, given the effects of this 
oxidant on glycolysis, and that previous data have shown that HOSCN can inhibit glucose 
uptake in Streptococcus agalactiae [385]. Results of the studies in this Chapter indicate that 
HOSCN does not influence that ability of the cells to uptake glucose. This suggests that 
HOSCN is unable to oxidise glucose uptake proteins on the cellular membrane of J774A.1 
macrophages, in contrast to previous studies where HOSCN inhibits glucose uptake in 
bacterial cells [379]. Similarly, no evidence for significant cell death was obtained under 
conditions where perturbations in glycolysis and lactate release are observed.  
Lloyd et al. published results indicating that HOSCN induced significant cell lysis in J774A.1 
cells [91], under comparable oxidant doses, but over a longer incubation time (3 h), using a 
different lysis assay, measuring DNA release. DNA release requires the lysis of both the 
cellular membrane and the nuclear envelope [387], while the LDH assay only requires the 
lysis of the cellular membrane [388, 389]. The LDH activity assay was not performed by Lloyd 
et al. owing to the ability of HOCl to inhibit LDH activity, causing an underestimation of 
damage caused by the oxidant to the cells [91, 183]. In this Thesis, the mode of death was 
not studied, but Lloyd et al. showed that in J774A.1 cells, with comparable HOSCN 
concentrations at 1-2 h that cell death occurs by apoptosis [91]. The results of this Chapter 
indicate that a possible trigger for this apoptosis is the perturbation of glycolysis in J774A.1 
cells. 
The results imply that HOSCN alters glycolysis by directly interacting with cellular enzymes. 
The formation of sulfenic acids may play a role given the overlay of the DCP-Bio1 Western 
blots with aldolase, TPI and GAPDH. The activities of thiol-dependent enzymes have been 
known to be critical to glycolysis for many years now [198, 390]. Data show the inhibition of 
GAPDH and aldolase in Clostridium perfringens correlates with a loss in reduced thiols and a 
loss in the growth of C. perfringens, with the inhibition postulated to be caused by an 
interaction of the treatment with reactive sulfhydryl groups, which could include sulfenic 
acids [391]. The inhibition of growth and metabolism may be a result of HOSCN-induced thiol 
oxidation in bacteria, though in many cases no significant loss in bacterial viability is noted. 
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Moreover, in some cases, HOSCN-induced damage in regard to glycolysis is reversible once 
the oxidant is removed from Streptococci [199, 392]. 
Glucose uptake in J774A.1 macrophages was not affected by HOSCN-induced oxidation, in 
contrast to data showing that HOSCN can attenuate the ability of bacterial cells to transport 
glucose into the cytosol, for it to be catabolised [200, 379, 385]. In bacteria there are 
numerous systems involved in glucose uptake, a well characterised system is the 
phosphoenolpyruvate (PEP) group translocation, also known as the phosphotransferase 
system (PTS), first described in 1966 [393]. The PTS is responsible for transporting many 
carbohydrates into bacteria such as mannose, fructose and glucose, after phosphorylating 
the carbohydrates at the expense of phosphoenolpyruvate (PEP). The PTS is a group of 
phosphoproteins, mainly enzyme I and Histidine protein (HPr); the proteins which transfer 
the phospho-group from PEP to the sugar, which contains an essential cysteine residue that 
acts as a proton donor during catalysis [394]. The second group of the PTS is enzyme II; the 
enzyme responsible for glucose transport across the cell membrane, which requires the 
transfer of a phosphoryl group to a cysteine residue contained within the protein [395, 396]. 
Mammalian cells employ a different system, using Na+ - dependent co-transporters and 
simple facilitative uniporters; GLUT proteins. These proteins are not required to modify the 
carbohydrate to move it across the cell membrane, and only need to move the substrate 
down the concentration gradient, as the concentration within the cell is modified by 
modifying the concentration of glucose in the cells environment e.g. the bloodstream or 
extracellular fluids [397, 398]. 
The functional differences between bacterial and mammalian glucose transporters may help 
to explain that HOSCN has a differential effect on glucose transport in bacterial cells 
compared to macrophages. The PTS system requires cysteines, the major target of HOSCN, 
which are important in the transfer of phosphoryl-groups from PEP to the carbohydrate via 
the action of enzyme I and HPr [395, 396]. The PTS is also responsible for the transfer of the 
phosphorylated sugars through the cell membrane, which requires a subsequent transfer of 
a phosphoryl group to the cysteine residue of enzyme II [395, 396]. Mammalian cells are less 
reliant on cysteines and only require the facilitative movement of glucose down the 
concentration gradient, making them less susceptible to HOSCN induced damage and 
inhibition. 
The HOSCN-induced inhibition of glycolysis has numerous implications for the J774A.1 cells, 
which bear some similarities to the behaviour of HOSCN-treated bacterial cells. While not 
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necessarily causing cell death, HOSCN-induced oxidation of glycolytic proteins is likely to 
result in an inhibition in growth and proliferation, as these pathways require ATP, the 
energetic end-product of glycolysis. Interestingly, because of the location of aldolase, TPI and 
GAPDH within the glycolytic pathway, inhibition of these enzymes would cause a significant 
loss in ATP formation. Studies investigating male rat fertility have shown that the inhibition 
of GAPDH and TPI has a dramatic effect on the formation of ATP within sperm cells without 
causing cell death [399]. The rationale for this is that these enzymes appear in the glycolytic 
pathways at the end of the preparatory phase, when the cell has expended 2 molecules of 
ATP per glucose molecule, but before the pay-off phase where there is a net gain of 2 ATP 
molecules per glucose molecule [158, 400], and without the formation of ATP, cells reduce 
their use of ATP by only performing processes vital for survival.  
Lactate is also important in terms of glycolysis and cell survival, as lactate is formed by LDH 
in a reversible reaction from pyruvate [401]. The inhibition of glycolysis by HOSCN will 
therefore reduce pyruvate production and cause a loss in energetic substrates for the 
electron transport chain (ETC). Another consequence of HOSCN-induced attenuation of 
lactate formation is the loss of NAD+. When lactate is formed by LDH, NAD+ is regenerated, 
which is used in concert with GAPDH to oxidise glyceraldehyde 3-phosphate to D-glycerate 
1,3-bisphosphate. This loss in the glycolytic capacity is then fed back into the pathway, 
further reducing the ability of key glycolytic enzymes to form the energetic substrates 
needed for proper cellular function [402]. 
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4.5 Summary 
The studies in this Chapter demonstrated that the addition of exogenously-added HOSCN 
has the ability to inhibit glycolysis in real-time in J774A.1 macrophages at physiologically 
relevant concentrations (≥ 25 µM). This is especially relevant to cigarette smokers, as the 
parent ion of HOSCN (SCN-) is found in plasma at concentrations up to and exceeding exceed 
300 μM [80, 82, 83]. Data are consistent with the formation of sulfenic acids on the glycolytic 
proteins GAPDH, TPI and aldolase in cells exposed to HOSCN, rather than the oxidation and 
inhibition of glucose uptake proteins on the cellular membrane or significant cell lysis. 
Lactate release from the J774A.1 cells was also inhibited in cells treated with HOSCN, 
validating the results of the real-time glycolytic assay showing that HOSCN inhibits glycolysis 
and the formation of glycolytic end-products, while HOCl was unable to inhibit lactate 
release. Further studies were performed to examine whether the inhibitory effects of HOSCN 
on glycolysis and the decreased production of energetic substrates affects oxidative 
phosphorylation and the integrity of mitochondria of J774A.1 cells.  
 116 
 
5 Hypothiocyanous Acid Induces Mitochondrial Dysfunction 
in J774A.1 macrophages 
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5.1 Introduction 
In a biological setting, the hypohalous acids play a role in innate immune defence. While 
HOCl is primarily responsible for bacterial cell killing, HOSCN has a bacteriostatic effect. 
HOSCN reversibly oxidises bacterial protein thiols, with a major target of this reversible 
oxidation being bacterial glycolytic proteins [56, 197, 199, 379]. The results of the previous 
Chapter showed that HOSCN can also attenuate glycolysis in mammalian J774A.1 
macrophages. 
HOSCN affects glycolysis by oxidising critical enzymes along the glycolytic pathway, leading 
to a decrease in the availability of pyruvate, the glycolytic end-product. Pyruvate is then 
dehydrogenated by pyruvate dehydrogenase to form acetyl-CoA, which is shuttled toward 
the mitochondria to participate in the citric acid cycle (or tricarboxylic acid cycle; TCA cycle) 
[403]. This cycle is important in aerobic metabolism as the product is NADH, a critical co-
factor, is fed into the electron transport chain and is required for oxidative phosphorylation, 
mitochondrial respiration and ATP production [404, 405]. For this reason, cellular NADH 
concentrations have been used as a marker of mitochondrial and cellular bioenergetic health 
[406]. Changes in the formation of glycolytic end-products not only have various effects on 
the energetic status of the cell but can also affect cellular growth [407], much in the same 
way HOSCN affects bacterial cell growth. Additionally, HOCl has also been shown to perturb 
mitochondrial function [187], though the results of the previous Chapter indicate that 
HOSCN may be more potent given its effects on glycolysis. 
Mitochondrial electron transport chain enzymes contain critical thiols and iron-sulfur 
clusters, which play an important role in the regulation and activity of the TCA cycle and 
mitochondrial oxidative phosphorylation [408, 409]. Proteins such as aconitase 2, complex I, 
complex II, complex III and complex V all contain viable targets for HOSCN oxidation [207-
213], and the oxidation of these proteins is predicted to lead to a decrease in the efficiency 
of the electron transport chain (ETC). Another protein that is critical for the function of the 
ETC, but is not directly involved in the shuttling of electrons across the pathway is VDAC-1, 
which also contains thiol residues and is located on the outer mitochondrial membrane [214, 
215].  
Interestingly, the inhibition of mitochondrial respiration has numerous consequences for the 
mitochondria. As ATP production is reduced, either via a reduction in the formation of 
glycolytic end-products or by the oxidation of ETC proteins, the mitochondrial permeability 
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transition pores (MPTP) are formed. The induction of MPTP increases the permeability of 
mitochondria, causing a depolarization of the mitochondria, which allows for the movement 
of small molecules across the mitochondrial membrane, including protons [410, 411]. The 
free movement of protons across the mitochondrial membrane means a loss in the 
electrochemical gradient that is needed to produce the proton-motive force required for the 
production of ATP and the viability of the cell [412, 413]. The induction of the MPTP also 
causes the leakages of pro-apoptotic factors, such and cytochrome c into the cytosol, 
triggering cell death by apoptosis [414]. 
 
5.2 Aim 
The aim of this Chapter is to determine if HOSCN is able to inhibit J774A.1 macrophage-
mitochondrial respiration and induce mitochondrial dysfunction. HOSCN-induced changes to 
the mitochondria and electron transport chain will be probed by using real-time 
mitochondrial respiration assays, probing the mitochondria for changes in the membrane 
potential and ATP, the end-product of the bioenergetic pathway, will be quantified. 
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5.3 Results 
5.3.1 The effect of HOSCN on J774A.1 mitochondrial respiration 
To determine the effect of HOSCN on mitochondrial respiration and oxidative 
phosphorylation in J774A.1 cells, the Seahorse XF bioanalyser was used. In these 
experiments the analyser was used to measure the oxygen consumption rate (OCR) of the 
cells. OCR is a measure of mitochondrial respiration, as cells respire, the concentration of 
dissolved O2 in the extracellular milieu changes directly above the cells. By using solid state 
sensor probes, the change (flux) in O2 concentrations can be determined, which is directly 
correlated to the activity of the electron transport chain of mitochondria. The result is a real-
time graph displaying changes to the respiratory profile of the cell. 
To obtain the respiratory profile, the cells are allowed to metabolise glucose (10 mM), which 
in turn allows for the baseline respiration to be determined. Then oligomycin is injected into 
the cell media, inhibiting ATP synthase and attenuating oxidative phosphorylation so the ATP 
coupler response (proton leak) can be observed. Next FCCP, an ionophore which shuttles 
protons through the mitochondrial membrane, is injected, disrupting the proton gradient, 
causes the mitochondria to increase their O2 consumption, with no ATP formation, so the 
ETC accelerator response can be observed. Finally, a mixture of rotenone and antimycin A 
are injected, causing a complete shutdown of the mitochondrial ETC, so non-mitochondrial 
O2 consumption can be determined. This result is then deducted from all previous 
observations.  
After the experiment, two more mitochondrial states can then be determined. The first is 
the spare respiratory capacity, which describes the stress of the mitochondria, is calculated 
as the ratio between the ETC accelerator response and the baseline respiration. Finally, the 
coupling efficiency, the ratio between the baseline respiration and the ATP coupling 
response, is a measurement of the efficiency of ATP formation. 
Before performing the glycolytic stress tests, the optimal cell number and oligomycin 
concentration was optimised (Section 4.3.2.1 and 4.3.2.2). Here the concentrations of FCCP, 
antimycin A and rotenone were optimised, after doing this the baseline OCR and 
mitochondrial stress test experiments were performed to determine if HOSCN and its role in 
inhibiting glycolysis also attenuates mitochondrial respiration and energy production. 
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Figure 5.1: The mitochondrial respiratory profile. 
The mitochondrial stress test consists of distinct 4 parts. Firstly, baseline respiration is taken 
while the cells are in 10 mM glucose media, analogous to the baseline glycolysis reading. The 
1.5 µM oligomycin is injected and the ATP coupler response is recorded, determining the 
amount of proton leak. Then 0.5 µM FCCP is injected to determine the ETC accelerator 
response, the maximum O2 consumption ability of the cell. Then 1.5 µM rotenone and 
antimycin A are injected, giving non-mitochondrial O2 consumption. This allows for the 
determination of the spare respiratory capacity ratio; a measure of mitochondrial stress and 
coupling efficiency; a measure of how efficiently ATP is produced. 
 
5.3.1.1 FCCP concentration optimisation 
Before performing the mitochondrial stress test, the concentrations of the various inhibitors 
were determined. To determine which concentration would be used, the greatest response 
with the lowest amount of inhibitor was chosen, as high concentrations can be toxic or in the 
case of FCCP, can totally collapse the mitochondrial membrane potential. FCCP is an 
ionophore, and is used as an uncoupling agent in experiments analysing mitochondrial 
respiration. It disrupts ATP synthesis by transporting H+ across the mitochondrial membrane, 
reducing the proton gradient before the protons can be used to provide energy for oxidative 
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phosphorylation, resulting in an increase in O2 consumption to correct for the decrease in 
ATP formation. 
The cells were plated into the XF24 cell culture plate (7.5 × 104 cells/well, based on the 
optimal number of cells to form a viable monolayer) (Section 4.3.2.1) and left to adhere to 
the plate for 20 min before being placed into the analyser where FCCP was injected from the 
probe cartridge after the cells were allowed to have their baseline OCR recorded for 3 cycles. 
The results indicate that 0.5 µM FCCP elicited the best response, increasing the OCR of the 
cells with the greatest efficiency (Figure 5.2). The lower concentration (0.1 µM) did not elicit 
a response, while 0.75, 1.0 and 1.5 µM did not perform as well as 0.5 µM FCCP, with lower 
overall OCR readings. The highest treatment of FCCP (3.0 µM) caused a decrease in OCR from 
baseline, indicating that the mitochondria had become completely uncoupled. 
 
 
Figure 5.2: FCCP concentration optimisation using J774A.1 cells. 
J774A.1 cells (7.5 × 104 cells) were seeded into an XF24 cell culture plate in XF basal DMEM 
(10 mM glucose) and placed into the Seahorse XF bioanalyser where increasing 
concentrations 0.1 (), 0.5 (), 0.75 (), 1.0 (), 1.5 () and 3.0 () µM of the 
mitochondrial uncoupler, FCCP, were injected and the response was recorded. The results are 
the average of 1 experiment run with triplicate treatments ± S.E.M. 
 
 
 122 
 
5.3.1.2 Antimycin A and rotenone concentration optimisation 
It was also necessary to optimise the concentrations of rotenone, which inhibits complex I 
by inhibiting the transfer of its electrons to ubiquinone, and antimycin A, a complex III 
inhibitor which binds to the Qi site, attenuating the reduction of ubiquinone [415]. The 
inhibition of complex I and III in the last step of the experiment, results in the shutdown of 
the mitochondria, resulting in no mitochondrial consumption of O2. This enables 
determination of background O2-consuming processes in the cell. 
The results of the mitochondrial inhibitor optimisation indicated that 0.5 µM antimycin A 
(Figure 5.3A) and 0.5 µM rotenone (Figure 5.3B) were the optimal concentrations to elicit a 
shutdown of the ETC in J774A.1 cells. When J774A.1 (7.5 × 104 cells) cells were treated with 
< 0.5 µM antimycin A, no decrease in the OCR was observed. The higher concentrations (1.0, 
1.5 & 3.0 µM) caused a substantial decrease, with OCR that was close to 0 pM/min, 
consistent with the shutdown of mitochondrial utilisation of O2 and other O2 consuming 
processes. 
The concentration that met the criteria needed for the experiments was 0.5 µM antimycin 
A, as its ability to cause mitochondrial shutdown was the same as the 0.75 µM treatment, 
while background oxygen consumption was still observed, indicating that the cells were still 
functional. A similar trend was observed after treating with the complex I inhibitor, rotenone. 
Treatment with 0.1 µM rotenone led to a decrease in OCR, but a greater extent of inhibition 
of respiration was seen with 0.5, 0.75 and 1.0 µM rotenone, with the ETC being almost 
completely inhibited while maintaining background oxygen consuming processes. 
Treatments with 1.5 and 3.0 µM rotenone led to an OCR close to 0 pM/min, indicating no 
oxygen consuming processes were taking place within the cell and that these concentrations 
may cause a loss in viability. Thus, a rotenone concentration of 0.5 µM was used in the 
mitochondrial stress test. 
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Figure 5.3: Optimisation of the mitochondrial inhibitors Antimycin A and Rotenone on 
J774A.1 cells. 
J774A.1 cells (7.5 × 104 cells) were seeded into an XF24 cell culture plate in XF basal DMEM 
(10 mM glucose) and placed into the Seahorse XF bioanalyser where increasing 
concentrations 0.1 (), 0.5 (), 0.75 (), 1.0 (), 1.5 () and 3.0 () µM of (A) Antimycin 
A, a complex III inhibitor and (B) Rotenone, a complex I inhibitor were injected and the 
response was recorded. The results are the average of 1 experiment run with triplicate 
treatments ± S.E.M. 
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5.3.2  HOSCN inhibits mitochondrial respiration in J774A.1 macrophages 
The J774A.1 cells were plated (7.5 × 104 cells/well) in the XF24 cell culture plate and then 
treated with HOSCN (0 – 150 µM) in the XF basal DMEM. The Seahorse XF DMEM was used 
as it does not have a buffering capacity, unlike HBSS or PBS. Media with a buffering capacity 
does not allow for the determination of pH and O2 flux of the media, which is required to 
determine the bioenergetic status of the cells. After the addition of HOSCN, the cells were 
transferred immediately into the analyser and their OCR was recorded for 1 h, not including 
a 15 min period at the beginning, where the cells and media were allowed to equilibrate. The 
results of baseline OCR readings in J774A.1 cells showed that HOSCN causes a decrease in 
cellular OCR, with concentrations of ≥ 100 µM HOSCN inducing a significant decrease in 
baseline OCR over the hour (Figure 5.4.).  
 
Figure 5.4: J774A.1 cells treated with HOSCN exhibit changes to baseline respiration. 
Treatment of J774A.1 cells (7.5 × 104 cells) with 0 (), 50 (), 75 (), 100 () or 150 () µM 
HOSCN in XF basal DMEM for 1 h at 37 C led to the attenuation of baseline mitochondrial 
respiration.  Cells were treated with HOSCN and were immediately placed into the Seahorse 
analyser for the duration of the treatment. The beginning of OCR recording occurs after a 15-
minute equilibration phase. Results show that under basal conditions, respiration is clearly 
attenuated at even low levels of HOSCN exposure when compared against baseline wells. 
Results are the average of 3 independent experiments ± S.E.M. **, *** and **** show a 
significant (p < 0.01, 0.001 and 0.0001, respectively) decrease compared to respective 
controls and #, ## show a significant (p < 0.05, 0.01, respectively) decrease over time by 
Repeated Measures two-way ANOVA with a post-hoc Tukey’s test. 
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The J774A.1 cells were plated in the wells of the XF24 cell culture plate (7.5 × 104 cells/well) 
and after leaving the cells to attach for 20 min at 37 ˚C and 5 % CO2, they were treated with 
HOSCN (0 – 150 µM) for 1 h at 22 ˚C. The cells were then placed into the analyser where the 
media and cells were further equilibrated for 15 min at 37 ˚C. After equilibration, the 
mitochondrial stress test was performed (Figure 5.5). First, baseline OCR was recorded, 
which resulted in a similar inhibition of basal respiration compared to that seen in Figure 5.4 
(Figure 5.6A), which supports HOSCN playing a role in inhibiting basal respiration. After the 
addition of oligomycin, which blocks the F0 portion of ATP synthase and inhibits state 3 
phosphorylating respiration, a decrease is observed in the ATP coupler response following 
HOSCN treatment (Figure 5.6B). After the FCCP injection, to stimulate maximum respiration 
and O2 consumption, the ETC accelerator response is recorded. The result shows that HOSCN 
has a profound effect on the cells ability to funnel O2 into the ETC, significantly inhibiting the 
ability of J774A.1 cells to increase oxygen consumption at every treatment concentration 
(Figure 5.6C). 
 
Figure 5.5: HOSCN causes the attenuation of the respiratory profile in J774A.1 cells. 
J774A.1 cells (7.5 × 104 cells) were treated with 0 (), 50 (), 75 (), 100 (), 150 () µM 
HOSCN in XF basal DMEM for 1 h at 22 C before being placed into the analyser to be 
equilibrated for 15 min, then the stress test was performed. Baseline respiration, ATP coupler 
response, ETC accelerator response, coupling efficiency and spare respiratory capacity were 
recorded. The results show J774A.1 cells were markedly affected by HOSCN treatment at 
many stages of respiration. These results are the average of 3 independent experiments ± 
S.E.M. 
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Figure 5.6: Changes in the respiratory profile of J774A.1 cells exposed to HOSCN. 
Analysis of the respiratory stress test performed on J774A.1 macrophages treated with 
HOSCN (0 – 150 µM). (A) Baseline respiration, which describes the effect of HOSCN on basal 
respiration. (B) ATP coupler response represents the minimum OCR reading in response to 
HOSCN and oligomycin. (C) The ETC accelerator response represents the highest possible OCR 
in response to HOSCN and FCCP. (D) The spare respiratory capacity provides details on the 
cells maximum ability to produce ATP while (E) coupling efficiency measures ATP turnover 
within the cell, describing the effect of HOSCN on baseline ATP production. Results are the 
average of 3 independent experiments ± S.E.M. *, **, *** and **** show a significant (p < 
0.05, 0.01, 0.001 and 0.0001, respectively) decrease compared to respective controls by 
Repeated Measures one-way ANOVA with a post-hoc Tukey’s test. 
 
 
  
 127 
 
When analysing the ratio of ETC accelerator response and basal respiration, spare respiratory 
capacity can be assessed, which is a measure of mitochondrial ‘stress’. The results show that 
HOSCN does not influence spare respiratory capacity in J774A.1 cells (Figure 5.6D). No 
change was observed due to the ratiometric decrease in both the basal respiration and the 
ETC accelerator response. Thus, although HOSCN perturbs basal respiration and the ETC 
accelerator response, the changes remained equal between the two profiles, maintaining a 
ca. 150 % spare respiratory capacity. 
 Finally, when the ratio between the ATP coupler response and basal respiration is analysed, 
the coupling efficiency can be determined. Coupling efficiency describes how much of the 
total O2 consumption is involved in the synthesis of ATP, while the rest is used to overcome 
the proton leak from the mitochondrial space. Results indicated that treating cells with 
HOSCN caused a loss in the efficiency at which ATP is formed (Figure 5.6E). At higher HOSCN 
concentrations (≥ 100 µM), a significant amount of O2 is either lost or used to overcome the 
proton leak, leading to a loss in ATP production. This result indicates that HOSCN plays a 
direct role in altering the mitochondria, and is possibly acting on transition and pore proteins, 
causing a loss in mitochondrial membrane potential. 
 
5.3.2.1 Cells treated with HOSCN are unable to maintain their ability to meet 
cellular energetic needs 
After determining the changes to glycolysis (Chapter 4) and mitochondrial respiration after 
HOSCN treatment further analysis was performed to better understand the energetic state 
of the cells in response to HOSCN. To determine this, an OCR/ECAR ratio was calculated 
(Figure 5.7), which combined data from both the glycolytic stress test (Section 4.3.3) and the 
mitochondrial stress test (Figure 5.5), and allowed for the visualisation of both glycolysis and 
oxidative phosphorylation, and how these two processes interact. 
The results of the OCR/ECAR analysis help to identify what is occurring within the J774A.1 
cells after HOSCN treatment in regards to their bioenergetic status. Firstly, with increasing 
concentrations of HOSCN, the baseline OCR and ECAR is attenuated (Figure 5.7). Treatment 
of J774A.1 macrophages with HOSCN also inhibits their response to oligomycin treatment. 
This result is not surprising in regards to the OCR, as oligomycin inhibits ATP synthase. But in 
 128 
 
response to oligomycin treatment, healthy cells are expected to increase their glycolytic 
activity to accommodate for the loss in ATP production by the mitochondria. 
Thus, in the non-treated cells, the addition of oligomycin causes an increase in ECAR, with a 
decrease in OCR. However, with the addition of HOSCN, the oligomycin ECAR response falls 
below basal rate. Indicating that the cells treated with HOSCN are unable to increase the rate 
of glycolysis is response to ATP synthase inhibition by oligomycin. These results demonstrate 
that HOSCN is very efficient at inducing bioenergetic dysfunction in J774A.1 macrophages. 
The results of the mitochondrial stress test indicate that HOSCN reduces the efficiency at 
which ATP is formed by the mitochondria. This reduced efficiency was hypothesised to be 
occurring as a response to proton leakage across the mitochondrial membrane. To test this 
hypothesis, mitochondrial membrane potential was studied using a fluorescent probe and 
flow cytometry, and assays to quantify cellular ATP levels were performed. 
 
 
Figure 5.7: Cells treated with HOSCN are unable to maintain their ability to meet 
bioenergetic needs. 
After performing both the glycolytic stress test and mitochondrial stress test, the condition of 
the J774A.1 cells was determined using an OCR/ECAR ratio. The OCR/ECAR ratios determined 
that in non-HOSCN treated cells (black), when oligomycin (black square) is added to basal 
state cells (black circle) and OCR is inhibited, ECAR can be increased to maintain the cells need 
for ATP. Treatment with 50 µM HOSCN (red) does not allow for increased glycolysis and ECAR 
to maintain energy production. 100 µM HOSCN (blue) affects glycolysis to a greater extent as 
it can no longer produce ATP. 
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5.3.3 HOSCN induces mitochondrial dysfunction by causing mitochondrial 
depolarisation 
To determine if the reduction in ATP coupling efficiency is due to a proton leak caused by 
HOSCN, a flow cytometry method was employed to examine whether HOSCN caused a 
reduction in the mitochondrial membrane potential. If mitochondrial depolarisation was 
observed, it would be indicative that HOSCN causes, at least partially, a loss of ATP 
production by inducing a proton leak from the mitochondria. 
To observe mitochondrial depolarisation, JC-1 was used. JC-1 is a cationic dye that 
accumulates within the mitochondria, where it forms J-aggregates, with broad excitation 
bands and an emission band at ca. 590 nm (red). As the mitochondria depolarise, the change 
in the membrane potential causes a ‘leakage’ of JC-1 into the cytosol, where the relative 
concentration is much lower, causing a dissociation of the J-aggregates and a shift in the 
emission spectra to ca. 530 nm (green). The formation of pores within the mitochondrial 
membrane, results in a decrease in the membrane potential to cause a leakage of JC-1 and a 
shift in the ratio of red:green fluorescence. 
The cells were plated (1 x 106 cells/well) in a 12-well plate and exposed to HOSCN (0 – 200 
µM) in HBSS for 1 h at 22 ˚C or CCCP, a positive control for mitochondrial depolarisation, for 
10 min at 5 % CO2 and 37 ˚C prior to the addition of JC-1. After incubation with JC-1, the cells 
were incubated for 15 min in an incubator of humidified 5 % CO2 at 37 ˚C and then the 
red:green fluorescence ratio was determined using the flow cytometer. Results indicated 
that with increasing concentrations of HOSCN, an increase in green fluorescence occurred 
(Figure 5.8). This means that with increasing concentrations of HOSCN, the J-aggregates 
within the mitochondria (red) begin to dissociate due to the depolarisation of the 
mitochondria and leakage into the cytosol (green). The increase in green fluorescence 
indicates that HOSCN is responsible for the change in mitochondrial membrane potential, 
which causes small molecules within the mitochondria to leak into the cytosol. This 
depolarisation could also explain the loss in the efficiency at which ATP is formed in the 
mitochondria in response to HOSCN treatment. The results indicate that a significant 
decrease in the mitochondrial membrane potential also occurs with CCCP treatment, 
indicating the positive control induces mitochondrial depolarisation (Figure 5.9). HOSCN-
induced a significant depolarisation of the mitochondria occurs at concentrations of HOSCN 
≥ 75 µM (Figure 5.9). At lower oxidant concentrations, there is an observable, but non-
significant decrease in the mitochondrial membrane potential. The results of this flow 
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cytometry experiment correlate well with the decrease in ATP production efficiency 
determined by the Seahorse XF mitochondrial stress test (Figure 5.6E). 
 
Figure 5.8: Mitochondrial depolarisation caused by HOSCN was probed using JC-1 
J774A.1 cells (1 × 106 cells) were treated with (B) 0, (C) 25, (D) 50, (E) 75, (F) 100, (G) 150 or 
(H) 200 µM HOSCN for 1 h at 22 ˚C or (A) 5 µM CCCP for 10 min at 37 ˚C. The cells were then 
labelled with JC-1 (2 µM) and left to incubate for 15 min at 37 ˚C. The formation of J-
aggregates in the mitochondria (red; λem = 590 nm) and the leak of these aggregates into the 
cytosol (green; λem = 529 nm) was analysed using flow cytometry. Results indicate that 
increasing concentrations of HOSCN decrease the mitochondrial membrane potential, with 
the increase in mitochondrial depolarisation causing the increased loss of J-aggregates from 
the mitochondria to the cytosol. The results pictured are a representation of data from 3 
separate experiments. 
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Figure 5.9: HOSCN causes mitochondrial depolarisation in J774A.1 cells. 
J774A.1 cells (1 × 106 cells) were treated with HOSCN (0 – 200 µM) for 1 h at 22 ˚C or 5 µM 
CCCP for 10 min at 37 ˚C. The cells were then labelled with JC-1 (2 µM) and left to incubate 
for 15 min at 37 ˚C. The formation of J-aggregates in the mitochondria (red; λem = 590 nm) 
and the leak of these aggregates into the cytosol (green; λem = 529 nm) was analysed using 
flow cytometry. Results are expressed as a ratio of red:green and indicate that HOSCN causes 
a decrease in the mitochondrial membrane potential, causing contents of the mitochondrial 
matrix to leak into the cytosol. Values of the results are the mean ± S.E.M (n = 3). *, ** and 
*** show a significant (p < 0.05, 0.01 and 0.001, respectively) decrease compared to the 
untreated control by Repeated Measures one-way ANOVA with a post-hoc Tukey’s test. 
 
 
 
After determining that HOSCN is able to cause a loss in the mitochondrial membrane 
potential, an experiment was performed to determine if the changes occur through the 
mitochondrial permeability transition pore (MPTP), by assessing whether the damage caused 
by HOSCN could be attenuated by inhibiting the action of the MPTP. 
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5.3.3.1 HOSCN induced mitochondrial depolarisation can be reversed 
To determine if the MPTP was involved in the HOSCN-induced attenuation of ATP synthesis, 
cyclosporin A (CsA) was used to inhibit the opening of MPTP and prevent depolarisation. The 
cells were plated (1 x 106 cells/well) in a 12-well plate and exposed to 1 µM CsA for 1 h at 5 
% CO2 and 37 ˚C. After treatment with CsA, the cells were washed three times with HBSS 
before being treated with HOSCN (0 – 200 µM) for 1 h at 22 ˚C or CCCP for 10 min at 5 % CO2 
and 37 ˚C prior to the addition of JC-1. The results show that pre-treating cells with CsA (1 
µM) before HOSCN treatment prevented the loss of mitochondrial membrane potential at 
all of the HOSCN concentrations tested (Figure 5.10), while non-CsA treated cells were still 
affected by CCCP and HOSCN. These data are consistent with HOSCN playing a role in the 
opening of the MPTP and attenuation of ATP coupling in J774A.1 macrophages. 
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Figure 5.10: Cyclosporin A is able to inhibit the mitochondrial membrane depolarisation 
caused by HOSCN. 
J774A.1 cells (1 × 106 cells) were treated with CsA (1 µM) for 1 h before HOSCN (0 – 200 µM) 
treatment for 1 h at 22 ˚C or 5 µM CCCP for 10 min at 37 ˚C. The cells were then labelled with 
JC-1 (2 µM) and left to incubate for 15 min at 37 ˚C. The formation of J-aggregates in the 
mitochondria (red; λem = 590 nm) and the leak of these aggregates into the cytosol (green; 
λem = 529 nm) was analysed using flow cytometry and the results show that pre-treating 
J774A.1 cells with CsA protects against HOSCN-induced mitochondrial depolarisation at all 
the concentrations tested, indicating that HOSCN may interact with the MPTP. Values of the 
results are the mean ± S.E.M (n = 3).  *** shows a significant (p < 0.001) decrease compared 
to the untreated control, # shows a significant (p < 0.05) decrease compared to CsA treated 
samples of the same HOSCN treatment concentration by Repeated Measures one-way 
ANOVA with a post-hoc Tukey’s test. 
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5.3.4 HOSCN induced oxidation of J774A.1 cells attenuated the synthesis of ATP 
As HOSCN treatment of J774A.1 cells has been shown to attenuate glycolysis and 
mitochondrial respiration, experiments were performed to determine if the inhibition of 
these energy producing pathways had an effect on the formation of the final energetic 
substrate, ATP. Cells (1 × 106 cells/well) were treated with HOSCN (0 – 200 µM) in HBSS for 1 
h at 22 ˚C before being scraped and pipetted into a 96-well plate, where they were lysed, 
and a D-luciferin and luciferase solution added. The D-luciferin is converted to oxyluciferin 
by luciferase at the expense of ATP; the amount of luminescent oxyluciferin created is 
directly related to the concentration of ATP in the sample. Luminescence was recorded at 
570 nm and the results show that HOSCN decreased the intracellular ATP concentration in 
J774A.1 cells in a dose-dependent manner (Figure 5.11). A significant decrease in 
intracellular ATP concentration was observed at ≥ 50 µM HOSCN treatments. This result 
indicates that the attenuation of glycolysis and mitochondrial respiration by HOSCN reduces 
ATP production. 
 
 
 
 
 
 135 
 
 
Figure 5.11: HOSCN reduces the concentration of intracellular ATP in J774A.1 cells. 
J774A.1 cells (1 × 106 cells) were treated with HOSCN (0 – 200 µM) for 1 h at 22 ˚C before 
being lysed and added to a solution of D-luciferin and luciferase. ATP from the cell lysate is 
consumed in the reaction which produces visible light (570 nm) allowing for the quantification 
of intracellular ATP concentration. Results show a dose-dependent decrease in intracellular 
ATP concentration with increases in HOSCN treatment concentration. Values of the results 
are the mean ± S.E.M (n = 3). * and *** show a significant (p < 0.05 and 0.001, respectively) 
decrease compared to the untreated control by Repeated Measures one-way ANOVA with a 
post-hoc Tukey’s test. 
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5.3.4.1 CsA treatment can help prevent the loss of intracellular ATP by HOSCN 
After determining that HOSCN causes a decrease in the intracellular ATP concentration, and 
that CsA could inhibit the opening of the MPTP, an experiment was performed to determine 
if CsA could also prevent the decrease in intracellular ATP concentrations caused by HOSCN. 
Results showed that pre-treating J774A.1 cells with 1 µM CsA for 1 h prior to treating with 
HOSCN could prevent the decrease in intracellular ATP (Figure 5.12). In the previous 
experiment, a significant decrease in ATP concentration was observed at 50 µM HOSCN 
(Figure 5.11), whereas a decrease was only noted at the highest treatment concentration 
(200 µM) after pre-treatment with CsA (1 µM). This result indicates that the loss of 
intracellular ATP is significantly affected by the condition of the MPTP. 
 
 
Figure 5.12: Cyclosporin A is able to prevent the loss of intracellular ATP after HOSCN 
treatment. 
J774A.1 cells (1 × 106 cells) were treated with CsA (1 µM) for 1 h before HOSCN (0 – 200 µM) 
treatment for 1 h at 22 ˚C before being lysed and added to a solution of D-luciferin and 
luciferase. ATP form the cell lysate is consumed in the reaction which produces visible light 
(570 nm) allowing for the quantification of intracellular ATP concentration. Results show that 
the pre-treatment of J774A.1 cells with CsA can help prevent the loss of intracellular ATP 
caused by HOSCN. Values of the results are the mean ± S.E.M (n = 3). * shows a significant (p 
< 0.05) decrease compared to the untreated control by Repeated Measures one-way ANOVA 
with a post-hoc Tukey’s test.  
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5.4 Discussion 
This Thesis has previously shown that HOSCN can induce the formation of sulfenic acids on 
both cytosolic and mitochondrial proteins in J774A.1 cells. Data have also been presented 
showing the attenuation of glycolysis in cells exposed to HOSCN. This attenuation of 
glycolysis ultimately results in the decreased production of the energetic end-product, 
lactate, consistent with a reduction in pyruvate, the substrate for the tricarboxylic (TCA) 
cycle. From the TCA cycle, NADH is produced, which is fed into the ETC for oxidative 
phosphorylation, ultimately yielding ATP for the cell. The results of this Chapter have shown 
that HOSCN attenuates mitochondrial respiration, increases mitochondrial membrane 
permeability and reduces the ability of the mitochondria to produce ATP (Figure 5.13). 
 
 
Figure 5.13: The interaction of HOSCN with the metabolic pathways of glycolysis and 
oxidative phosphorylation. 
  
The inhibition of mitochondrial respiration in cells exposed to HOSCN could occur through 
two mechanisms, either by direct oxidation of mitochondrial proteins or indirectly via the 
lack of glycolysis end-product formation. Previously published data have shown that reaction 
of mitochondrial thiols with diamide (250 µM), which preferentially reacts with small acidic 
thiols, for 40 min results in a decrease of OCR in rat aortic smooth muscle cells, in a similar 
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fashion to the results reported in this Chapter [416]. Results have shown that HOSCN is able 
to form sulfenic acids on mitochondrial proteins in HOSCN treated cells after 1 h. The results 
of the Seahorse XF assay have shown that baseline respiration can be affected in less than 
20 min. There are currently no published data involving mitochondrial protein oxidation and 
HOSCN. Previous data suggest that HOSCN is able to affect cytosolic proteins in time periods 
as short as 5 and 15 min, as shown by experiments using ThioGlo-1 and IAF to probe for 
intracellular thiols [91, 179, 201]. Together, these data support a possible role of HOSCN-
mediated mitochondrial thiol oxidation as a pathway to the disruption of mitochondrial 
respiration and ATP production. 
The role of thiol oxidation as a pathway to mitochondrial dysfunction is further highlighted 
by previous studies that have shown that mitochondrial electron transfer chains can be 
inhibited the ebselen-induced oxidation of critical thiols in mitochondrial complexes I and II 
[417, 418], which would cause decreases in ATP production. Similarly, trichlorotelluro-
dypnones are able to reduce the number of free protein thiols in rat liver mitochondria, 
which correlates with a decrease in state 3 and state 4 respiration, reducing the respiratory 
control ratio (RCR) of the isolated mitochondria [419]. RCR can only be measured in isolated 
mitochondria, but a decrease in the RCR indicates a decrease in substrate oxidation and ATP 
turnover, and a high proton leak, supporting the HOSCN data. The results of this study clearly 
indicate that thiols are critical in the bioenergetic pathway of mitochondria, and that 
inhibiting them, much in the same way HOSCN inhibits thiols, reduces the ATP turnover 
within the mitochondria. 
The role of thiols in energy production has also been studied using diamide, which causes 
protein S-glutathionylation by reacting with free GSH. Treatment with diamide caused the 
loss of free thiols within rat aortic smooth muscle cells [416]. This S-glutathionylation and 
the subsequent removal of protein thiols from the system led to decreases in the OCR/ECAR 
ratio, causing the cells to become both less aerobic and less glycolytic. These results 
corroborate with data obtained in this Chapter. HOSCN causes a loss in free thiols by oxidising 
them, inhibiting their reductive potential much in the same way as diamide, causing a 
decrease in the OCR/ECAR ratio, indicating that thiols are critical in oxidative 
phosphorylation. 
A further potential contributor to reduced mitochondrial respiration is a decrease in the 
mitochondrial membrane potential. Depolarisation of the mitochondria leads to the 
increased permeability of mitochondria which causes a subsequent loss in small molecules, 
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such as cytochrome c and protons, from the inner mitochondrial space into the cytosol. The 
loss of the mitochondrial membrane potential becomes significant at the 50 µM HOSCN 
treatment concentration (Figure 5.9), with the loss of membrane potential decreasing 
further with increases in the HOSCN concentration. For the positive control, CCCP was used, 
as it uncouples the ETC to cause a loss in the proton gradient. The results indicate that 200 
µM HOSCN is able to disrupt the mitochondrial membrane potential to a similar extent as 
CCCP (Figure 5.9). This result indicates that HOSCN may act in a similar fashion to CCCP or 
that the consequences of HOSCN-induced oxidation have a mitochondrial membrane-
destabilising side effect. Thus, VDAC, which is located on the outer mitochondrial membrane 
is crucial for the diffusion of small molecules across the membrane [420, 421], and contains 
transmembrane cysteine residues that are critical for protein function [215]. HOSCN (100 
µM) has been shown to cause a loss in the mitochondrial membrane potential in human 
coronary artery endothelial cells treated for 2 h [185], which was associated with the release 
of mitochondrial enzymes cytochrome c, apoptosis inducing factor (AIF) and EndoG. Other 
studies have shown that modifying mitochondrial thiols induces apoptosis and a subsequent 
mitochondrial depolarisation [192, 422], which supports the idea that HOSCN-induced 
mitochondrial depolarisation is caused by a change in the level of reduced thiols within the 
mitochondria, resulting in a leak of small molecules from the mitochondria into the cytosol, 
which would, in turn, cause a loss in the ATP turnover of mitochondria. 
HOSCN was shown to reduce the intracellular ATP concentration in treated J774A.1 cells. 
ATP, in mammalian cells, is formed primarily through 2 processes. Glycolysis, which has been 
shown previously to be inhibited by HOSCN treatment and via cellular respiration, which has 
been shown to be attenuated, either by direct oxidation of associated protein thiols by 
HOSCN, or due to a decrease in the production of energetic substrates from glycolysis. 
Results of this Chapter also showed that intracellular ATP levels could be recovered to some 
extent by pre-treating J774A.1 cells with 1 µM CsA. This was surprising, given the extent of 
HOSCN-induced perturbation of glycolysis. Further experiments are required to elucidate the 
process by which CsA protects the intracellular ATP levels.  
The inhibition of ATP production has numerous implications, as ATP is the primary energetic 
currency of cells. Previous data have shown that minor changes in the ADP/ATP ratio of cells 
can impair cellular growth, causing apoptosis in some cases [412, 413]. ATP is important in 
cellular growth as cells can undergo cell cycle arrest, activating catabolic metabolism and 
autophagy when the ability to produce ATP from glucose is impaired [423, 424]. These results 
 140 
 
draw comparisons between the lack of ATP production in mammalian cells and the 
bacteriostatic action of HOSCN. In E. coli, when outgrowing from stationary phase, the 
intracellular concentration of ATP increases significantly, resulting in an increase in rRNA 
synthesis with subsequent protein synthesis and cellular proliferation, while a decrease in 
intracellular ATP leads to a decrease in these processes [425, 426]. Studies on bacterial cell 
growth and HOSCN have shown that while S. typhimurium is resistant to cell death after 
treatment with the LPO/H2O2/SCN- system but is susceptible to the bacteriostatic effect 
[427]. HOSCN caused decreases in cell growth and proliferation, though, whether this was 
an ATP dependent process was not investigated, it draws similar conclusions between the 
results of this study and published data. ATP has been found to be critical to macrophage 
function and proliferation, by delivering ATP to full-thickness skin wounds, there is a mass 
activation and subsequent proliferation of macrophages [428]. ATP administration begins 
the initiation of wound-healing within 24 h, rather than the traditional 3-6 day lag, indicating 
that ATP is crucial for macrophage proliferation and activation [428, 429] and has been 
hypothesised to be due to the direct increase of cellular energy supplies.   
The effect of HOCl on mitochondrial respiration was not explored in this Chapter. This is 
because HOCl was found to be too reactive, reacting preferentially with the DMEM used 
during the respiration experiments, and the Cell-Tak adhesive, rather than the cells. 
However, it has been reported previously that HOCl activates the MPTP and induces 
apoptosis in HepG2 cells [187]. Despite its ability to induce the MPTP, it was shown in the 
previous Chapter that HOCl had no effect on the formation of lactate in J774A.1 cells, 
implying that it does not attenuate glycolysis. In this setting, HOSCN may be more deleterious 
to J774A.1 energy production compared to HOCl, as HOSCN attenuates glycolysis by oxidising 
glycolytic enzymes, reducing the formation of substrates for oxidative phosphorylation, 
while possibly also oxidising the proteins involved in the ETC. 
The implication of HOSCN-induced mitochondrial dysfunction becomes clear, as HOSCN 
oxidises glycolytic proteins, fewer energetic substrates become available for use during 
mitochondrial respiration. The mitochondria may also be subjected to protein oxidation by 
HOSCN, further reducing the ability of the mitochondria to produce ATP, inhibiting cell 
growth and proliferation while not allowing the macrophages to perform as they should, 
analogous to the growth inhibition reported in bacteria exposed to this oxidant [379]. 
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5.5 Summary 
The results of this Chapter demonstrated that HOSCN has the ability to inhibit mitochondrial 
function in real time in J774A.1 macrophages at low concentrations of HOSCN (50 µM), while 
inhibiting ATP turnover and the efficiency of ATP formation at concentrations ≥ 100 µM 
HOSCN. It is hypothesised that this loss in ATP formation efficiency is due to HOSCN causing 
an efflux of protons from the mitochondria via changes in the mitochondrial membrane 
potential. Results using JC-1 indicated that HOSCN does cause mitochondrial depolarisation 
and a subsequent decrease in intracellular ATP concentrations. This was further verified by 
pre-treating the cells with CsA, an inhibitor of the MPTP. Results showed that CsA was able 
to inhibit the opening of the MPTP and therefore reduce the damage caused by HOSCN in 
regards to mitochondrial membrane permeability and prevent the loss of intracellular ATP. 
The metabolic profile of the cells and targets of the MPO-derived oxidants in macrophages 
will be examined further using vibrational spectroscopy, to give a more global overview of 
the patterns of oxidative damage observed with HOSCN, and how that compares to that seen 
with HOCl. 
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6 Identifying Cellular Damage Caused by Hypothiocyanous 
Acid Using Fourier Transform Infra-Red Spectroscopy 
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6.1 Introduction 
There is a lack of a specific chemical biomarker for HOSCN, which makes accessing the 
reactivity of this oxidant in vivo quite difficult. HOSCN is a hypohalous acid like HOCl and 
HOBr, except HOSCN has a more limited range of targets with which it interacts with and 
oxidises [380]. Low-molecular mass thiols such as GSH are targets of HOSCN-induced 
oxidation, resulting in the formation of unstable sulfenyl thiocyanate (RS-SCN) species and 
the perturbation of the GSH/GSSG ratio [84, 91, 430]. Another important target of HOSCN-
induced oxidation is proteins, as HOSCN favourably oxidises protein thiols [56, 97, 107, 130]. 
It has been postulated that the reaction of HOSCN and protein thiols creates RS-SCN which 
are hydrolysed to sulfenic acids or react with another thiol to form a disulfide, all of which 
are readily reduced in a cellular system [109, 431]. 
In terms of biomarker development, a problem with HOSCN-induced damage relates to its 
ability to reversibly oxidise targets [97, 432]. There is a lack of direct evidence for the 
formation of RS-SCN species on proteins, and the formation of sulfenic acids and disulfides 
is not only attributable to HOSCN [49, 107, 130]. Fluorescent probes have been used to assess 
the reactivity of HOSCN with its targets, but there are various limitations imposed on the use 
of probes, such as probe accessibility to the target and non-specific binding of the probe 
[433, 434]. Fluorescent probes also have a limitation that reduces the amount of data that 
can be obtained in an experiment, in that they are specific, only allowing for the 
determination of the structure or chemical group labelled with the probe, and hence 
determining the fate of a pathway, such as glycolysis or mitochondrial respiration, can 
become impractical [434].  A surrogate biomarker is homocitrulline from carbamylation of 
lysine by cyanate (OCN-), a decomposition product of HOSCN. However, OCN- can be 
produced by other biological pathways, for example, uraemia and hence lacks specificity 
[81]. 
To try and overcome these limitations and further investigate the effect of HOSCN in cellular 
systems, infra-red spectroscopy was utilised to probe cells for HOSCN-induced damage. 
Fourier transform infra-red (FTIR) spectroscopy allows for non-destructive analysis of 
biological samples without the need for probes or chemical tagging, but requires the 
dehydration of cells before scanning, as H2O is a strong absorber of IR [435]. FTIR allows for 
the interrogation of a wide number of chemical groups within the cells that can be identified 
by individual spectral peaks in the mid-IR range [436], allowing for an alternative method for 
determining HOSCN-induced cell damage. Chemical covalent bonds with an electric dipole 
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moment that can change via atomic displacement by natural vibrations are IR active and 
these vibrational modes can be quantitatively measured by FTIR spectroscopy [436]. The use 
of FTIR in a disease diagnosis and screening setting has been investigated, and exploring the 
effects of diseases on various tissues has been studied in numerous disease settings including 
cervical dysplasia [437], coeliac disease [438] and also in determining surgery outcomes in 
breast cancer cases [439]. 
 
6.2 Aim 
The aim of the study presented in this Chapter is to use FTIR spectroscopy and multivariate 
data analysis as techniques to quantify and assess the pattern of HOSCN-induced cellular 
damage and the inhibition of cellular metabolism. 
 
6.3 Methods 
6.3.1 Infra-red spectroscopy 
6.3.1.1 Oxidant treatment of J774A.1 cells and plating to silicon nitride plates 
For the experiments detailed in this Chapter, cells were plated at 3 × 106 cells/flask in DMEM 
and allowed to adhere in a 25 cm2 flask, in an incubator overnight at 5 % CO2 and 37 ˚C. The 
next day, cells were washed twice with HBSS prior to incubation with 3 mL of either a control 
solution (HBSS), HOSCN (50, 100 or 200 µM), decomposed HOSCN (dHOSCN) or HOCl (200 
µM) for 1 h at 22 ˚ C. Following oxidant treatment, the media was removed from the cells and 
the cells were washed and resuspended in 1 mL of HBSS (3 × 106 cells/mL) before counting 
using a haemocytometer in the presence of 0.2% v/v trypan blue. Cells were then centrifuged 
in an Allegra X-15R centrifuge (Beckman Coulter) at 400 g for 5 min at 22 ˚C to form a cell 
pellet. The pellet was resuspended in HBSS to the required density of cells (1.25 × 106 cells/ 
100 µL). After resuspension, 20 µL of the sample was pipetted onto a 96-well silicon nitride 
plate (Figure 6.1), making sure to load the cells evenly within the well to avoid clumping and 
uneven layers. 
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After loading the samples onto the silicon nitride plate in triplicate, the plate was transferred 
into a desiccator and left overnight at 22 ˚C to remove moisture from the samples [435], 
before being analysed using the Bruker Tensor 27 HTS-XT. 
 
 
 
Figure 6.1: Silicon nitride 96-well plate. 
The silicon nitride plate is a flat plate, with 96 marked circles marking where the spectrometer 
takes measurements. The representative image shows how the samples appeared after 
desiccating overnight at 22 ˚C. 
 
6.3.1.2 Infra-red spectroscopy using the Bruker Tensor 27 HTS-XT 
The instrument used for Fourier transform infra-red (FTIR) spectroscopy was a Bruker Tensor 
27 FTIR spectrometer coupled to a HTS-XT sampling accessory. The silicon nitride plate 
containing samples was loaded into the spectrometer and each sample was run in triplicate 
to ensure reproducibility. Spectra were collected over the mid infra-red region (4000 – 400 
cm-1) at a spectral resolution of 4 cm-1 with 256 co-added scans and background scans, 
allowing for greater resolution of the data sets. All the data were recorded using Opus 6.5 
(Section 6.3.2.1). 
 
 146 
 
6.3.2 Data analysis 
Pre-processing of the spectra was performed on each software package, which both used 
the same algorithms. The derivatives used were second-order derivatives, calculated using a 
Savitzky-Golay algorithm with nine smoothing points. All data was normalised to either the 
CH region (3000 – 2800 cm-1), the protein region (1800 – 1400 cm-1) or the fingerprint region 
(1400 – 700 cm-1). Other conditions are discussed in the relevant section of the Chapter. 
 
6.3.2.1 Opus 6.5 
Opus (version 6.5, Bruker, Germany) was used to control the instrument and collect data. It 
was also used to consolidate the separate scans to create the average spectra of 256 scans 
across triplicate samples in 3 separate experiments. After creating the averaged spectra, the 
peaks could then be normalised to their respective regions using vector normalisation, which 
calculates the average y-values and divides it by the square root of the sum (‘Manipulate’  
‘Normalisation’). The peaks could then be compared by using an integration method 
(‘Evaluate’  ‘Integration’), which allows for the calculation of peak heights and area by 
drawing a straight line between the peaks of the two frequency limits defined. Each peak 
was analysed separately using this method, after which, the peak heights were compared to 
each other. 
 
6.3.2.2 The Unscrambler X 10.3 
The Unscrambler (10.3, Camo, Oslo, Norway) is a chemometrics software program that 
incorporates numerous algorithms for use in large data analysis. The software is also able to 
directly import native instrument file formats, such as the Opus spectral files. 
In this study, principal component analysis (PCA) was performed on the pre-processed opus 
data files only. To analyse this data, non-linear partial-least –squares algorithm was 
employed with a full-cross validation (to determine the number of principal components to 
retain to account for data variability). Additionally, a Savitzky-Golay convolution algorithm 
was used to normalise, increase the signal-to-noise ratio, smooth the data and obtain the 
second order derivatives. In this analysis, only principal components (PC) 1 and 2 were 
assessed by using the PC scores and loading plots (as determined by full-cross validation).  
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6.4 Results 
Previous Chapters have shown that HOSCN can attenuate the energy producing pathways of 
glycolysis and mitochondrial respiration in J774A.1 cells. Initial studies were performed to 
determine if changes in the bioenergetic status of the cells could be determined using FTIR 
spectroscopy. Mid-infra-red (mid-IR) light (4000 – 400 cm-1) can be used to study 
fundamental vibrations and rotational-vibrations, by passing IR light through the cells. When 
the frequency of the IR light is the same as the vibrational frequency of a bond, the light is 
absorbed. This light is then transmitted by the sample, which reveals how much energy has 
been absorbed at any particular frequency. For a molecule to be IR active, it must be able to 
change its dipole moment, and the occurring vibration is called a ‘vibrational mode’. 
J774A.1 cells (3 × 106 in a 25 cm2 flask) were treated with either a control solution (HBSS), 
HOSCN (50, 100 or 200 µM), decomposed HOSCN or HOCl (200 µM) for 1 h at 22 ˚C. One 
concentration of HOCl was employed as a comparison with HOSCN, as it is known that 
extensive cellular damage occurs upon treatment of cells with high concentrations of HOCl. 
The cells were then washed and plated onto a silicon nitride plate at a density of 2.5 × 105 
cells/spot and desiccated for 18 h at 22 ˚C before being sampled in the mid-IR range using a 
Bruker HTS IR spectrometer (256 scans per sample). After sampling, the data were processed 
using Opus 6.5, the second-order derivative was performed (negative peaks), then each peak 
could be analysed, and its area determined and compared against other treatments. 
 
6.4.1 HOSCN affects the CH region of J774A.1 cells 
The results of the FTIR spectroscopy from J774A.1 cells were analysed over different spectral 
regions. The first region is the higher wavenumber region (ca. 2800 – 3000 cm-1) that is 
associated with stretching vibrations of S-H, O-H, N-H and C-H, and will be called the CH 
region from this point on. Because of cellular hierarchy and its relative abundance, the CH 
region is usually indicative of changes that occur to phospholipids of the cellular membrane 
[436]. 
When observing the CH region (Figure 6.2), it appears that very little change in the spectra is 
observed as a result of oxidant treatment. This could be due to the abundance of CH2 and 
CH3 bonds relative to the concentration of oxidant used. But after peak integration, the 
results indicated that HOSCN, dHOSCN and HOCl were unable to influence CH3 symmetric (s) 
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or asymmetric (as) stretching (v) (Figure 6.3A & C) while 200 µM HOSCN, 200 µM HOCl and 
dHOSCN was able to significantly reduce CH2 asymmetric stretches (vas) (Figure 6.3B) and 
increase CH2 symmetric stretches (vs) (Figure 6.3D). This result is consistent with some 
interaction or reaction of the treatments with the phospholipid bilayer of J774A.1 
macrophages. 
 
 
Figure 6.2: The CH region of J774A.1 cells visualised using FTIR. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT infra-red spectrometer 
(256 scans) after being treated with either a control solution (HBSS), HOSCN (50, 100, 200 
µM), dHOSCN or HOCl (200 µM) in HBSS for 1 h at 22 ˚C. The CH region (ca. 2800 – 3000 cm-
1) has four distinct peaks, CH2 (vs); 2852 cm-1, CH3 (vs); 2870 cm-1, CH2 (vas); 2927 cm-1, CH3 
(vas); 2960 cm-1 which can be observed after performing a second derivative Fourier 
transformation. Each spectrum is the average of triplicates from 3 separate experiments. 
Control (blue), 50 µM HOSCN (red), 100 µM HOSCN (green), 200 µM HOSCN (black), 200 µM 
HOCl (orange), dHOSCN (pink). 
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Figure 6.3: Changes to the CH region of J774A.1 cells by hypohalous acids. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT IR spectrometer (256 
scans) after being treated with either HBSS, HOSCN (50, 100, 200 µM), dHOSCN or 200 µM 
HOCl in HBSS for 1 h at 22 ˚C. Second derivative Fourier transformation, peak integration and 
peak area were determined. Results indicate that none of the treatments influenced CH3 
vibrational modes (A & C) while 200 µM HOSCN, dHOSCN and 200 µM HOCl were able to (B) 
attenuate the CH2 (vas) vibrational mode and (D) increase the CH2 (vs) vibrational mode. All 
data are the average of 3 separate experiments ± S.E.M. *, **, *** and **** show a 
significant (p < 0.05, 0.01, 0.001 and 0.0001, respectively) decrease or increase compared to 
respective controls by Repeated Measures one-way ANOVA with a post-hoc Tukey’s test. 
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6.4.2 HOSCN affects infra-red spectra of the protein region in J774A.1 cells 
The second region within the IR spectra is comprised of wavenumbers from 1800 – 1450 cm-
1, and will be called the protein region from this point on. This region contains peaks mainly 
associated with the stretching and bending bonds of proteins [436]. 
After J774A.1 cells were treated and interrogated using the Bruker HTS-XT, changes in peak 
height were easily identifiable upon inspection. Even before peak integration, it was possible 
to determine that HOSCN, HOCl and to some extent, dHOSCN, was able to influence the 
vibrational modes of protein bonds. The assignment of bonds is indicated in Figure 6.4 and 
the respective Figure legend. 
 
Figure 6.4: The protein region of J774A.1 cells visualised using FTIR. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT infra-red spectrometer 
(256 scans) after being treated with either a control solution (HBSS), HOSCN (50, 100, 200 
µM), dHOSCN or HOCl (200 µM) in HBSS for 1 h at 22 ˚C. In the protein region (ca. 1450 – 
1800 cm-1), eight peaks could be identified, tyrosine (C-C v); 1515 cm-1, N-H (δ), C-N (v) peptide 
linkages; 1545 cm-1, COO- (vas); 1576 cm-1, amide I – beta sheets; 1637 cm-1, amide I – alpha 
helix; 1656 cm-1, beta sheets and beta turns; 1682 cm-1, DNA and RNA (C=O); 1713 cm-1, 
triglycerides; 1743 cm-1. Each spectra is the average of triplicates from 3 separate 
experiments. Control (blue), 50 µM HOSCN (red), 100 µM HOSCN (green), 200 µM HOSCN 
(black), 200 µM HOCl (orange), dHOSCN (pink). 
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.  
Figure 6.5: Hypohalous acids cause changes to the protein region of J774A.1 cells. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT IR spectrometer (256 
scans) after being treated with either HBSS, HOSCN (50, 100, 200 µM), dHOSCN or 200 µM 
HOCl in HBSS for 1 h at 22 ˚C. Second derivative Fourier transformation, peak integration and 
peak area were determined. Results indicate that HOSCN influences (A) tyrosine, (B) peptide 
linkages, (C) COO-, (D) protein beta sheets, (E) alpha helices, (G) DNA/RNA and (H) 
triglycerides. dHOSCN affects COO-, DNA/RNA, and triglycerides. HOCl affects tyrosine, 
peptide linkage, COO-, protein beta sheets, DNA/RNA, and triglycerides. No treatment 
affected (F) mixed parallel beta formations.  All data are the average of 3 separate 
experiments ± S.E.M. *, **, *** and **** show a significant (p < 0.05, 0.01, 0.001 and 0.0001, 
respectively) decrease or increase compared to respective controls by Repeated Measures 
one-way ANOVA with a post-hoc Tukey’s test. 
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After peak analysis using Opus 6.5 was completed, multiple changes in the vibrational modes 
of protein bonds were identified. The first peak change identified was at 1515 cm-1 which 
was indicative of changes to the vibrational mode of the aromatic C-C bonds of tyrosine 
(Figure 6.5A).  Increases in C-C (v) vibrations were identified with 100 and 200 µM HOSCN 
and with 200 µM HOCl. Major changes were identified with (Figure 6.5B) peptide linkages 
(N-H (δ) and C-N (v)) (1576 cm-1) and (Figure 6.5D) C=O amide I – beta sheets (1637 cm-1) 
after treatment with ≥ 50 µM HOSCN and 200 µM HOCl. An increase in (Figure 6.5C) COO- 
(vas) was also identified with 200 µM HOSCN, dHOSCN and 200 µM HOCl treatments (1576 
cm-1). Concerning the amide I – alpha helices (1656 cm-1), only 200 µM HOSCN induced a 
significant decrease in the C=O vibrational mode (Figure 6.5E). Finally, there was no 
significant change in the vibrational mode of mixed parallel/antiparallel beta pleated sheets 
or beta turns (1680 cm-1) in any of the treatment conditions (Figure 6.5F). 
Non-protein related peaks were also identified in this portion of the spectra, the first was a 
DNA and RNA peak related to the vibrational C=O mode (1713 cm-1), which experienced a 
significant decrease after treatment with 200 µM HOSCN, dHOSCN and 200 µM HOCl (Figure 
6.5G). The second peak was associated with the vibration of triglycerides (1743 cm-1), and 
increases in the vibrational mode were observed at ≥ 50 µM HOSCN, dHOSCN and 200 µM 
HOCl (Figure 6.5H).  
 
6.4.3 Reactivity of HOSCN with the fingerprint region 
The third region within the IR spectra is comprised of wavenumbers from 1450 – 700 cm-1, 
and will be called the fingerprint region from this point on. This region contains low-energy 
peaks mainly associated with bending (δ), stretching and carbon skeleton fingerprint 
vibrations. This area is quite complex as the peaks can be associated with various different 
classes of biological chemicals, including lipids, nucleic acids and carbohydrates, resulting in 
spectra that is unique to specific cells and cell types [436]. 
After J774A.1 cells were treated, and the IR spectra were interrogated using the Bruker HTS-
XT, the collected data were run through an algorithm to determine the second-derivative 
peaks. Upon inspection of the spectra, differences between treatments were immediately 
observed, with substantial changes in peak area seen between 1250 – 950  
cm-1 (Figure 6.6). These peaks were then integrated using Opus 6.5 and compared against 
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other treatments to quantify the changes in vibrational modes. The vibration of specific 
bonds is given in Figure 6.6. 
 
 
Figure 6.6: The fingerprint region of J774A.1 cells visualised using FTIR. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT infra-red spectrometer 
(256 scans) after being treated with either a control solution (HBSS), HOSCN (50, 100, 200 
µM), dHOSCN or HOCl (200 µM) in HBSS for 1 h at 22 ˚C. In the fingerprint region (600 – 1450 
cm-1) nine peaks were identified, choline phospholipids (vas); 967 cm-1, carbohydrates; 1011 
cm-1, fatty acids; 1031 cm-1, nucleic acids (v); 1052 cm-1, hypophosphite (vs); 1080 cm-1, 
glucose; 1105 cm-1, lactate; 1152 cm-1, P=O (v) and hypophosphite (vas); 1242 cm-1, and 
terminal CH3 (δs) and lipids; 1385 cm-1. Each spectra is the average of triplicates from 3 
separate experiments. Control (blue), 50 µM HOSCN (red), 100 µM HOSCN (green), 200 µM 
HOSCN (black), 200 µM HOCl (orange), dHOSCN (pink). 
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After peak analysis, numerous changes were identified in this region. An increase in vas 
vibrational mode of choline phospholipids (967 cm-1) was observed after treatment of the 
J774A.1 cells with ≥ 100 µM HOSCN and 200 µM HOCl (Figure 6.7A). A decrease in fatty acid 
C-O (1031 cm-1) vibrations were seen with 100 and 200 µM HOSCN (Figure 6.7B). The C-O (v) 
vibrational mode of nucleic acids (1052 cm-1) were increased significantly after 200 µM 
HOSCN treatment (Figure 6.7C). The compound hypophosphinate (PO2-) and O-O-C (vs) 
vibrational modes (1080 cm-1) were decreased by ≥ 100 µM HOSCN treatment and 200 µM 
HOCl (Figure 6.7D), while an increase in PO2- (vas) and P=O (v) (1242 cm-1) were noted with 
200 µM HOSCN and HOCl (Figure 6.7E). Finally, there was a significant increase in terminal 
CH3 (δ) (1385 cm-1) after 200 µM HOCl treatment (Figure 6.7F). 
In support of the data from Chapter 4, changes were also identified in the vibrational modes 
of various carbohydrates and glycolytic products in J774A.1 cells after treatment with 
HOSCN. The peak at 1011 cm-1 is indicative of the C-O bonds of carbohydrate molecules, and 
the data show that treatment of J774A.1 cells with ≥ 100 µM HOSCN led to a significant 
decrease in the vibrational mode of carbohydrates (Figure 6.8A). Glucose was identified due 
to its C-O-C bond (1105 cm-1), and a significant decrease in the glucose vibration was 
detected after treatment with 200 µM HOSCN (Figure 6.8B). Finally, lactate (C-O (v) – 1152 
cm-1), an end-product of glycolysis whose production was shown to decrease after HOSCN 
treatment, was significantly decreased after ≥ 100 HOSCN in these experiments (Figure 6.8C).  
After completing the analysis of J774A.1 IR spectra using Opus 6.5, the data were analysed 
using multivariate data analysis. This multivariate data analysis allows for the analysis of large 
data sets, which in turn, allows a global assessment of cellular damage and the localisation 
or nature of this damage. 
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Figure 6.7: Hypohalous acids cause changes to the fingerprint region of FTIR-interrogated 
J774A.1 cells. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT IR spectrometer (256 
scans) after being treated with either HBSS, HOSCN (50, 100, 200 µM), dHOSCN or 200 µM 
HOCl in HBSS for 1 h at 22 ˚C. Second derivative Fourier transformation, peak integration and 
peak area were determined. Results indicate that high concentrations of HOSCN were able to 
significantly influence (A) choline phospholipid (vas), (B) fatty acid (C-O), (C) nucleic acid (C-O 
v), (D) PO2 (O-O-C vs), and (E) P=O (v) and PO2 (vas) vibrations. HOCl was also able to influence 
phospholipid (vas), PO2 (O-O-C vs), P=O (v) and PO2 (vas) and terminal CH3 (δs). dHOSCN did 
not influence any vibrational modes in this region. All data are the average of 3 separate 
experiments ± S.E.M. *, **, *** and **** show a significant (p < 0.05, 0.01, 0.001 and 0.0001, 
respectively) decrease or increase compared to respective controls by Repeated Measures 
one-way ANOVA with a post-hoc Tukey’s test. 
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Figure 6.8: HOSCN attenuates the recognition of bioenergetic molecules. 
J774A.1 cells (2.5 × 105 cells) were interrogated using a Bruker HTS-XT infra-red spectrometer 
(256 scans) after being treated with either a control solution (HBSS), HOSCN (50, 100, 200 
µM), dHOSCN or HOCl (200 µM) in HBSS for 1 h at 22 ˚C. After second derivative Fourier 
transformation, the peaks were integrated and the peak area was determined. In the 
fingerprint region (600 – 1450 cm-1) three peaks were identified that are involved in cellular 
bioenergetics. The results showed that only higher concentrations of HOSCN were able to 
attenuate the vibrational modes of (A) carbohydrates, (B) glucose and (C) lactate in J774A.1 
macrophages. All data are the average of 3 separate experiments ± S.E.M. *, ** and *** show 
a significant (p < 0.05, 0.01 and 0.001, respectively) decrease compared to respective controls 
by Repeated Measures one-way ANOVA with a post-hoc Tukey’s test. 
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6.4.4 Multivariate data analysis 
To further analyse the data gathered by FTIR, multivariate data analysis was performed. To 
do this, a statistical procedure called ‘principal component analysis’ (PCA) was employed. In 
short, the data, which is correlated, is converted into a set of numbered matrices, which are 
linearly uncorrelated, the variables of which are called ‘principal components’. The number 
of principal components possible is equal to the number of original variables (i.e. the 
intensity at each wavenumber is the variable), where they are arranged so that the first 
principal component explains the largest possible variance and each succeeding component 
has the next largest. 
By using this statistical procedure, it is possible to see which chemical groups within the 
J774A.1 cells are affected the most by oxidant treatment without the need for analysing the 
peaks. In this way, bias in the data analysis is removed and each point is compared to every 
other peak within the set. After the completion of the procedure, a PCA scores plot and PCA 
loadings plot is formed. The scores plot is used as a tool to determine whether the global 
changes, due to a treatment, causes a change in the cellular chemistry and is determined via 
a separation in the points of the two groups, while the loadings plot indicate where these 
changes in the spectra and therefore, the cell, have occurred. The loadings plot also give 
information about the relative abundance and/or detection of each chemical group, with 
negative values indicating a decrease, and positive values indicating an increase. 
The results of the PCA between the control and 50 µM HOSCN-treated cells revealed that 50 
µM HOSCN did alter J774A.1 cell chemistry on a global cellular scale, but the change that 
occurred was weak. The PCA scores plot (Figure 6.9A) showed a large variation in the control 
points across both the PC-1 and PC-2 axis, while cells treated with 50 µM HOSCN had a large 
variation on the PC-1 axis and less on the PC-2. The score plot also showed that the points 
between these two groups are not totally separated, indicating that the difference between 
these two conditions is weak. The loadings plot shows the variation on the PC-1 axis 
(explaining 74% of variation) (Figure 6.9B). The PC-1 axis is explaining some variation 
between the two treatments, but not enough to determine whether the change seen is 
caused by HOSCN. 
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Figure 6.9: PCA of J774A.1 cells treated with 50 µM HOSCN. 
Principal component analysis scores and PC-1 loading plots of second derivatives of the 
spectra (Savitzky-Golay 9 points) comparing control and 50 µM HOSCN treatments. (A) The 
PCA scores plot comparing control and 50 µM HOSCN on PC-1 and PC-2 axes. (B) The PC-1 
loading plot describes where in the spectra the variation occurs. These data show that there 
is a weak separation between control and 50 µM HOSCN treated cells, indicating that the 
changes induced by HOSCN at this concentration are minimal on a global cellular level. 
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The next PCA was performed to determine the changes that occurred to J774A.1 cells after 
100 µM HOSCN treatment. The results show that 100 µM HOSCN was able to alter J774A.1 
chemistry significantly. The PCA scores plot (Figure 6.10A) showed a large variation of control 
cells across both the PC-1 and PC-2 axis, while the 100 µM HOSCN treated samples are 
grouped more tightly, in comparison across both axes, indicating that HOSCN has affected 
the treated cells in a specific way. In addition, there is an observable difference and 
separation between the control points and the 100 µM HOSCN treated points, indicating a 
strong difference between the two. The separation between the control and 100 µM HOSCN 
treated cells occurs on the PC-1 axis, so a PC-1 loadings plot was generated (Figure 6.10B). 
This loadings plot indicates which peaks of the spectra are affected the most, causing the 
separation in the PC-1 axis split between the two treatment conditions. Table 6.1 lists the 
different peaks identified on the PC-1 loadings plots, which had a clear and observable 
change in intensity from the baseline. 
After the analysis of control and 100 µM HOSCN treated samples, the control and 200 µM 
HOSCN treated samples were analysed. The results showed that 200 µM HOSCN influenced 
J774A.1 chemistry very strongly. The PCA scores plot (Figure 6.11A) showed a large 
separation between control samples and 200 µM HOSCN treated samples across the PC-1 
axis, indicating that the variability between the two groups can be primarily explained on the 
PC-1 loading plot (Figure 6.11B). Interestingly, across the PC-2 axis, there is a very tight 
grouping of the HOSCN treated group, while the control group is spread across the entire 
axis (Figure 6.11C), indicating that the natural variation in the control cells can be visualised 
on the PC-2 loading plot. Tables were constructed to determine which peaks in the spectra 
were most affected by the 200 µM HOSCN treatment (Table 6.2) with peaks in the fingerprint 
region, such as nucleic acids, PO2-, lactate and carbohydrates found to contribute the most 
to these differences. 
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Figure 6.10: PCA of J774A.1 cells treated with 100 µM HOSCN. 
Principal component analysis scores and PC-1 loading plots of second derivatives of the 
spectra (Savitzky-Golay 9 points) comparing control and 100 µM HOSCN treatments. (A) The 
PCA scores plot comparing control and 100 µM HOSCN on PC-1 and PC-2 axes. (B) The PC-1 
loading plot describes where in the spectra the variation occurs. These data show that there 
is a significant separation between control and 100 µM HOSCN treated cells on the PC-1 axis, 
indicating that the changes induced by HOSCN at this concentration are significant on a 
global cellular level. 
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Table 6.1: Groups identified using PC-1 loadings between control and 100 µM HOSCN 
treated groups. 
Wavenumber (cm-1) Chemical Group 
620 N.A. ↓ 
970 Choline phospholipids (vas) ↓ 
987 N.A. ↓ 
1011 Carbohydrates (C-O) ↓ 
1031 Fatty acids (C-O) ↓ 
1052 Nucleic acids (C-O) (v) ↓ 
1080 O-O-C PO2- (vs) ↓ 
1091 N.A. ↑ 
1105 Glucose (C-O-C) ↓ 
1152 Lactate (C-O) (v) ↓ 
1195 N.A. ↓ 
1400 N.A. ↑ 
1547 N-H (δ), C-N (v) peptide linkages ↓ 
1637 Amide I – beta sheet (C=O) ↓ 
↓ - decrease, ↑ - increase,  N.A.  – Not available, peak has not yet been identified. Spectral 
assignments [440-442]. 
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Figure 6.11: PCA score plot of J774A.1 cells treated with 200 µM HOSCN. 
Principal component analysis scores and, PC-1 and PC-2 loading plots of second derivatives 
of the spectra (Savitzky-Golay 9 points) comparing control and 200 µM HOSCN treatments. 
(A) The PCA scores plot comparing control and 200 µM HOSCN on PC-1 and PC-2 axes. (B) The 
PC-1 loading plot describes where in the spectra the variation occurs. (C) The PC-2 axis 
explains the variation in the control data as it is spread across the axis, while 200 µM treated 
sampes do not move along this axis. These data show that there is a significant separation 
between control and 200 µM HOSCN treated cells on the PC-1 axis, indicating that the 
changes induced by HOSCN at this concentration are significant on a global cellular level. The 
variation on the PC-2 axis explains natural variation across the control cells. 
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Table 6.2: Groups identified using PC-1 loadings between control and 200 µM HOSCN 
treated groups. 
Wavenumber (cm-1) Chemical Group 
620 N.A. ↓ 
967 Choline phospholipids (vas) ↓ 
987 N.A. ↓ 
1011 Carbohydrates (C-O) ↓ 
1031 Fatty acids (C-O) ↓ 
1052 Nucleic acids (C-O) (v) ↓ 
1080 O-O-C PO2- (vs) ↓ 
1091 N.A. ↑ 
1105 Glucose (C-O-C) ↓ 
1152 Lactate (C-O) (v) ↓ 
1195 N.A. ↓ 
1400 N.A. ↑ 
1545 N-H (δ), C-N (v) peptide linkages ↓ 
1637 Amide I – beta sheet (C=O) ↑ 
1656 Amide I – alpha helix (C=O) ↑ 
2852 CH2 (vs) ↑ 
2927 CH2 (vas) ↑ 
↓ - decrease, ↑ - increase, N.A.  – Not available, peak has not yet been identified. Spectral 
assignments [440-442]. 
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Table 6.3: Groups identified using PC-2 loadings between control and 200 µM HOSCN 
treated groups. 
Wavenumber (cm-1) Chemical Group 
951 N.A. ↓ 
967 Choline phospholipids (vas) ↓ 
987 N.A. ↑ 
1052 Nucleic acids (C-O) (v) ↓ 
1080 O-O-C PO2- (vs) ↓ 
1604 N.A. ↑ 
1637 Amide I – beta sheet (C=O) ↓ 
1680 Mixed parallel/antiparallel beta 
sheets/turns ↑ 
1714 DNA, RNA (C=O) ↑ 
2852 CH2 (vs) ↓ 
2921 c.a. CH2 (vas) ↓ 
↓ - decrease, ↑ - increase, N.A.  – Not available, peak has not yet been identified; c.a. – 
approximately. Spectral assignments [440-442]. 
 
Interestingly, after generating a PC-2 loading plot for the control and 200 µM HOSCN groups, 
it was possible to see which peaks in the spectra contributed the most to the natural variation 
of the control groups, due to their large spread across the PC-2 axis. After generating the PC-
2 loading plot (Figure 6.11C), a table was generated listing the major peaks identified in the 
loadings plot (Table 6.3). The peaks identified indicate that across the untreated J774A.1 
cells, the variation occurs across various classes of chemicals, such as the phospholipid 
membrane, proteins and nucleic acids, with no variation seen in the carbohydrate pool. This 
suggests that HOSCN is primarily responsible for changes in the carbohydrate, glucose and 
lactate levels within the J774A.1 cells. 
dHOSCN was compared against the control samples using PCA. The data show that there is 
a cellular response to treatment with dHOSCN with a clear separation between the control 
and dHOSCN groups on the PC-1 axis. Though, there was one group of dHOSCN treated cells 
that seemed to be an outlier, appearing in the control sample grouping (Figure 6.12A). The 
control samples also seemed to be spread across the PC-2 axis, which when analysed 
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exhibited the same natural variation as the control group from the previous analysis. The PC-
1 loadings plot (Figure 6.12B) was generated and Table 6.4 describes which peaks were 
affected by the dHOSCN treatment, contributing to the separation in the two groups. 
 
 
Figure 6.12: PCA scores of J774A.1 cells treated with decomposed HOSCN. 
Principal component analysis scores and PC-1 loading plots of second derivatives of the 
spectra (Savitzky-Golay 9 points) comparing control and decomposed HOSCN treatments. (A) 
The PCA scores plot comparing control and dHOSCN on PC-1 and PC-2 axes. (B) The PC-1 
loading plot describes where in the spectra any variation occurs. These data show that there 
is a strong separation between control and dHOSCN treated cells on the PC-1 axis, indicating 
that the changes induced by dHOSCN are significant on a global cellular level. 
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Table 6.4: Groups identified using PC-1 loadings between control and decomposed HOSCN 
treated groups. 
Wavenumber (cm-1) Chemical Group 
620 N.A. ↓ 
967 Choline phospholipids (vas) ↓ 
989 N.A. ↑ 
1033 Fatty acids (C-O) ↓ 
1080 O-O-C PO2- (vs) ↓ 
1193 N.A. ↑ 
1385 Terminal CH3 ↑ 
1545 N-H (δ), C-N (v) peptide linkages ↑ 
2852 CH2 (vs) ↓ 
2927 CH2 (vas) ↑ 
2960 CH3 (vas) ↑ 
↓ - decrease, ↑ - increase, N.A.  – Not available, peak has not yet been identified. Spectral 
assignments [440-442].  
 
After identifying the peaks affected by decomposed HOSCN, it was noted that none of the 
peaks associated with carbohydrates, glucose or lactate were identified. This corroborates 
the hypothesis that HOSCN is required to oxidise J774A.1 glycolytic proteins, reducing the 
level of carbohydrates and lactate within the cell, and it is the oxidative ability of HOSCN that 
causes this attenuation of glycolysis, and not a latent effect of the non-oxidising components 
of HOSCN.  
Finally, dHOSCN was compared against 200 µM HOSCN. Interestingly, the separation 
between both treatments occurred on the PC-2 axis, rather than the PC-1 axis (Figure 6.13A). 
This is indicative of the similarities between both treatments, and the difference on the PC-
2 axis is hypothesised to account for the difference in the oxidative ability between both 
treatments (Figure 6.13B). The differences between 200 µM HOSCN and dHOSCN are 
primarily attributed to their ability to interact with lipids, proteins and in one case, DNA/RNA. 
More importantly, the PC-2 axis also shows the ability of 200 µM HOSCN to influence the 
glucose and lactate concentration in J774A.1 cells. Table 6.5 lists the different peaks 
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identified on the PC-2 loading plots, which had a clear and observable change in intensity 
from the baseline. 
 
 
Figure 6.13: PCA scores of J774A.1 cells treated with 200 µM HOSCN or decomposed 
HOSCN. 
Principal component analysis scores and PC-2 loading plots of second derivatives of the 
spectra (Savitzky-Golay 9 points) comparing 200 µM HOSCN and decomposed HOSCN 
treatments. (A) The PCA scores plot comparing 200 µM HOSCN and dHOSCN on PC-1 and PC-
2 axes. (B) The PC-2 loading plot describes where in the spectra any variation occurs. These 
data show that there is a separation between 200 µM HOSCN and dHOSCN treated cells on 
the PC-2 axis, indicating that the differences between both treatments are significant on a 
global cellular level. 
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Table 6.5: Groups identified using PC-2 loadings between 200 µM HOSCN and dHOSCN 
treated groups. 
Wavenumber (cm-1) Chemical Group 
715 Rocking band of methylene in lipid chains ↓ 
1080 O-O-C PO2- (vs) ↓ 
1105 Glucose (C-O-C) ↓ 
1152 Lactate (C-O) (v) ↓ 
1452 N.A. ↓ 
1494 N.A. ↓ 
1637 Amide I – beta sheet (C=O) ↓ 
1656 Amide I – alpha helix (C=O) ↑ 
1685 c.a. Mixed parallel/antiparallel beta 
sheets/turns ↓ 
1714 DNA, RNA (C=O) ↑ 
2927 CH2 (vas) ↓ 
↓ - decrease, ↑ - increase, N.A.  – Not available, peak has not yet been identified. c.a. – 
approximately. Spectral assignments [440-442]. 
 
6.4.4.1 HOCl induces changes to J774A.1 macrophages in a similar manner to 
HOSCN 
PCA was also performed to compare control cells with cells treated with 200 µM HOCl. The 
data indicate that HOCl also causes significant changes to the chemistry of J774A.1 cells 
(Figure 6.14A), with a similar pattern of separation between control and 200 µM HOCl, and 
control and 200 µM HOSCN. Between the control group and the HOCl treatment group, the 
separation occurs mainly on the PC-1 axis, so a PC-1 loading plot was generated (Figure 
6.14B) and the peaks which contributed most to the separation, and therefore were most 
affect by HOCl were listed in Table 6.6. The control group was spread throughout the PC-2, 
similar to the 200 µM HOSCN and dHOSCN treatments, and the variation on this axis explains 
the natural variation between the cells in the control group. 
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Figure 6.14: PCA score plot of J774A.1 cells treated with 200 µM HOCl. 
Principal component analysis scores and PC-1 loading plots of second derivatives of the 
spectra (Savitzky-Golay 9 points) comparing control and 200 µM HOCl treatments. (A) The 
PCA scores plot comparing control and 200 µM HOCl on PC-1 and PC-2 axes. (B) The PC-1 
loading plot describes where in the spectra any variation occurs. These data show that there 
is a strong separation between control and 200 µM HOCl treated cells on the PC-1 axis, 
indicating that the changes induced by 200 µM HOCl are significant on a global cellular level. 
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Table 6.6: Groups identified using PC-1 loadings between control and 200 µM HOCl treated 
groups. 
Wavenumber (cm-1) Chemical Group 
620 N.A. ↓ 
989 N.A. ↑ 
1033 Fatty acids (C-O) ↓ 
1052 Nucleic acids (C-O) (v) ↓ 
1080 O-O-C PO2- (vs) ↓ 
1093 N.A. ↑ 
1242 P=O (v), PO2- (vas) ↑ 
1398 N.A. ↓ 
1483 N.A. ↓ 
1545 N-H (δ), C-N (v) peptide linkages ↑ 
1637 Amide I – beta sheet (C=O) ↑ 
2852 CH2 (vs) ↑ 
2927 CH2 (vas) ↑ 
2960 CH3 (vas) ↑ 
↓ - decrease, ↑ - increase, N.A.  – Not available, peak has not yet been identified. Spectral 
assignments [440-442]. 
 
 
Once again, after identifying the peaks in the spectra that contributed most to the separation 
between the control and 200 µM HOCl treatment groups, many of the differences noted 
between the control and HOCl treated cells occurred to the phospholipid membrane, 
proteins, nucleic acids and fatty acids. Interestingly the carbohydrates, glucose and lactate 
were not identified in the control and HOCl principal component analysis, a similar result to 
the control and dHOSCN principal component analysis. This suggests that HOCl and dHOSCN 
alter the chemistry of J774A.1 cells in a different manner than HOSCN, in accord with data 
reported in the previous Chapters. Thus, results are consistent with HOSCN rather than HOCl 
or the non-oxidative decomposition products of HOSCN causing a loss in glycolytic ability.  
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6.5 Discussion 
This Chapter examined the pattern and the extent of damage caused to J774A.1 
macrophages after treatment with HOSCN, HOCl and decomposed HOSCN (dHOSCN). HOCl 
(200 µM) was used as a comparison for cell damage caused by HOSCN while dHOSCN was 
used as a non-oxidative (negative) control for HOSCN-induced damage. Exposure of J774A.1 
macrophage cells to HOSCN, HOCl and dHOSCN resulted in changes to the biochemistry of 
the cells, which could be monitored by IR spectroscopy. All the treatments caused some 
perturbation or changes in the relative abundance of lipids, proteins and nucleic acids, while 
only HOSCN was able to attenuate the detection and/or abundance of carbohydrate and 
lactate vibrational modes. Those results do not necessarily indicate a direct reaction of the 
targets with any of the treatments; the results represent changes in the vibrational mode of 
specific bonds contained within specific molecules. For example, the decrease in the 
detection of glucose and lactate correlates with data obtained in previously published 
studies and in Chapter 4 of this Thesis. However, in Chapter 4, the decrease is the result of 
an inhibition of glycolytic proteins by HOSCN [199, 201], resulting in a decrease in the 
formation of glycolytic end-products such and pyruvate and lactate. 
The spectra of J774A.1 cells can be analysed as 3 distinct areas. The first is the CH region (ca. 
2800 – 3000 cm-1), and changes in CH2 vibrational modes (both vs and vas) were observed 
with 200 µM HOSCN, 200 µM HOCl and dHOSCN. These CH2 peaks correspond with the fatty 
acyl chain of the phospholipid membrane [443]. Reaction of J774A.1 cells with 200 µM HOCl 
may result in the formation of fatty acyl chlorohydrins on the cell membrane, as has been 
shown to occur to red blood cell membrane extracts upon exposure to HOCl [180]. The 
alteration of CH2 vibrational modes may also occur after treatment of dHOSCN with the 
J774A.1 cells, though it is not possible to determine the nature of the modification, as the 
decomposition products of HOSCN are a complex mixture [75, 76]. It is possible that dHOSCN 
may cause carbamylation of the phospholipid acyl chain via the formation of cyanate (-OCN) 
which is a major product of HOSCN decay [77, 93]. The results also indicated that 200 µM 
HOSCN induced changes to the vibrational mode of CH2 peaks (both vas and vs), though no 
data exists indicating that HOSCN would react directly with the CH2 bonds of phospholipids 
indicating that this may be a secondary effect of HOSCN oxidation, or indeed a 
decomposition product of HOSCN. 
The second spectral area of the J774A.1 cells is the protein region (1800 – 1450 cm-1), 
consisting mainly of protein related peaks that relate to protein structure and backbone 
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chemistry, and two peaks that are not protein related. The PCA loadings and scores, and the 
FTIR results of this region indicate that HOSCN and HOCl both have a significant effect on 
J774A.1 protein chemistry and structure, while dHOSCN, though not as effective, also has a 
role influencing protein stretches and structure. Tyrosine, an aromatic amino acid that plays 
a role in many signal transduction processes [444], was significantly affected by HOCl 
treatment. The vibrational mode altered is related to the stretching of the aromatic C-C 
bonds of tyrosine. The reaction of HOCl with tyrosine results in the addition of a chlorine 
atom to the 3-position of the aromatic ring, forming 3-chlorotyrosine [299], this new 
asymmetry in the phenol ring results in an altered vibration. Unexpectedly, increases were 
also detected in HOSCN-treated samples (≥ 100 µM), though HOSCN demonstrates low 
reactivity with tyrosine [49]. This increase could be a secondary effect of HOSCN treatment, 
as previously published data has shown that HOSCN can inhibit protein tyrosine 
phosphatases (PTPs) via the oxidation of active-site cysteines [179]. Therefore, the result 
obtained by this experiment could indicate that the increase in tyrosine recognition (via C-C 
stretching of the phenol ring) is due to a decrease in phosphate removal from tyrosine 
residues by PTPs, as the phosphate (PO43−) would act similarly to the Cl-, increasing the 
asymmetry of the C-C bond, resulting in increased detection.  
Increases were also detected on the amino and carboxyl group of amino acids. J774A.1 cells 
treated with ≥ 50 µM HOSCN or 200 µM HOCl saw an increase in the vibrational mode of the 
N-H (δ) or C-N (v) peptide linkage, while treatment with 200 µM HOSCN, HOCl or dHOSCN 
led to a significant increase in the carboxyl vibrational mode. These may indicate some 
reaction of the oxidants with these groups, though it is unexpected as amino acid side chains, 
such as cysteine, are more favourable targets [11, 49]. It is likely that the increases in the 
backbone vibrational modes correlate with changes in the protein secondary structure and 
the increases in the amide I – β-sheet vibrational mode. Treatment of J774A.1 cells with ≥ 50 
µM HOSCN or 200 µM HOCl caused increases in the vibrational intensity, and possibly the 
formation of structures correlating with β-sheets. The oxidation of cysteine residues by 
HOSCN or HOCl can cause the formation of inter-strand disulfide bonds [95, 107, 380], and 
while it is rare to find disulfide bonds in β-sheets, data suggests that the formation of 
disulfides helps to stabilise and define the extent of β-sheet secondary structure [445]. This 
disulfide bond formation and β-sheet stabilisation would account for the increase in the 
amide I - β-sheet vibrational mode. The protein amide I – α-helix also experienced a decrease 
in vibrational mode after 200 µM HOSCN treatment, which could be attributed to a 
conformational transition (α-helix to β-sheet) due to oxidant treatment [446-450]. 
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In the third spectral area (1450 – 700 cm-1), the fingerprint region, there are numerous peaks 
that correspond with many different chemical groups, not all of which have been identified. 
Of the identified peaks, many were affected by HOSCN or HOCl treatment, while none were 
affected by dHOSCN. The most interesting changes have been attributed to molecules that 
are related to the glycolytic pathway, such as carbohydrates, glucose and lactate. After the 
treatment of J774A.1 cells with HOSCN, decreases were observed in the vibrational modes 
and PCA loadings of carbohydrates (≥ 100 µM) and glucose (200 µM), which was an 
unexpected result. Results of the previous Chapter indicate that HOSCN inhibits glycolytic 
proteins without influencing the uptake of glucose by J774A.1 cells. However, the glucose 
uptake assay performed in Chapter 4 was performed using a fluorescent glucose analog, 2-
NBDG, which cannot be phosphorylated by hexokinase, the first enzyme of glycolysis, which 
prepares glucose for further catabolic steps. In cells treated with HOSCN, it has been shown 
that GAPDH, the sixth glycolytic enzyme, is inhibited [201]. The result is the catabolism of 
glucose by hexokinase and downstream enzymes up until GAPDH, leading to a reduction of 
carbohydrate and glucose levels, and a build-up in glyceraldehyde 3-phophate levels without 
a payoff of ATP, pyruvate or NADH. The FTIR also revealed a decrease in the lactate 
concentration, which corroborates with the data obtained in Chapter 4. A decrease in the 
lactate concentration can be explained by the inhibition of glycolysis, inhibiting the formation 
of pyruvate, which is converted to lactate by LDH, serving as a marker for glycolytic activity 
[334]. 
After the completion of these experiments it became clear that FTIR and PCA are reliable and 
accurate measures for determining oxidant damage within cellular systems. The use of 
principal component analysis allowed for the computation of large data sets without bias. 
The resulting plots allowed for the determination of treatment efficacy (PCA scores) and 
favourable targets within the samples (loadings plots). Using these plots, the pattern of 
damage caused by HOSCN, HOCl and also dHOSCN was clearly visible. Despite the similarities 
between the treatments used, there were subtle and specific changes that occur, which are 
dependent on the treatment. Specifically, HOSCN was able to induce changes in the 
vibrational mode of proteins, lipids, nucleic acids and molecules involved in glycolysis. 
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6.6 Summary 
The study in this Chapter demonstrated that HOSCN and HOCl-induced damage to J774A.1 
macrophages can be identified using FTIR spectroscopy and principal component analysis. 
The results show that the damage caused by HOCl extends to lipids, proteins and nucleic 
acids while HOSCN is also able to induce changes in the vibrational mode of lipids, proteins, 
nucleic acids and carbohydrates including glucose, corroborating data from a previous 
Chapter. Further corroboration was revealed after determining that lactate could be 
identified using FTIR, and the inhibition of the lactate vibration further supports HOSCN as 
an inhibitor of glycolysis. The final study of this Thesis will further investigate the role of 
HOSCN in cellular damage by using Raman spectroscopy and microscopy to image and map 
the damage caused to cells after HOSCN-induced oxidation. 
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7 Using Raman Spectroscopy to Image Hypothiocyanous Acid-
Induced Damage 
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7.1 Introduction 
A common method of interrogating cells is via the use of microscopy. There are multiple 
microscopy techniques including bright field microscopy, which uses simple illumination of 
the sample, dark field microscopy, which is used to improve the contrast of unstained 
samples, and phase contrast microscopy, which allows for the visualisation of differences in 
refractive index of a sample as changes in contrast [451-453]. Another widely used 
microscopy technique is fluorescent microscopy, which requires the use of fluorescent 
probes or conjugated antibodies. Although a powerful technique, there are some limitations 
in the use of fluorescent probes in biological studies. For example, fluorophores can undergo 
photo-bleaching, which occurs as they are illuminated by the microscope light, due to the 
excitation of electrons during fluorescence [454]. Another limitation of fluorescent 
microscopy stems from the specificity of the fluorescent probes. Fluorescent microscopy 
only allows for the observation of structures that have been labelled with the fluorophore, 
for example, the fluorophore, 4',6-diamidino-2-phenylindole (DAPI) is used widely to image 
DNA [455]. DAPI only binds to the A-T rich regions of DNA, so only the DNA within the cell is 
imaged and nothing else about the cell is revealed [456]. Another fluorescent probe is 
dihydroethidium (DHE), which is used to monitor ROS-induced damage in vitro [457, 458]. 
DHE also has limitations in its use, including auto-oxidation, photo-oxidation and photo-
conversion, interfering with oxidant reactivity and the knowledge of the concentration-
response relationship between the probe and the substrate [459]. Finally, the target must 
be known in order to employ the correct probe, therefore the use of this technique to 
interrogate HOSCN-induced damage is difficult, as the reactivity of HOSCN is limited to thiols. 
Difficulty assessing damage in vivo is also compounded by the lack of a HOSCN-specific 
biomarker. Unlike 3-chlorotyrosine, which allows for the visualisation of HOCl-induced 
damage using an antibody approach, there currently is no probe to detect HOSCN-induced 
damage [460, 461]. 
Raman spectroscopy is an alternative technique that can be used to map cellular damage 
with the advantage of no requirement for probes. When monochromatic light interacts with 
the covalent bonds of a sample, the interaction can result in the shifting of the energy of the 
light (Stokes Raman scattering; decrease in energy, Anti-Stokes Raman scattering; increase 
in energy), and the degree of the shift allows for the determination of a chemical bond and 
group within a sample. By measuring the Raman scattering (inelastic scattering), an entire 
cell can be interrogated, and the gross chemical make-up or  chemical ‘fingerprint’  can be 
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determined, along with a  visual map of the cell that displays where in the cell certain 
chemical groups exist [462].  
Recently, due to its ability to identify a wide range of chemical groups within a sample, 
Raman spectroscopy and mapping has been used as a diagnostic tool in every step of disease 
screening and treatment. For example, Raman spectroscopy has been used in studies 
analysing the chemical composition of skin, determining the possible pathological state and 
investigating the kinetics of drug penetration into the various dermal layers [463]. Due to its 
ability to discriminate between chemical compositions of different samples, Raman 
spectroscopy has also been used to determine the chemical changes in cancer cell formation, 
for use in a diagnostic setting [464-466]. Given that Raman spectroscopy can be used to 
generate image maps in the absence of chemical probes, the method allowed for an 
alternative way to image HOSCN-induced oxidative damage to macrophages.  
 
7.2 Aims 
The aim of the study presented in this Chapter is determine whether HOSCN-induced 
oxidative damage to J774A.1 macrophages can be visualised using Raman spectroscopy. This 
proof-of-concept study was also extended to utilising Raman microscopy techniques to gain 
spatial and qualitative data on J774A.1 cells with and without oxidant treatment. 
 
7.3 Methods 
7.3.1 Preparation of J774A.1 macrophages 
7.3.1.1 J774A.1 murine macrophage cells 
The cell experiments performed in this Chapter were carried out using J774A.1 cells, a murine 
macrophage-like cell line.  
Prior to the experiment, cells were washed with fresh DMEM, followed by scraping from the 
flasks (175 cm2) into 10 mL of DMEM and counted using a haemocytometer in the presence 
of 0.2% v/v trypan blue to exclude dead cells. Cells were then centrifuged in an Allegra X-15R 
centrifuge (Beckman Coulter) at 400 g for 5 min at 22 ˚C to form a cell pellet. The pellet was 
resuspended in DMEM to the required density of cells (1 × 106 cells mL-1) before being 
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transferred to a 12-well cell culture plate at a density of 1 × 106 cells/well and incubated in a 
sterile environment, overnight at 5% CO2 and 37 ˚C. 
 
7.3.1.2 Oxidant treatment of J774A.1 cells 
For the experiments detailed in this Chapter, cells were plated at 1 × 106 cells/well in DMEM 
and allowed to adhere in a 12-well plate, in an incubator, overnight at 5 % CO2 and 37 ˚C. The 
next day, cells were washed twice with HBSS prior to incubation with 3 mL of either a control 
solution (HBSS) or HOSCN (200 µM) in HBSS for 1 h at 22 ˚C. Following oxidant treatment, 
the media was removed from the cells and the cells were washed with HBSS to prevent any 
reactions resulting from residual oxidant of media components. 
 
7.3.1.3 Preparing cells on calcium fluoride slides 
Calcium fluoride (Crystran, UK) was chosen as the surface for plating cells as it is transparent 
over a wide range of light frequencies (single Raman peak at 312 cm-1) and silicon nitride 
(used for FTIR) can auto-fluoresce in the conditions used for Raman spectroscopy. 
After oxidant treatment and washing, the cells were resuspended in 1 mL HBSS:H2O (1:1) 
(this ratio was used to reduce the salt concentration within the media) at 1 × 106 cells/mL 
and counted using a haemocytometer in the presence of 0.2 % v/v trypan blue. Cells were 
then centrifuged in an Allegra X-15R centrifuge (Beckman Coulter) at 400 g for 5 min at 22 
˚C to form a cell pellet. The pellet was then resuspended to the required density of cells (1 × 
106 cells/ 500 µL). After resuspension, 10 µL of the sample was pipetted onto the calcium 
fluoride slide, making sure to keep the slide horizontal, as to avoid movement and clumping 
of the cells within the sample. 
After loading samples onto the calcium fluoride slide, the slide was left to rest in sterile 
conditions for 20 min at 22 ˚C, before being transferred into a desiccator and left for 1 h at 
22 ˚C to remove moisture from the sample, before being analysed, as described below, using 
a Renishaw inVia Raman microscope. 
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7.3.2 Raman microscopy and mapping 
The instrument used for Raman microscopy was a Renishaw inVia (United Kingdom) coupled 
to a light microscope to allow for visualisation of the sample before testing. The calcium 
fluoride slide was placed on the sampling stage and the cell to be sampled was centred in 
the middle of the viewing area. Before mapping, the Raman laser was set to 785 nm at 50 % 
power and mapping was performed by sampling the Raman shift between 400 – 3200 cm-1. 
The resolution used was chosen based on optimisation steps taken, quality and time required 
to map. 1 µm steps were chosen, with each step taking ca. 3 min (each cell took ca. 3 h to 
map). 
 
7.3.3 Data processing 
Once the data was acquired using the Renishaw inVia, the raw data were processed using 
WiRE (4.1, Renishaw, United Kingdom). First the maps were loaded onto the software and 
the data were analysed to remove cosmic rays that interfere with the data acquisition. Using 
the ‘cosmic ray removal’ tool. Cosmic rays were removed by identifying them by their 
characteristically sharp peaks and ‘width of features’ algorithm was employed and was set 
to a width parameter = 3 and a height parameter = 15. 
After the cosmic rays were removed, vector normalisation, which calculates the average y-
values and divides it by the square root of the sum. The peaks could then be compared by 
using an integration method, which allows for the calculation of peak heights by drawing a 
straight line between the peaks of the two frequency limits defined. Each peak was analysed 
separately using this method, after which, the peak heights were compared to each other. 
For both the control and HOSCN treated cells, a noise filter level of 3 was chosen, which 
explained > 99 % of the variance within the data. Once completed, the heat maps were 
generated, which allowed for the visualisation of data variance and they were analysed by 
employing a ‘signal to baseline’ algorithm. After the peak was identified, normalisation was 
performed by adjusting the ‘min’ and ‘max’ states of the look-up table (LUT) between the 
control and HOSCN treated samples, and setting them equally. 
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7.4 Results 
7.4.1 Optimisation of Raman spectroscopy 
7.4.1.1 Determination of cell media salt concentration 
To determine the correct conditions required to obtain Raman spectra, various permutations 
were tested using the Renishaw inVia Raman microscope. Because the samples were living 
cells, HBSS was used throughout the cell preparation steps. The use of 1 × HBSS caused the 
formation of large crystals on the slide which caused salt artifacts to occur within the Raman 
spectra. To determine an optimal salt concentration, serial dilutions of HBSS were prepared 
with H2O (1:0, 3:1, 1:1 and 1:3 – HBSS:H2O) then images were taken. The images show that 
a ratio of 1:0 and 3:1 (HBSS:H2O) resulted in extensive crystal formation, leading to cells being 
trapped within the formed crystals (red arrows) (Figure 7.1A & B). A ratio of 1:1 resulted in 
the trapping of fewer cells within salt crystals, and fewer salt crystals being formed (Figure 
7.1C). Finally, a ratio of 1:3 resulted in minimal salt crystal formation, but resulted in cell 
blebbing and irregularity in shape (black arrows), which was hypothesised to be a result of 
the lack of salt within the media, causing an osmotic accumulation of H2O within the cells 
(Figure 7.1D).  
 
 181 
 
 
Figure 7.1: Optimisation of HBSS concentration for J774A.1 cell resuspension. 
J774A.1 cells were resuspended in various concentrations of HBSS in H2O to determine the 
optimal concentration of salt in the resuspension solution, before being plated onto stainless 
steel slides. A) J774A.1 cells in 100 % HBSS, B) J774A.1 cells in 75 % HBSS, C) J774A.1 cells in 
50 % HBSS and D) J774A.1 cells in 25 % HBSS. The image is a representative of 1 experiment 
run in triplicate. Red arrows indicate cells trapped within salt crystals. Black dashed arrows 
indicate blebbing and irregularly shaped cells.  
 
7.4.1.2 Optimisation of plating surface material and laser power 
After optimising the concentration of HBSS to resuspend cells, stainless steel was chosen as 
the plating material due to the ease of handling and cost, rather than calcium fluoride, which 
is markedly more expensive and difficult to handle. To begin, a 512 nm laser was chosen to 
probe the cells for Raman shift between 600 – 1700 cm-1, but this led to the burning and 
destruction of cell samples at all the power levels tested (results not shown). A weaker laser 
was chosen (785 nm) and laser settings were applied to a data optimised mode (DOM), which 
increased scan time to improve peak identification (3.18 s per point, 100 % laser power). 
However, preliminary experiments using stainless steel were unsuccessful as spectra were 
weak, leading to a loss in peak differentiation (Figure 7.2A). 
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Figure 7.2: A comparison of stainless steel and calcium fluoride. 
The raw spectra of single, J774A.1 cells on A) Stainless steel and B) calcium fluoride plating 
surfaces. The results show very little differentiation and weak intensity of the Raman spectra 
when J774A.1 cells were plated on stainless steel. When J774A.1 cells were plated on calcium 
fluoride, both the differentiation and intensity improved using the same laser settings at 785 
nm (DOM = 3.18 s per point, 100% laser power). 
 
When J774A.1 cells were plated on calcium fluoride then probed using the same laser setting 
as previously (785 nm, DOM = 3.18 s per point, 100% laser power), peak intensity (counts) 
and differentiation improved significantly, which allowed the data to be analysed and the 
chemical peaks to be extracted using second derivative Fourier transform (not shown) in 
WiRE 4.0. After determining the correct laser settings and surface material, Raman mapping 
was performed on cells treated with or without HOSCN. 
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7.4.2 HOSCN affects the Raman scattering of J774A.1 cells 
The previous Chapter has shown that HOSCN-induced changes to cellular components can 
be identified by using infra-red spectroscopy coupled with principal component analysis. By 
using these methods, a pattern of the damage caused to J774A.1 cells by HOSCN was 
identified, including changes to proteins, lipids and the concentration of carbohydrates 
within the cells, and compared to that seen with decomposed HOSCN and HOCl. The study 
presented in this Chapter utilises Raman spectroscopy to map and visualise the changes that 
occur in J774A.1 cells after HOSCN-induced oxidation. 
J774A.1 cells (1 × 106 cells/well) were treated with either a control solution (HBSS) or 200 
µM HOSCN for 1 h at 22 ˚ C. After treatment the cells were washed in HBSS, and then the cells 
were set onto a calcium fluoride slide before being desiccated for 1 h at 22 ˚C to remove 
moisture from the sample. The cells were then analysed using a Renishaw inVia Raman 
spectrometer coupled to a light microscope at 785 nm. The Raman scattering was recorded 
(400 – 3200 cm-1) at 1 µM spots across the entire cell. The results show gross changes in the 
Raman scattering between the control and HOSCN-treated samples across the entire 
spectrum (Figure 7.3). Upon observation, large changes can be seen in the quantity of lipids, 
proteins, nucleic acids and carbohydrates in the J774A.1 cells. Though it must be mentioned 
that this data is preliminary with further experiments needed to improve the conditions used 
for the spectroscopy portion of this experiment. 
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Figure 7.3: The Raman spectra of J774A.1 macrophages is affected by HOSCN 
Raw single cell Raman spectra of control (red) and HOSCN (200 µM) (black) treated J774A.1 
cells plated on calcium fluoride slides. The spectra were obtained by interrogating the cells 
with monochromatic light at 785 nm at 50 % power and recording the Raman scattering 
between 400 – 3200 cm-1, then the individual spectra were averaged and compiled. No 
normalisation was performed on these spectra as normalisation was performed on a peak-
by-peak basis. The presented spectrum is a representative spectrum of 3 different 
experiments. 
 
7.4.3 HOSCN interacts with and alters lipids in J774A.1 cells 
 After treating the cells with HOSCN (200 µM), there were numerous changes in lipid 
composition and location in J774A.1 cells. There were changes in the CH region (2810 – 3026 
cm-1) after HOSCN treatment, with a decrease in the heat map density. This is consistent with 
reaction of HOSCN with the lipid membrane of the J774A.1 cells (Figure 7.4A). The 
lipid/protein region (2859 – 2901 cm-1) was also affected by HOSCN, the heat map shows the 
formation of another hot spot (red), indicating that the membrane of the J774A.1 cell is being 
altered and indicates a change in the shape of the cell after HOSCN treatment (Figure 7.4B). 
The membrane of mammalian cells contain high levels of unsaturated fatty acids (UFA) [467]. 
In the non-treated cells, UFA (1624 – 1706 cm-1) can be detected throughout the cell, 
consistent with localisation of these species to the cell membrane. The results also indicate 
that treatment with HOSCN greatly reduces the concentration UFAs or alters the 
environment surrounding UFAs in J774A.1 cells (Figure 7.4C). 
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Figure 7.4: Raman heat maps of peaks related to lipids and fatty acids in J774A.1 cells. 
J774A.1 cells (1 × 106) were treated either with a control solution (HBSS) or HOSCN (200 µM) 
for 1 h at 22 ˚C before single cells were interrogated with a Renishaw inVia Raman 
spectrometer and microscope. After performing a cosmic ray removal and principal 
component analysis (noise filter), a map of the cell was created using peaks to visualise the 
location and relative concentration of various molecules. (A) The 2810 – 3026 cm-1 peak which 
correlates with scattering of CH bonds. (B) The 2859 – 2901 cm-1 peak which correlates with 
the scattering of lipids and proteins. (C) The 1624 – 1706 cm-1 peak which correlates with the 
scattering of unsaturated fatty acids. The maps are a visualisation of the principal 
components and representative of the maps generated in 3 separate experiments.   
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7.4.4 HOSCN interacts and alters the proteins of J774A.1 cells 
After J774A.1 cells were treated and interrogated using the Renishaw inVia Raman 
spectrometer, maps were created to visualise the peaks that correlated to proteins in the 
cells. Because proteins occur in large concentrations within the cytosol and in the cellular 
membrane, due to the resolution used in the imaging of the cells, it is currently not possible 
to determine where the imaged proteins occur within the samples. 
 Upon analysis of the spectra (Figure 7.3), changes in the protein peaks were easily identified 
and the maps indicate that HOSCN alters the concentration and localisation of proteins 
within treated cells. The protein region (2902 – 2954 cm-1) indicates that proteins are located 
throughout the entire cell in the untreated cells, possibly in the cytosol, due to the decrease 
in the heat map intensity around the cell border. Treating the cells with HOSCN (200 µM) 
causes a loss in protein distribution, conversely, because the protein region is related to 
protein structure, the loss of heat map intensity could indicate a loss in protein structure 
(Figure 7.5A). This indicates that HOSCN has altered protein structure, in a way that causes a 
decrease in Raman scattering. After treating the cells with HOSCN (200 µM), a decrease is 
also seen in the protein/lipid peak (1426 – 1491 cm-1) (Figure 7.5B) in the J774A.1 cells. This 
is indicative of changes to both intracellular proteins and membrane bound proteins, 
indicating an interaction of HOSCN with these elements.  
The amide III band (1216 – 1280 cm-1) consists of C-N stretching and N-H bending bands and 
correlates primarily with protein structure. This peak can give information about cellular 
protein structure, and in non-treated cells the heat map shows a large distribution of protein 
in the middle of the cell. Exposure of cells to HOSCN results in a decrease in amide III peak 
intensity, while also altering amide III distribution in J774A.1 cells (Figure 7.5C). This result is 
consistent with the idea that HOSCN treatment alters protein structure and location within 
the cell after treatment, while the tighter grouping and splitting of the amide II peak group 
into two separate groups being consistent with protein aggregation. 
Finally, the last peak identified was the peak the correlates with protein disulfide bond 
stretching (502 – 535 cm-1). The results show that disulfides are present in the untreated cells 
and treating J774A.1 cells with HOSCN (200 µM) increases disulfide bond distribution within 
the J774A.1 cells (Figure 7.5D). This result is consistent with the chemistry of HOSCN, as the 
oxidation of thiols by HOSCN causes the formation of a sulfenyl thiocyanate, this product can 
react with neighbouring thiols to form a disulfide bridge [62]. 
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Figure 7.5: Raman heat maps of the peaks associated with proteins in J774A.1 cells. 
J774A.1 cells (1 × 106) were treated either with a control solution (HBSS) or HOSCN (200 µM) 
for 1 h at 22 ˚C before single cells were interrogated with a Renishaw inVia Raman 
spectrometer and microscope. After performing a cosmic ray removal and principal 
component analysis (noise filter), a map of the cell was created using peaks to visualise the 
location and relative concentration of various molecules. (A) The 2902 – 2954 cm-1 peak 
correlates with the scattering of proteins. (B) The 1426 - 1491 cm-1 peak that correlates with 
the scattering of proteins and lipids. (C) The 1216 – 1280 cm-1 peak that correlates with the 
scattering of the amide III region. (D) The 502 – 535 cm-1 peak that correlates with the 
scattering of protein disulfide bonds. The maps are a visualisation of the principal 
components and representative of the maps generated in 3 separate experiments. 
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7.4.5 HOSCN interacts with J774A.1 nucleic acids 
The nucleic acid region was the next group to be mapped out after analysing the J774A.1 
cells using the Renishaw inVia Raman spectrometer. After mapping, there were two peaks 
of interest that were affected by the treatment of J774A.1 cells by HOSCN (200 µM). 
The first peak was the nucleic acid peak (1561 – 1591 cm-1), this peak is confined to the centre 
of the cell in the control cell, indicating that the majority of the nucleic acids are found in the 
nucleus of the cell. After treating the J774A.1 cells with HOSCN, a change in nucleic acid 
location is detected (Figure 7.6A), where the originally tight grouping of the nucleic acids in 
the non-treated samples becoming dispersed throughout the cell after HOSCN treatment. 
This result could indicate a structural abnormality of the nucleus or an increase in the 
formation of mRNA, making its way into the cytosol. 
The next peak correlates with the DNA backbone, uracil, thymine and cytosine ring breathing 
and phosphatidylserine (770 – 800 cm-1). In the control cell, these groups can be seen being 
confined to the centre of the cell, indicating a high concentration of these within the nucleus 
of the cell, which is similar in the pattern of distribution as the previous nucleic acid peak. 
After HOSCN treatment, these DNA and RNA constituents can be found in other parts of the 
cell, and has been speculated that HOSCN either causes damage to the nuclear envelope, 
causing a loss in genetic material, or HOSCN-induced oxidation is activating the formation of 
mRNA that is being sent into the cytosol, and it is the RNA that is being detected (Figure 
7.6B). 
Interestingly, the peak at 770 – 800 cm-1 also correlates with phosphatidylserine, a 
phospholipid membrane component that plays a key role in apoptosis. Though 
phosphatidylserine must be exposed on the cell membrane to indicate apoptosis is occurring, 
this result suggests that HOSCN may play a role in apoptosis. This result may be consistent 
with early apoptosis as the increased distribution of phosphatidylserine in the 200 µM 
HOSCN-treated samples may be located on the cellular membrane.  
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Figure 7.6: Raman heat maps of peaks associated with nucleic acids in J774A.1 cells. 
J774A.1 cells (1 × 106) were treated either with a control solution (HBSS) or HOSCN (200 µM) 
for 1 h at 22 ˚C before single cells were interrogated with a Renishaw inVia Raman 
spectrometer and microscope. After performing a cosmic ray removal and principal 
component analysis (noise filter), a map of the cell was created using peaks to visualise the 
location and relative concentration of various molecules. (A) The 1561 – 1591 cm-1 peak 
correlates with nucleic acids. (B) The 770 – 800 cm-1 peak correlates with O-P-O backbone 
and U,T,C ring breathing of DNA/RNA. The maps are a visualisation of the principal 
components and representative of the maps generated in 3 separate experiments.  
 
7.4.6 HOSCN causes a depletion of molecules involved in J774A.1 bioenergetics 
Raman spectroscopy can also be used to assess the distribution of substrates involved in 
glycolysis and bioenergetics, including glycolysis and NADH [468]. This is important as 
previous results indicate that HOSCN affects glycolysis, resulting in a decrease in glycolytic 
end-products. In addition, the FTIR data presented in Chapter 6 are consistent with a 
decrease in intracellular glucose and lactate concentrations. 
The first peak correlated with glucose (1326 – 1349 cm-1), and in the untreated cells, glucose 
was identified throughout the entire cell. After treating the cells with 200 µM HOSCN a 
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marked reduction in intracellular glucose was observed (Figure 7.7A). The next peak was a 
NADH (988 – 997 cm-1), which was observed throughout much of the cell in the untreated 
samples, while treating the cells with 200 µM HOSCN led to a complete loss in the NADH 
peak, indicating that no NADH was identified within the cell (Figure 7.7B). 
 
  
Figure 7.7: Raman heat maps of peaks associated with molecules related to glycolysis in 
J774A.1 cells. 
J774A.1 cells (1 × 106) were treated either with a control solution (HBSS) or HOSCN (200 µM) 
for 1 h at 22 ˚C before single cells were interrogated with a Renishaw inVia Raman 
spectrometer and microscope. After performing a cosmic ray removal and principal 
component analysis (noise filter), a map of the cell was created using peaks to visualise the 
location and relative concentration of various molecules. (A) The 1326 – 1349 cm-1 peak 
correlates with glucose. (B) The 988 - 997 cm-1 peak correlates with NADH. The maps are a 
visualisation of the principal components and representative of the maps generated in 3 
separate experiments.   
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7.5 Discussion 
This Chapter was a preliminary study to determine whether HOSCN-induced damage to 
J774A.1 cells could be visually mapped using Raman spectroscopy. The results of this Chapter 
support previous data in this Thesis, and are consistent with HOSCN induction of extensive 
changes in the biochemistry of cells exposed to this oxidant. Changes in the concentration 
and location of lipids, proteins, nucleic acids and molecules involved in cellular energy 
production were observed. 
HOSCN induced changes to lipid peaks of the Raman spectra as assessed by measuring 
changes in the CH region (2310 – 3026 cm-1), lipid/protein region (2859 – 2901 cm-1) and 
unsaturated fatty acid region (1624 – 1706 cm-1). Data are consistent with HOSCN interacting 
directly or indirectly with the lipids of J774A.1 macrophages. The CH region corresponds with 
fatty acyl chains of the lipid membrane [443]. However, no data exists that would explain the 
interaction of HOSCN with the fatty acyl groups of the membrane. Instead, this may be a 
secondary interaction, as one of the many decomposition products of HOSCN may cause the 
carbamylation of fatty acyl groups, which could explain the observed changes in the CH 
region. Changes were also seen in the lipid/protein region, which would most likely indicate 
an interaction between HOSCN and protein, rather than lipid. Decreases were also seen in 
the unsaturated fatty acid (UFA) peak throughout the cell, indicating a loss in recognition. No 
data currently exists to explain this phenomenon, as this type of chemistry is not known to 
exist between HOSCN and UFAs, though data has been shown that HOSCN can react with 
cholesteryl esters to form lipid hydroperoxides, 9-hydroxy-10,12-octadecadienoic acid (9-
HODE) and F2-isoprostanes [142]. This loss in recognition would be expected upon treatment 
with HOCl, as HOCl can cause the formation of chlorohydrins upon reaction with UFA in 
phospholipids [143], this result is most likely due to a secondary reaction. 
HOSCN caused numerous changes in the protein peaks (protein region, 2902 – 2954 cm-1; 
protein/lipid, 1426 – 1491 cm-1; amide III, 1216 – 1280 cm-1 and protein disulfides, 502 – 535 
cm-1) detected by Raman spectroscopy. The first was a decrease in the recognition of the 
protein peak, the protein/lipid peak and the amide III peak, consistent with multiple chemical 
and structural changes to protein folding and secondary structure [469, 470]. The oxidation 
of cysteine residues by HOSCN could induce changes to protein structure in the cell, which 
could cause the aggregation of proteins within the cytosol. There is considerable evidence 
showing that the oxidation and reduction of cysteine residues constitutes a redox switch that 
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controls the structure and function of proteins, indicating that HOSCN may play a role in 
redox signaling [471].  
The next peak identified was the disulfide peak, because symmetrical bonds tend to be better 
Raman scatterers, disulfide bonds can be quite easily observed. The results show that HOSCN 
causes an increase in the formation of disulfide bonds on proteins in the J774A.1 cells. This 
result is indicative of the chemistry of HOSCN with cysteine residues. When HOSCN oxidises 
thiols a sulfenyl thiocyanate product is formed, which can react with a neighbouring thiol to 
form a disulfide bond [62, 101, 102]. This result also complements the data acquired in 
Chapter 3, outlining that HOSCN-induced oxidation of thiols are reversible. 
Raman mapping was also used to examine the effect of HOSCN on nucleic acids. In non-
treated cells, the nucleic acids were confined entirely at the centre of the cell, indicating their 
location within the nucleus. Upon HOSCN treatment, both the nucleic acid peak and the peak 
associated with the DNA backbone, and the U, T and C rings were located in other locations 
of the cell. This result could indicate one of two possibilities, the first being that HOSCN 
causes structural abnormalities in the nuclear envelope, causing a leak in the genetic 
material. This may be unlikely, as no data exists corroborating the interaction of HOSCN with 
the nuclear envelope or DNA, even at concentrations exceeding the requirement to produce 
an antibacterial effect [134]. It is also possible that HOSCN-induced oxidation of J774A.1 cells 
causes an increase in transcription, leading to an increase in mRNA within the cytosol. This 
is supported by previous data, where HOSCN has been shown to inhibit protein tyrosine 
phosphatases, resulting in the hyperphosphorylation of MAPK [176, 179], which can lead to 
the increase in transcription factor activation, and potentially increase mRNA synthesis [472].  
The Raman data also reflect a decrease in the intracellular glucose concentration in HOSCN-
treated cells. Previous results in this Thesis show that glucose transport is not inhibited in 
HOSCN-treated cells. The decrease in intracellular glucose concentration could reflect a 
reduced rate of glycolysis in HOSCN treated cells, supported by data in Chapters 4 and 6, 
showing a reduction in intracellular lactate concentration. Studies with a fluorescent glucose 
analog (2-NBDG), employed to determine glucose uptake, and showed a similar extent of 
fluorescence in the presence and absence of HOSCN. However, 2-NBDG is unable to be 
phosphorylated by hexokinase, and used in glycolysis, and is only suitable for determining 
glucose uptake in cells, rather than as a measure of intracellular glucose concentration. Thus, 
the decrease in the intracellular glucose concentration in HOSCN-treated cells is 
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hypothesised to be a feedback loop due to the decreased activity of glycolysis, as discussed 
in Chapter 6. 
NADH, a co-enzyme that plays a key role in redox reactions by shuttling electrons was 
identified, though further experiments and analysis are required to support this result [473]. 
In the control cells, NADH is distributed throughout much of the cell. However, on exposure 
of the cells to HOSCN (200 µM), a dramatic loss of NADH was seen, shown by the absence of 
this peak and the shift in the heat map. This may reflect that glycolysis was completely 
inhibited in J774A.1 cells after treatment with 200 µM HOSCN. Glycolysis is a process in which 
the free energy formed is used to create the high-energy products of ATP, pyruvate and 
NADH [158, 474]. With the inhibition of NADH formation, import redox reactions are unable 
to occur, such as oxidative phosphorylation and ATP formation, which ultimately leads to 
cellular dysfunction, and the inhibition of cell growth and proliferation [404, 406, 475, 476]. 
After analysis, it was concluded that the data obtained in this Chapter compared well with 
data obtained using FTIR, and with the data of the glycolytic stress test. However, these data 
were only preliminary, but they outline the potential advantages of this technique, including 
the large amount of biochemical information that can be probed via the use of Raman 
spectroscopy. To further establish the effect of HOSCN on J774A.1 cells, further 
concentrations should be tested, along with a decomposed HOSCN treatment and HOCl 
treatment. To further improve on the data quality, the limitations must be reduced, for 
example, a sampling method should be further trialled, as to increase the resolution and 
spatial quality of images obtained while decreasing the time taken to map the samples. 
 
7.6 Summary 
The study in this Chapter was a proof-of-concept experiment that attempted to use Raman 
spectroscopy to visually map the damage caused to J774A.1 cells by HOSCN-induced 
oxidation. The results show that the concentration of HOSCN used was able to induce 
changes to the concentration and location of lipids, proteins, disulfide bonds and nucleic 
acids in the cell. These preliminary data also corroborated previous results reported in this 
Thesis, supporting data that HOSCN was able to completely inhibit glycolysis after mapping 
and visualising the concentration of the co-factor, NADH. This study confirms the data of 
previous sections and presents a novel method to detect hypohalous acid-induced damage 
to cells in vitro. 
 194 
 
8 Discussion, Future Studies and Concluding Remarks 
  
 195 
 
8.1 Discussion 
The role of hypohalous acids is primarily in the innate immune system, as they are utilised 
by neutrophils to oxidise and destroy invading pathogens [19, 49, 432]. This Thesis has 
explored the role of hypohalous acid-induced oxidation on the function of macrophages. A 
major target of hypohalous acid-induced oxidation is the thiols contained on the free Cys 
residues of proteins and low molecular weight species such as GSH [95]. Essential cellular 
processes such as glycolysis, mitochondrial energy production, the formation of insulin by β-
cells and phosphate uptake require thiols [477-480]. Although uncommon residues, only 
making up ca. 2% of all known human proteins [481], thiols are susceptible to oxidation by 
many ROS. Upon reaction with ROS, a number of post-translational modifications are 
formed, some of which have been explored in this Thesis, including, but not limited to, inter- 
and intra-protein disulfides, sulfenic, sulfinic and sulfonic acids, sulfenyl halides and s-
glutathionylated species. This allows Cys residues to have a diverse effect on important 
regulatory roles in enzyme function [102, 135, 329, 353, 367, 431]. Enzymes with active site 
cysteine residues typically employ the deprotonated, thiolate (RS-) form and activity can be 
enhanced by the microenvironment, especially by neighbouring amino acids that reduce the 
usually high pKa of Cys (ca. 8.5) to a value lower than the pKa at neutral pH [482].  
Enzymes with low pKa Cys are more readily oxidised, meaning that proteins requiring the use 
of Cys for function can be easily altered by oxidants such as H2O2, HOCl, ONOO- and HOSCN 
[483, 484]. Phosphorylation of Tyr plays an important part in many cellular processes 
including signal transduction, apoptosis, metabolic processes and cell cycle progression, with 
the reversibility of phosphorylation playing a major part [485, 486]. Protein tyrosine 
phosphatases (PTPs) contain an active-site Cys with a low pKa that dephosphorylates its 
substrate generating a cysteinyl phosphate, which becomes hydrolysed to reform the 
original thiol, and its activity has been shown to be inhibited by HOSCN, resulting in the 
hyperphosphorylation of cellular proteins [179, 487]. Another group of enzymes that contain 
important Cys residues are thiol proteases such as caspases and cathepsins [488]. These 
enzymes catalyse proteolysis using the Cys thiolate as the attacking nucleophile, and the 
activity of these enzymes has been shown to be modulated via the formation of sulfenic acids 
by H2O2 and NO donors, and caspase activity has been shown to be inhibited by HOSCN in 
cells exposed for ≥ 2 h [91, 92, 489, 490]. Conversely caspase activation has been observed 
in HUVECs exposed to HOCl [191].  
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The most studied of the hypohalous acids, HOCl, can react with mammalian cells, oxidising 
numerous biomolecules, particularly proteins, to alter their function and perturb cellular 
function [62, 66, 70, 96]. The reaction of HOCl with DNA can cause the formation of 
chloramines, which causes a loss in the of hydrogen-bonding and the dissociation of the DNA 
double-bonds [66]. The oxidation of DNA bases with HOCl causes the formation of numerous 
chlorinated products such as, 5-chlorocytosine, 5-chlorouracil, 8-chloroadenosine and 8-
chloroguanosine [132, 135, 137, 296]. HOCl also reacts readily with unsaturated fatty acids 
and cholesterol to form chlorohydrins, to destabilise cell membranes and cause cell lysis, and 
with antioxidants such as GSH, which result in the alteration of cell function [135, 143, 145, 
180, 181, 491]. The alteration of these molecules is important in the progression of diseases, 
such as atherosclerosis, and the reaction of HOCl with the amino acid Tyr can lead to the 
formation of the biomarker, 3-chlorotyrosine [125, 299, 492]. The use of this biomarker has 
allowed for the probing of HOCl-induced damage and the determination of the role of this 
oxidant in disease progression in vivo. On the contrary, there is no biomarker for HOSCN-
induced oxidative damage, partially because the oxidation products formed by HOSCN are 
not unique to this oxidant [432]. Because the reactivity of HOSCN and HOCl is different, the 
lack of biomarker means that the exact role of HOSCN in disease progression is currently 
unclear.  
The difference in the reactivity between HOSCN and HOCl was explored in Chapter 3, 
ThioGlo-1, a fluorescent maleimide, was used to assay HOSCN- and HOCl-treated cells for the 
concentration of free thiols. This method does not determine the oxidative species formed 
on the thiol after treatment, but by using sulfenic acid-specific probes, sulfenic acids were 
observed to be a major species formed upon treatment of cells with HOSCN, but not HOCl, 
where non-reversible oxidation of thiols was observed. While these methods allow for a 
determination of the state of intracellular thiols, they give very little information on the 
secondary or alternate effects of HOSCN/HOCl-induced oxidation of cells. Another 
complication of identifying hypohalous acid-induced damage in cells is the lack of a HOSCN-
specific biomarker. HOCl-induced oxidation can be identified via the determination of 3-
chlorotyrosine levels, and has been used to identify the role of MPO and HOCl in the 
progression of atherosclerosis [299, 316]. At this point in time, no such marker exists to 
identify HOSCN-induced damage to cells in vivo or in vitro, due to the oxidative nature of 
HOSCN and the reversible products formed by HOSCN, which are either unstable or also 
formed by numerous other oxidants including HOCl, NO and H2O2 [201, 489, 493, 494]. 
Protein carbamylation of Lys residues by OCN- and the formation of homocitrulline has been 
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used as a surrogate biomarker to implicate HOSCN as playing a role in the progression of 
atherosclerosis [81]. However, the use of homocitrulline as a biomarker for HOSCN-induced 
damage in atherosclerosis has limitations, particularly on analysis of plasma samples 
obtained from uremic patients, as protein carbamylation is a phenomenon of uraemia due 
to elevated OCN-. 
Apart from its ability to form reversibly oxidised Cys oxyforms, the role and activity of HOSCN 
in cellular systems is somewhat different to HOCl, as it is usually regarded as a milder oxidant, 
with a different pattern of reactivity [19]. It has been hypothesised that the presence of SCN- 
and the formation of HOSCN is protective in some conditions, as it removes more damaging 
oxidants, such as HOCl, from the cellular environment [495, 496]. In contrast to HOCl, HOSCN 
is bacteriostatic rather than bactericidal as HOSCN is known to inhibit bacterial growth and 
proliferation rather than causing bacterial cell death [427]. The results of this Thesis show 
that HOSCN is more potent than HOCl at inhibiting glycolysis in J774A.1 macrophages [56, 
198, 379]. The method by which HOSCN inhibits bacterial cell growth is via the oxidation of 
glycolytic enzymes that contain critical thiol groups, such as bacterial GAPDH, hexokinase, 
aldolase, glucose 6-phosphate dehydrogenase and glucose transporters, which results in the 
inhibition of glycolysis [56, 198-200, 385, 390]. For decades, the production of HOSCN was 
postulated to be normal and healthy for the host as it was thought that HOSCN only affected 
bacteria [54]. But due to the targeting of thiols, HOSCN may be detrimental to the host under 
inflammatory conditions, as shown by recently published data, showing that HOSCN can 
potentially perpetuate inflammation, deplete GSH and inhibit a wide array of proteins such 
as PTPs, GAPDH and ATPases [84, 91, 174, 179, 185, 201].  
This Thesis explored the attenuation of energy production in macrophages after exposure to 
HOSCN as GAPDH contains an active-site Cys, which is reported to be a key target for oxidants 
including HOSCN and HOCl [185, 201]. This enzyme plays an important role in glycolysis, and 
ultimately, energy production, by converting glyceraldehyde 3-phosphate to glycerate 1, 3-
bisphosphate. Its activity has been reported to be inhibited by HOSCN-induced sulfenic acid 
formation, while it has also been shown to be susceptible NO and to the formation of S-
glutathionylated species [201, 497, 498]. The inhibition of the GAPDH has interesting 
modulatory effects on the protein, as the formation of a sulfenic acid at the active-site Cys 
not only inhibits its dehydrogenase activity, but switches the enzyme to acyl phosphatase 
activity [499]. In essence, GAPDH begins to catalyse the reverse reaction, uncoupling 
glycolysis from the production of ATP at the reactions that follow in the glycolytic pathway 
 198 
 
[498, 499]. Along with its metabolic role, GAPDH has been shown to move between the 
cytosol and nucleus to activate transcription, implicating a role between the metabolic state 
of the cell and transcription [500]. This modulation in GAPDH activity has a pivotal 
consequence on the cell, with results from the functional glycolysis assays showing that 
treatment of J774A.1 macrophages with low concentrations (≥ 25 µM) of HOSCN was enough 
to significantly reduce the ability of the cells to metabolise glucose at baseline conditions. 
The attenuation of glycolysis results in a dynamic reduction of substrates for oxidative 
phosphorylation including pyruvate and NADH (shown in Chapter 7). This results in the 
alteration of the cellular metabolic state and could also have serious implications for gene 
transcription [500]. 
Because glucose metabolism and ATP production via oxidative phosphorylation is a 
connected and dynamic process, it was hypothesised that the inhibition of glycolysis and 
reduction of glycolytic end-products would inhibit mitochondrial oxidative phosphorylation. 
Results also showed that HOSCN oxidises mitochondrial thiols forming sulfenic acids and 
inhibits mitochondrial respiration. These results correlate with previously published data 
showing that the removal of thiols from the mitochondria inhibits mitochondrial function 
and respiration [192, 213, 416]. The data of this Thesis indicate that HOSCN affects 
mammalian bioenergetics via multiple pathways, indicating a systemic influence of HOSCN 
on macrophage energy production. The inhibiting of glycolysis has numerous consequences 
for cells, with these consequences having been trialled in treatment for cancer. Reports have 
shown that the inhibition of glycolysis in cancer cells with mitochondrial defects (analogous 
to the HOSCN-induced mitochondrial damage observed in Chapter 5), causes a severe 
depletion of ATP and the dephosphorylation of Bcl-2-associated death promoter. This causes 
a relocation of Bcl-2-associated X protein to the mitochondria causing cell death [501]. By a 
similar process of influencing the energy producing pathways in macrophages, HOSCN could 
also propagate lesion development in atherosclerosis.  
In addition, by the inhibition of glycolysis and mitochondrial respiration in macrophages, 
HOSCN could also promote foam cell formation seen in early atherosclerotic lesions. After 
treating J774A.1 cells with HOSCN, glucose is no longer able to be utilised for energy 
production and the cells must begin using another substrate for energy production [502]. A 
major energetic substrate found within the atherosclerotic lesion is lipoprotein-cholesterol, 
which can be taken up by macrophages [503-505]. Once taken up by the macrophages, the 
lipids undergo lipolysis to liberate glycerol and fatty acids, and it is the free fatty acids that 
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the cells could use for energy production after the inhibition of glycolysis by HOSCN [506]. 
The process by which fatty acids are catabolised for energy production is called ‘β-oxidation’, 
where, through a series of enzymatic steps, acetyl-CoA is formed [507]. Interestingly, this 
process takes place entirely within the mitochondria, which the results of this Thesis have 
shown, is heavily influenced by HOSCN-induced oxidation, indicating that much like the 
glycolytic pathway, the substrate is able to enter the pathway but the energetic end-product 
is unable to be formed due to the HOSCN-induced oxidation of a critical enzyme. 
Experiments were performed to determine whether the damage caused by HOSCN, such as 
the attenuation of energy production, could be alleviated using inhibitors and reducing 
agents. Results indicated that CsA could reverse the mitochondrial depolarisation caused by 
HOSCN, consistent with the interaction of the oxidant with the mitochondrial-permeability 
transition pore (MPTP) [508]. CsA also restored ATP levels within the treated cells, though 
the mechanism involved remains unclear. While thiol loss has explained the attenuation of 
glycolysis and mitochondrial respiration, previous data have shown that a loss in 
mitochondrial respiration due to thiol modification could be completely repaired after 
treating rat aortic smooth muscle cells with DTT [416]. 
Perturbation of bioenergetics and cellular dysfunction was supported by the use of FTIR, and 
this damage could be mapped visually using Raman spectroscopy techniques. The results of 
the FTIR and Raman also allows for a novel method of detecting HOSCN-induced damage 
which is significant in light of the lack of a chemical biomarker. These methods allow for the 
visualisation of HOSCN-induced damage by interrogating the change in chemical bond 
vibrations, which can then be analysed using PCA. By using PCA, the changes at each point in 
the spectra were compared to changes in other treatment groups, allowing for gross 
chemical changes within the cell to be identified with a unique spectral fingerprint [509, 510]. 
The results of both the FTIR and Raman mapping showed reduction in the intracellular 
glucose concentration and the glycolytic by-products, lactate and NADH, which is an 
energetic substrate required for oxidative phosphorylation. Furthermore, changes in the 
protein peaks determined that HOSCN caused structural and locational changes to proteins, 
indicating that HOSCN caused protein aggregation and increases in disulfide bond formation, 
which correlates with the chemistry of HOSCN [511]. The results of the Raman mapping also 
showed a reduction in the intracellular concentration of unsaturated fatty acids, which is 
hypothesised to be due to the reduction in glycolysis, as the cells require a new energy 
source, they undergo β-oxidation, which could be a trigger for foam-cell formation. The 
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results of this study implicate a role of HOSCN in the formation and progression of 
atherosclerotic lesions, particularly in smokers who have been shown to have increased 
plasma SCN-, the precursor of HOSCN [83]. 
The use of FTIR and Raman spectroscopy are interesting and novel methods by which oxidant 
damage to cells can be studied. The advantages include the large amounts of information 
that can be obtained, without the restrictions of fluorescent probes, which only allow the 
visualisation of tagged substrate, and in some cases, can alter the function of the substrate 
of interest. But there are limitations to the FTIR and Raman methods used in this Thesis, 
including the need to dehydrate the sample and the long sampling times required for Raman 
mapping. By using these techniques and with further optimisation, methods can be 
developed to identify HOSCN-induced damage throughout atherosclerotic disease 
progression, as various biochemical changes occur to cells contained within the lesion over 
time, such as the increase in LDL cholesterol [512]. The use of this method is further 
strengthened as it has been used in recent years to identify cellular changes in disease 
processes like cancer and metabolic disorders [439, 513, 514]. 
Taken together, the data in this Thesis with isolated HOSCN and macrophages support a role 
for this oxidant in promoting dysfunction and potentially disease, which may be more 
relevant for smokers with elevated plasma SCN-. This supports data showing correlations 
between plasma SCN- and early markers of macrophage dysfunction and lipid uptake [515, 
516]. However, data have also shown that patients with a previous myocardial infarct (MI) 
had better survival rates when plasma MPO was below median and SCN- was above median, 
while patients with the worst survival rate had above median MPO levels and below median 
SCN- over a period of ca. 12 years. However, the study included deaths from all causes, so 
mortality may be unrelated to cardiovascular disease [517]. The investigators hypothesised 
that the patients with above median SCN- and below median MPO had higher survival rates 
resulting from a decrease in HOCl-induced oxidation due to the formation of HOSCN, via the 
reaction of HOCl with the excess SCN-. These results are open for interpretation, primarily 
due to the lack of a HOSCN-specific biomarker, as the group with the lowest survival rates 
had high levels of plasma MPO and low levels of SCN-. These results also conflict with the 
results of a previous study, which linked high plasma protein-carbamylation via MPO 
oxidation of SCN-, with a positive relation to future myocardial infarction, stroke and death 
[81]. Knowing that these patients are survivors of a previous MI implies a chronic 
inflammatory condition and the constant formation of hypohalous acids. Kinetic data have 
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shown that the specificity of SCN- for MPO is much higher than that of Cl- for MPO (730:1) 
[48, 49, 518]. Upon extrapolation, these results may reflect that the reduction of plasma SCN- 
is an effect of the increased formation of HOSCN (high MPO, low SCN-), and that this is the 
cause of the reduced survival increased in this condition, rather than the increased survival 
being a result of HOCl being preferentially formed by MPO then reacting with SCN- to form 
HOSCN.  
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8.2 Future studies 
This Thesis showed, for the first time, that HOSCN can target mitochondrial proteins to form 
sulfenic acids. The results also showed that, unlike previously thought, HOSCN is able to 
inhibit glycolysis and oxidative phosphorylation in mammalian cells, and that HOSCN-
induced damage could be visualised and quantified using FTIR and Raman spectroscopy.  
The first and key future direction of this work would be to identify both the cytosolic and 
mitochondrial proteins affected by HOSCN-induced sulfenic acid formation. Proteomic 
analysis has been considered, using methods such as tandem mass spectrometry and matrix-
assisted desorption/ionisation (MALDI) would allow for the identification and 
characterisation of the proteins oxidised by HOSCN in J774A.1 macrophages, and whether 
these proteins are involved in cellular energy producing pathways. 
HOSCN has previously been shown to inhibit GAPDH, and this study saw a functional effect 
on glycolysis after HOSCN treatment [201]. Because GAPDH has been found to influence a 
link between metabolism and gene transcription, future studies could also attempt to 
determine the changes that occur to gene expression after HOSCN treatment, especially 
those involved in the S-phase of the cell cycle [500]. Though, despite HOSCN attenuating 
glycolysis and mitochondrial oxidative phosphorylation, very little cell death was observed 
as a function of cell lysis in the LDH activity assays. It was hypothesised that perhaps the cells 
after a 1 h treatment with HOSCN were not dying, or were in the early stages of apoptosis as 
implied by increases in the recognition of phosphatidylserine in the Raman mapping 
experiments. By using flow cytometry, further studies could identify a link between the 
inhibition of glycolysis and oxidative phosphorylation with increases in apoptosis and 
necrosis.  
In regard to the mitochondrial dysfunction and inhibition of oxidative phosphorylation 
induced by HOSCN treatment, it was proposed that the uncoupling of the electron transport 
chain would cause an increase in ROS within the mitochondria. This could be measured using 
an HPLC method and dihydroethidium, which is oxidised to a specific product, 2-
hydroxyethidine by O2•- [519]. This method would also allow for the determination of the 
feasibility of antioxidants as a treatment to prevent HOSCN-induced damage. A previous 
report showed that MitoQ, which uses ubiquinone as the active antioxidant, was able to 
prevent HOCl-induced mitochondrial damage and cell death [520]. 
 203 
 
Another hypothesis that appeared throughout this Thesis, which was proposed due to the 
lack of cell death observed after the LDH assays, was that the cells are switching their primary 
energy producing pathway to lipolysis and β-oxidation after HOSCN treatment. This would 
have interesting implications on the formation of foam cells in atherosclerosis. There is an 
assay kit available by Seahorse Bioscience, which probes cells for fatty acid oxidation. It has 
been hypothesised that, because β-oxidation occurs in the mitochondria and the 
mitochondria are influenced by HOSCN-induced sulfenic acid formation, the XF fatty acid 
oxidation assay would help to connect the role of cellular bioenergetics with the progression 
of atherosclerosis. 
The Raman spectroscopy allowed for a visualisation of HOSCN-induced oxidation in J774A.1 
cells and in regards to the proof-of-concept study the data obtained was invaluable, but 
further analysis was not performed due to the time constraints. Further studies could 
continue optimising the assay, which would allow for quicker preparation of the cells and 
faster imaging, while increasing the quality of the images taken. This could be achieved by 
further optimising the laser power, for example, using a wavelength such as 633 nm, may 
allow for quicker imaging and better spectral resolution, without burning samples. One of 
the hopes of this study was to image organelles within the J774A.1 macrophages, allowing 
for the determination of chemical changes within different cellular compartments upon 
treatment with HOSCN or HOCl. Increasing the number of treatment concentrations would 
first allow for a comparative study to visualise the progression of HOSCN-induced damage, 
while the use of a synchrotron would give high-quality, high resolution data. 
The results of this Thesis have also extended the knowledge of the role of HOSCN in a cellular 
model. HOSCN’s ability to modulate metabolic function has consequences that can be 
further studied and elucidated, allowing for further understanding about the involvement of 
HOSCN in atherosclerosis and other diseases where oxidative stress plays a key role. 
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8.3 Concluding remarks 
This Thesis explored the involvement of HOCl and HOSCN in regards to thiol oxidation in 
J774A.1 cells. The results indicate that HOCl induces thiol loss in an irreversible manner, while 
HOSCN induced the formation of reversible products, including sulfenic acids on protein 
thiols in the cytosol and mitochondria. The formation of these reversible species was 
investigated in regards to the functional aspects of glycolysis and mitochondrial oxidative 
phosphorylation. The study concluded that HOSCN induces glycolytic inhibition, and that the 
reduction in glycolytic end-products ultimately affects the function of the mitochondrial 
electron transport chain and the formation of the energetic end-product, ATP. The results of 
the lactate assay also indicate that this process is not reversible upon the reculture of cells 
in the absence of HOSCN, despite the reversible nature of HOSCN-induced oxidation. The 
gross effects of HOSCN and HOCl were also investigated using FTIR, Raman spectroscopy and 
PCA, and the results indicate that both oxidants affect multiple cellular components, 
including proteins, DNA/RNA, lipids, while HOSCN was also able to attenuate the levels of 
carbohydrates within the cell. These data strengthen the argument that HOSCN could play a 
role in the progression of inflammatory disease, including atherosclerosis. This helps to 
rationalise why smokers, who have elevated plasma SCN-, exhibit increased inflammatory 
conditions within the large arteries and have higher incidences of atherosclerosis. However, 
the lack of a HOSCN-specific biomarker limits the ability of researchers to fully understand 
the role of HOSCN-induced oxidation of biological targets in vivo, which means further 
investigations into the targets and patterns of damage caused by HOSCN must performed. 
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